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This thesis describes a) the isolation and mapping of new markers from human
chromosome 1 lq 12-13 and b) the mutational analysis of a gene from this region as
a candidate for an inherited deafness syndrome. Chromosome llql2-13 is
estimated to comprise 28Mb of DNA, is gene rich, and encodes a number of
important disease loci, associated with deafness, eye retinopathies, cancer and
diabetes. We had at hand a number of somatic cell hybrids containing different sub
fragments of this region, which I wished to exploit for the isolation and mapping of
new markers. I developed a two step Alu PCR amplification protocol which
allowed the majority of products to be used as genomic probes without
competitive hybridisation. I compared the efficiency of different cloning methods
and demonstrated the value of Turbo cloning, a new method for blunt end cloning.
Markers were then ordered along the chromosome using the hybrid panel. A
number of markers were concentrated in a sub region of 1 lq 13 which had been
linked to several important disorders, and these were used to isolate YACs. Thus
the formation of a cloned DNA map of the region was initiated.
In parallel I examined the Olfactory Marker Protein (OMP) gene as a candidate for
Usher Syndrome Type IB, by DNA sequencing and mutational analysis of affected
individuals. Usher syndrome is characterised by deafness and retinitis pigmentosa.
In Type I, vestibular dysfunction is also a feature of the disorder. The disorder is
genetically heterogeneous and for each subtype several genetic loci have been
linked in individual populations: Type IB has been linked to 1 lql3. A stereociliary
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defect was proposed, and the mapping of OMP to the linked region, its expression
in olfactory nasal cilia and the CNS, and the mapping of the mouse Omp gene to
the syntenic region on mouse chromosome 7 very close to Shaker-1, a possible
mouse homologue of Usher syndrome type I, justified close examination of OMP
as a candidate for both disorders. A human genomic clone was therefore obtained
and sequenced, several different methods of mutation detection compared, and the
value of the chemical mismatch cleavage technique demonstrated. At the same
time, comparative mapping was carried out by mapping candidates from the
Shaker-1 nonrecombinant region on the somatic cell hybrid panel. Variants of the
OMP gene were identifed, but it was formally excluded as candidate when a gene
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BAC bacterial artificial chromosome
bp base pairs
BSA bovine serum albumin
cDNA complementary DNA
cM centimorgan
CMGT chromosome mediated gene transfer















EDTA ethylenediaminetetra-acetic acid disodium salt
EST expressed sequence tag
FISH fluorescence in-situ hybridisation
IRS interspersed repetitive sequence
IPTG isopropyl P-D-thiogalactopyranoside
EBD identical by descent
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1. Introduction
1.1 Producing and ordering a library of repeat free clones
from chromosome 11q12-13
The initial aims of the Human Genome Mapping Project (HGMP) were to establish
physical and genetic maps including features such as polymorphisms, genes, and
specific DNA sequences. The intentions were two fold: the development of unique
sets of PCR primers that would recognise sites ~100kb apart across the entire
genome (STSs); and to begin to assemble large segments (2Mb equivalent to ~\%
of the X chromosome) of contiguous cloned DNA at different defined sites in the
genome (Hoffman 1994). This has led to large scale mapping projects, with the
most impressive results to date being produced by Genethon in the form of dense
genetic maps (Gyapay et al., 1994). The availability of increasing numbers of
polymorphic markers has greatly aided linkage studies of genetic disorders and
consequently led to physical mapping and assembly of cloned DNA maps of linked
regions. Large scale physical mapping efforts have also been undertaken leading to
the construction of megabase YAC contigs spanning whole chromosomes (Gaston
et al., 1991), most of the work has, however, concentrated on the construction of
contigs spanning disease associated regions (Todd et al., 1995).
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One of the objectives of my PhD was to produce a map of chromosome 1 lq 12-13.
This was undertaken for several reasons; a) studies have shown the region to be
gene rich and not surprisingly therefore several human genetic disorders had been
assigned to the region and b) the region was relatively poorly mapped, but
resources were available in the laboratory which would be valuable in generating
new markers. To be useful, such markers must contain a minimal amount of
repetitive DNA and be large enough to allow efficient labelling and hybridisation.
My aim was therefore to develop a method which could generally be applied to the
generation of clone-based physical maps of such regions.
Clone-based physical maps are extremely useful as a framework for many types of
structural and biological studies and are resources for characterisation and
understanding of human genes, diseases and development. Here an Alu-PCR
based approach was developed which can be used to assemble clone maps of a
specific chromosomal region. The inter-Alu products were cloned and as such
could be used directly to produce a map of the region or sequenced and the
sequence then released to others as a sequence tagged site (Smith et al., 1993).
The method developed here could equally be applied to other less well mapped
regions by selection of reduced somatic cell hybrids retaining the appropriate
region.
1.1.1 Somatic cell Hybrids
Producing and ordering a library of repeat free clones from chromosome 1 lql2-13
required a source of human DNA from this region. Conventional human-rodent
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somatic cell hybrids have been valuable in their ability to allow the assignment of
genes to specific chromosomes (Walter and Goodfellow 1993). The limitation of
this approach however is that it does not often allow markers to be located with
high resolution. Subchromosomal localisation of genes using human-rodent
somatic cell hybrids requires the fragmentation and segregation of chromosomes by
y-irradiation induced chromosome breakage. Hybrids generated in this manner,
radiation hybrids, are readily usable in positional cloning experiments, and have
facilitated the mapping and cloning of sequences from defined regions of the
genome (Cox et al., 1990; James et al., 1994). Radiation hybrids are produced by
subjecting human-rodent hybrid cell lines, containing a single intact human
chromosome, to lethal X irradiation. This treatment breaks the chromosomes into
fragments and results in cell death. The irradiated donor cell line is then fused to a
recipient rodent cell line. Human material is usually retained at high frequency in
the absence of specific selection, although it is possible to select for the retention
of specific regions by using a recipient cell line deficient for a specific marker
(Walter and Goodfellow 1993). The human fragments can be distinguished from
the rodent background using the interspersed repetitive sequence polymerase chain
reaction (IRS-PCR). A single primer directed to human repetitive sequence
elements is used to amplify the DNA between two elements juxtaposed in opposing
orientations. Thus products are only obtained when a human fragment is present
and the resulting pattern can be indicative of a specific chromosome or
subchromosomal region (Guzzetta et al., 1991). Radiation hybrids allow the
separation of fragments of 0.3-30Mb and thus span the gap between the limits of
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cloning and mapping methods such as PFGE, YAC cloning, and conventional
somatic cell genetics.
Three different types of somatic cell hybrids were used to create a hybrid mapping
panel (figure 1.1): two chromosome 11 translocation cell lines; four X irradiation
hybrids specifically selected to contain particular fragments of chromosome llq;
and two independent HRAS 1 selected chromosome mediated gene transformants
which also contained several fragments of chromosome 11 (these are described in
more detail in section 3.1.3.1). The importance of the latter two types of hybrid is
that they contain multiple fragments of chromosome 11 and together comprise a
high resolution mapping panel often allowing markers to be assigned to small
intervals of llq with submegabase accuracy. Through mapping of markers on the
panel (Slorach et al., 1995; Evans et al., 1995) the region contained in the hybrids
has been well defined, and the irradiation hybrid WJX3.4 appeared to contain a
single contiguous region from llpl 1.2-1 lql3.5 (Fletcher et al., 1993).
Consequently WJX3.4 was used to produce a library of the region llql2-13, to
which a number of disease loci have been linked.
4
Figure 1.1 Regions of chromosome 11 contained in somatic cell hybrids
Diagrammatic representation of the chromosome 11 content of each of the
hybrids is shown on the right. Hybirds MIS7.4 and PG48 were not used in this study.
The positions of the chromsome 11 markers (Evans et al., 1995) and the ESTs
(Slorach et al., 1995) have been defined by others in the group. Markers are
shown in the correct order although evenly spaced for clarity. Regional
localisation bars show more accurate mapping positions.
EST 16* is shown in two possible locations since the data available is insufficient to
distinguish between the two
1.1.2 Cloned DNA maps
Somatic cell hybrids, which retain different fragments of a chromosome, allow
markers to be positioned relative to each other on the chromosome. Estimates can
be made of the physical distance between markers, and hence confirm their relative
positions, by looking at the frequency of chromosome breakage between them on
exposure to a particular dosage of X-rays (Cox et al., 1990). Genetic distance can
also be estimated, if markers are polymorphic, by looking at the frequency of
recombination between two alleles. Both maps provide information on the
distance between markers, although the resolving power of a radiation hybrid map
is generally greater than that of a linkage map which is limited by the availability
and spacing of polymorphic markers along the chromosome. Neither, however,
provides access to the intervening DNA which requires cloned DNA maps.
A cloned DNA map describes a genomic region as a series of overlapping cloned
molecules, such that each recombinant vector contains a piece of DNA that
partially overlaps with the DNA carried by the adjacent recombinant (Little 1992).
Cloned DNA maps are generally constructed using Yeast Artificial Chromosomes
(YACs). YAC vectors are capable of carrying several hundred kilobase-pairs of
DNA insert, consequendy contigs ( sets of overlapping clones or sequence) of up
to several megabases can be readily assembled. Individual YAC inserts can then be
subcloned into cosmids or plasmids, enabling their analysis down to the nucleotide
sequence level. Contigs are constructed by screening libraries such as the ICI
YAC library with suitable probes (Anand 1992).
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Mapping on somatic cell hybrids is an important intermediate stage when
assembling a YAC contig. It allows the rationalization of results of the primary
YAC library screen, for example if the same YAC is isolated using two markers
which are shown to be several megabase apart by mapping on somatic cell hybrids,
then this cannot be spanned by a single YAC but will probably be due to the
presence of related or repetitive sequence in the markers. It also means that the
location of the YAC can be confirmed by in situ hybridisation of YACs to somatic
cell hybrid chromosome spreads (FISH).
In the next section I will explain why the PCR amplification of human sequences
flanked by specific repeated sequences (Alu-PCR) was chosen as a means of
generating markers, and how the PCR was optimised to give the maximum
complexity of products, and the cloning strategy used. Later sections will explain
how clones suitable for mapping on somatic cell hybrids and YACs were selected,
and the isolation of CA repeat containing clones. First, however, I will discuss
why this region of chromosome 1 lq is so worthy of study.
1.1.3 Disease loci
A number of disease loci have been linked to this region of 1 lq. These include
genes for cancer, diabetes and hereditary deafness, (Fig. 2 shows their relative
positions). In order to facilitate cloning studies of such disease loci, new markers
were needed to fill the gaps in the existing map and help in the isolation of
candidate genes. These markers would be particularly interesting if they were
polymorphic as they would then also be useful in linkage analysis. In this section I
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Figure 1.2 Map positions of disease loci on 11 q
This map is based on that originally formulated by James et al (1994). The gene
linked to the prothrombin (F2) locus had only been positioned very roughly
(Royle et al., 1987) to llpll-ql2. Some of the polymorphic loci had not been
positioned on the radiation hybrids, but an indication of where they map has
been given: the SCA5 disease locus lies in an 8cM region between D11S913 and
GATA201; the EVRI disease locus has been tightly linked to D11S873 which lies in
the region 14cM distal to D11S533; MENI disease locus lies in an 3cM region
between PYGM and the more telomeric marker D11S480. The D1 IS- prefix has
been omitted from the microsatellite marker designations.
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Spinocerebellar ataxia type 5-SCA5
SCA5 is one of a group of clinically and genetically heterogeneous autosomal
dominant cerebellar ataxias (Ranum et al., 1994). The disease is characterised by
varying degrees of incoordination affecting gait, speech and swallowing, due to
progressive multisystem neurodegeneration, Four different SCA loci have
previously been identified on chromosomes 6p, 12q, 14q and 16q, one of which
(SCA1) has been shown to be caused by expansion of an unstable trinucleotide
repeat which may explain the anticipation and clinical variation associated with
these disorders (Jodice et al., 1994). A large, ten generation kindred used in
multipoint linkage and haplotype analyses provided strong evidence that the gene
was located in the 8cM region between GATA2A01 and D11S913.
Familial hypertrophic cardiomyopathy 4-CMH4
Hypertrophic cardiomyopathy (MIM - 192600) is a primary cardiac disease that is
usually transmitted as an autosomal dominant trait. It is the major cause of sudden
death in young athletes. The disorder was shown to be genetically heterogeneous,
when less than 50% of published pedigrees were found to be associated with
mutations in the (3 myosin heavy chain gene on chromosome 14qll-ql2 (CMH1 -
Solomon et al 1990). Two other loci were later identified on chromosome lq
(CMH2 - Watkins et al., 1993) and 15q2 (CMH3 - Thierfelder et al., 1993).
Genetic analyses of informative markers in a large family not linked to any of the
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previously identified loci, identified two haplotypes cosegregating with the disease.
This led to the tentative conclusion that the CMH4 locus lay between markers
AFM105xbl0 (D11S905) and AFM131ye5 (D11S987) in a 17cM region of
chromosome 11 (1 Ipl3-ql3) (Carrier et al., 1993).
Hypoprothrombinemia; dysprothrombinemia - F2
Hypoprothrombinemia and dysprothrombinemia result in an increased bleeding
tendency manifested especially in more marked or prolonged posttraumatic and
postoperative bleeding (MIM - 176930). Both are inherited in an autosomal
dominant manner, and are caused by mutations in the gene for prothrombin
(coagulation factor II): in hypoprothrombinemia no identifiable protein is
produced; whereas in dysprothrombinemia protein is produced, but is biologically
inactive (Lanchantin et al., 1968). The gene for human prothrombin (F2) was
assigned to 1 lpl l-ql2 by analysis of a panel of somatic cell hybrids and by in situ
hybridisation, using both cDNA and genomic probes (Royle et al., 1987).
Pyruvate carboxylase deficiency - PC
As the name suggests, this autosomal recessive disorder results from a deficiency
in pyruvate carboxylase (MIM - 266150), leading to abnormal gluconeogenesis.
Clinically this results in growth retardation, mental retardation, and infantile
subacute necrotizing encephalomyelopathy. Somatic cell hybrids were used to
localise the gene to the long arm of chromosome 11 (Freytag and Collier, 1984),
comparative mapping with the mouse suggested that the human PC locus was
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located in the proximal part of llq, perhaps at 1 lql2-13 (Rochelle et al., 1992).
This localisation has since been confirmed (Smith et al., 1993)
Congenital Pernicious anemia - GIF
Infantile onset pernicious anaemia is inherited in an autosomal recessive manner,
and results from a defect of intrinsic factor secretion (MIM - 26100). Clinically the
disorder results in jaundice, anaemia and mental retardation. Somatic cell hybrids
were used to localise the gene to chromosome 11 (Hewitt et al., 1991). This
localisation was later refined to 1 lq 12-13 by Stafford et al (1994).
Atopy - IGER
Atopy is a common condition in man, characterised by familial asthma, hay fever,
and eczema (MIM - 147050). It is caused by an excessive allergic response to
small quantities of common inhaled allergens such as pollens, animal dander, and
house dust mite, and is mediated by Immunoglobin E. Inheritance of this disorder
is complex but may involve autosomal dominant factors. Using sibpair analysis
which does not require prior assumptions about the mode of inheritance,
penetrance of the disease, or the gene frequency, an important locus for atopy in
1 lql2-13 was identified in British (Young et al., 1992) and Japanese families
(Shirakawa et al., 1991). The candidate region was later refined to an area
centromeric to the pepsinogen locus (PGA), centred around the CD20 gene
(Sandford et al., 1993). Recendy Stafford et al (1994) constructed a 2.8 Mb YAC
contig of this region, to which they localised two candidate genes for the disorder:
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the beta subunit of the high affinity immunoglobulin E receptor (FceRiP); and
CD20, a molecule involved in B cell differentiation.
Hereditary angioedema - C1NH
Hereditary angioedema is an autosomal dominant disorder characterised by
episodic local subcutaneous oedema and submucosal oedema involving the upper
respiratory and gastrointestinal tracts (MIM - 106100). It is caused by a deficiency
of activated CI esterase inhibitor (C1NH). The gene was assigned to llpll.2-ql3
using somatic cell hybrids (Bock et al., 1986). Theriault et al (1990) used in situ
hybridisation to obtain more precise localisation of the gene to 1 lql l-ql3.1.
McArdle disease - PYGM
McArdle disease is an autosomal recessive disorder caused by myophosphorylase
deficiency (MIM - 232600). Phenotypically this results in exercise intolerance,
with premature fatigue, and cramps in exercising muscles. The human muscle
glycogen phosphorylase (PYGM) gene has been assigned to chromosome 11 by
DNA spot blot analysis of chromosomes (Lebo et al., 1984) and mutations in this
have been shown to result in McArdle disease (Tsujino et al., 1993). Lebo et al
(1990) later sublocalised the gene to the proximal part of 1 lql3 by FISH.
Parathyroid adenomatosis 1-CCND1
Parathyroid adenomatosis is an autosomal dominant disorder in which parathyroid
adenomas result due to overexpression of PRAD1 (MIM - 16841) which encodes a
cyclin. The cyclin D1 gene (CCND1) was later assigned to llql3 by a
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combination of somatic cell hybrid studies and FISH (Inaba et al., 1992). CCND1
has been shown to have the ability to transform cultured cells and hence function as
an oncogene (Hinds et al., 1994), thus supporting its proposed role as a proto-
oncogene for parathyroid adenomas.
Chronic lymphatic B-cell leukemia - BCL1
Chronic lymphatic leukemia results in the malignant transformation of B cells
(MIM - 151400). The observation of a recurring t( 11; 14) translocation involving
the Ig heavy chain locus at 14q32 and 1 lq 13 (Tsujimoto et al., 1984) led to the
1 lq 13 being designated BCL1, for B-cell leukemia/lymphoma-1 The nature of the
gene located at llql3 which is involved in the malignant transformation of B cells
remained unclear until recent work by Komatsu et al (1994) showed that in a
particular translocation the PRAD1 gene was the sole candidate known to be
located between breakpoints. In addition, PRAD1 mRNA overexpression was
shown to be concordant with the presence of a translocation. These results
indicated that the putative BCL-1 gene activated by translocation is in fact
PRAD1.
Multiple endocrine neoplasia type 1-MEN1
Multiple endocrine neoplasia is an autosomal dominant disorder characterised by a
high frequency of peptic ulcer disease and primary endocrine abnormalities
involving the pituitary, parathyroid, and pancreas (MIM - 131100). Larsson et al
(1988) mapped the MEN1 locus to chromosome 11 by demonstrating linkage to a
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DNA probe derived from the PYGM locus. In addition to the linkage evidence,
loss of heterozygosity (LOH) on chromosome llq in MEN1 associated tumours
suggested the presence of a tumour suppressor gene in that region, and deletion
mapping in such tumours placed the MEN1 locus telomeric to PYGM at llql3
(Bystrom et al„ 1990). The genes PYGM and FAU have been ruled out as
candidates for MEN1 by analyses of DNA in MEN1 patients and MEN1 associated
tumours (Kas et al., 1993). A new gene (ZFM1) has, however, been isolated from
the associated region (Toda et al., 1994) and is currently being analysed.
Familial exudative vitreoretinopathy-FVTfi
Familial exudative vitreoretinopathy is an autosomal dominant disorder
characterised by incomplete vascularization of the peripheral retina. Clinical
expression of the disorder varies between lack of any visual symptoms and
considerable visual impairment which may lead to blindness at a young age (MIM -
133780). Extended multipoint linkage analyses on two families using 5 markers
from Ilql3-q23 showed the locus most likely maps between D11S533/D11S527
and D11S35 (Li,Y., 1992). Close linkage without recombination was observed
between D11S533 and D11S527. The location of EVR1 has recently been refmed




BBS is an uncommon, autosomal recessive disorder characterised by mental
retardation, post-axial polydactylia, obesity, hypogenitalism and retinitis
pigmentosa (MIM - 209900). A number of other traits have also been shown to be
frequently associated with the condition including urogenital malformations, renal
diseases and both conductive and sensorineural hearing impairments. Expression
of these features is variable both within and between families. Linkage analysis on
31 North American families showed significant linkage to the gene for human
muscle glycogen phosphorylase (PYGM) in 17 of the families (Leppert et al,
1994). Consideration of adjacent markers in linked families showed that BBS
mapped to a 3cM confidence interval between markers UT5150 and INT2, with
the favoured position at the PYGM locus. This locus heterogeneity was supported
by previous studies which had shown evidence for linkage to chromosome 16 in an
Israeli Bedouin kindred (Kwitek-Black et al., 1993). Here only three families gave
positive LOD scores to chromosome 16 markers and subsequently yielded a
negative LOD score from PYGM. Heterogeneity in the North American families
could not be explained by ethnic origin, and did not readily reflect phenotypic
characteristics.
Neovascular inflammatory vitreoretinopathy-V7?A7
Neovascular inflammatory vitreoretinopathy is an autosomal dominant disorder
characterised by retinal and iris neovascularisation, abnormal retinal pigmentation,
uveitis, cystoid macular oedema, vitreous haemorrhage, and traction retinal
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detachment (MIM - 193235). In linkage analysis using chromosomal loci that had
been associated with uveitis, neovascularisation, or retinal degeneration in previous
studies, markers at llql3 which were closely linked to Best's disease locus
revealed significant linkage (Sheffield et al., 1992). The most probable location of
ADNTV was at D11S527. This was confirmed by Stone et al (1992) who observed
no recombinants between the disease phenotype and D11S527. Linkage data
suggested that VRN1 and Best's disease, although mapping close to each other,
were in fact due to mutations in different genes (Sheffield et al., 1992). Similarly
VRN1 and EVR1, also appeared to result from mutations in different genes, since
EVR1 lies 7cM from D11S527 (Sheffield et al., 1993). The fact that several eye
disorders are linked to the same proximal portion of 1 lq may indicate the presence
of a cluster of genes that have a common function and owe their proximity to a
common ancestor. Although until the nature of the genes involved is determined
this remains a theory.
Insulin dependent diabetes melIitus-/Z)DM4
Insulin dependent diabetes mellitus is a disorder of glucose homeostasis that is
characterised by susceptibility to ketoacidosis in the absence of insulin therapy
(MIM - 222100). IDDM is a genetically heterogeneous autoimmune disease and
genetic studies have been aimed at the identification of loci associated with
increased susceptibility to this multifactorial phenotype. The major locus (IDDM 1
which accounts for 42% of familial cases) is encoded by the major
histocompatibility complex on chromosome 6p21, other loci, such as the insulin
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gene on chromsome 1 lp 15 (IDDM2), are more minor in their contribution (less
than 10%). By carrying out linkage tests of microsatellites (average spacing
llcM) Davies et al (1994) confirmed the presence of two other minor loci at llq
(IDDM4) and 6q (IDDM5). The presence of a susceptibility locus on llq was
confirmed by Hashimoto et al (1994).
Vitellliform macular dystrophy/Best's disease-VMD2
Best's disease is clinically defmed as vitelliform macular dystrophy. It is a juvenile
onset, autosomal dominant disorder characterised by an accumulation of yellowish
material in the macular area (MIM - 153700). The disease is slowly progressive
and eventually leads to atrophy of the retinal pigmented epithelium in
photoreceptor cells, severely impairing central vision. The biochemical defect
underlying this condition is unknown, but abnormal electroculography (EOG) and
histopathological studies, suggest the retinal pigment epithelium as the primary site
of the dysfunction. Linkage studies by Stone et al (1993) localised the gene to
1 lq 13, between INT2 and D11S871. Weber et al refined this localisation to a
3.7cM interval between D11S903 and PYGM, which by PCR mapping was shown
to span the centromere of chromosome 11. The gene encoding the retina specific
protein ROM1 has been isolated and shown to map to the Best's disease region
(Bascom et al., 1992a,b). Identification of a recombination event between ROM1
and the disease phenotype excluded ROM1 as the gene responsible for the disorder
(Stohr and Weber 1995).
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1.1.4 Physical mapping and human specific repeats
Various different resources can be used as a starting point from which to formulate
a physical map of a region. Essentially these depend on how the disorder was
mapped to the region in the first place. Various examples are given in the
disorders mentioned above; translocations, cytogenetically visible deletions, and
linkage disequilibrium. Translocations give a specific physical location to aim for,
whereas the area covered by a deletion, or surrounding a linked marker may be
quite large. Closer markers may first need to be isolated in each case and a cloned
DNA map assembled if there are no obvious candidate genes in the region.
The human genome contains a relatively large proportion of DNA which appears
as yet to serve no purpose. In contrast to the DNA of simpler organisms like
E.coli and yeast, human DNA contains large amounts of sequences present in
multiple copies and these form a large proportion of what has been termed 'junk'
DNA. While some repetitive sequences are located in disciete chromosomal
domains, for example alphoid sequences, most repetitive DNA has been shown to
be dispersed apparently at random throughout the entire genome in higher
organisms (Moyzis et al., 1989).
Initially it was thought that this prevalence of repeat sequences would complicate
the mapping of the human genome, but further investigation of repeat structure
revealed that the sequence of such elements was highly conserved. Thus with the
advent of the polymerase chain reaction, the frequency and conservation of these
sequences could be used to advantage in a technique known as interspersed
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repetitive sequence PCR. Interspersed repeat sequence DNAs are now classified
as SINES (short interspersed repeated sequences) or LINES (long interspersed
repeated sequences). In primates each class is dominated by a single DNA
sequence family. The major human LINES family is LI or Kpnl with a consensus
sequence length of approximately 6.4kb; many family members have serial
deletions of the 5 end or internal deletions and rearrangements, but most share the
3' end. The reiteration frequency is about 4,000- 20,000 for the 5' end and
increases to 50,000-100,000 for the 3' end (Korenberg and Rykowski 1988). The
major human SINE is the Alu sequence family. It has a consensus sequence of
about 300 base pairs and is reiterated 300,000- 900,000 times in the genome.
Early work had shown that for particular repeats there were local regions of
preference and exclusion (Moyzis et al., 1989). Further investigation revealed that
this bimodal distribution correlated with Giemsa dark and light chromosome bands:
the Alu family dominates in Reverse bands, and the LI family dominated in
Giemsa/Quinacrine positive bands. Each band type can be characterised by the
average G+C content, the stage in the DNA synthetic period when they replicate,
and the point at which they condense in mitotic prophase. Giemsa/Quinacrine
bands are relatively rich in adenine plus thymine (A+T), replicate their DNA during
late S phase, and condense early during mitosis. Reverse bands in contrast are
relatively rich in guanine plus cytosine (G+C), replicate their DNA early in S phase,
and condense late in mitotic prophase. Alus are composed of 56% G + C and Lis
58% A + T, in fitting with the overall DNA composition, and each may comprise
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13% to 18% of the total DNA in a chromosome band. It has been proposed
therefore that the distribution of these sequences may account for a large part of
human chromosome banding seen with fluorescent dyes (Korenberg and Rykowski
1988).
Alu repeat elements have been the preferred choice for IRS-PCR because of the
higher degree of conservation, their high reiteration frequency, the small distance
separating adjacent elements of inverted orientation and their location in R bands.
Alu repeat elements have been used in mapping in basically two different ways;
either a) to provide a reproducible fingerprint for a specific somatic cell hybrid,
YAC or cosmid, and consequently provide a means of confirming human specific
DNA content; or b) these template specific products can be cloned and mapped
back to a specific point in the resource from which they were obtained e.g. FISH
on a somatic cell/irradiation hybrid, Southern hybridisation to a restriction
fragment of a YAC or a cosmid. The former method is used routinely and presents
few technical problems. The latter, while frequently used, suffers from several
drawbacks which I have sought to overcome:
1. Alu PCR fragments are largely blunt ended and cloning is therefore inefficient
2. DNA fragments amplified using Alu PCR primers which generate the high
density of PCR products required are frequently small (Cole et al., 1992b) and
thus label poorly.
21
3. Alu-PCR products contain at least 100 base pairs of the Alu repeat sequence
which must be competed out so they can be used as a unique or low copy
hybridisation probes.
Each of these points will be addressed, but first I will discuss the structure and






Figure 1.3 The structure of an Alu repeat element
Figure 1.3 shows the structure of an Alu repeat element (Watson et al„ 1994).
Each Alu element is dimeric in structure, composed of two tandemly arranged
halves, with the right half containing an additional 3 lbp relative to the left half.
Alu repeat elements are transcribed by RNA polymerase III, which is directed by a
promoter lying within the repeat sequence and therefore is retained in the
transcribed sequence. Elements also contain a middle A-rich region and a 3' oligo
(dA) tail of variable length, consistent with the belief that these elements have
arisen as a result of reverse transcription through an RNA intermediate (Batzer and
Deininger 1991). Once transcribed into RNA it is proposed that the 3' oligo dUTP
tail formed at the 3' end of all RNA polymerase III products would fold back on
the lengthier A-rich tail, forming a primer and allowing reverse transcription of the
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repeat element into cDNA. This cDNA would eventually be inserted into the
genome via staggered nicks which are repaired to form the direct repeat sequences
seen to flank Alu repeat elements.
A theory for the origin of Alu elements is that they originated from a defective 7SL
RNA molecule which was reverse-transcribed into DNA and inserted into the
genome (retroposition) (Leigh-Brown 1984). 7SL is an abundant small RNA
which associates with six proteins to form a small cytoplasmic RNA-protein
complex (called SRP) that is essential for the translocation of newly synthesised
proteins across membranes of the rough endoplasmic reticulum in higher
eukaryotic cells (Watson et al., 1994). Alus are thought to be stable in the genome
because a 7SL pseudogene may not possess or respond to any mechanism for
excision or transposition. Thus, unless its presence is detrimental to the
chromosome in which it inserts, it will be stably maintained throughout replication
and cell division. Despite the presence of thousands of copies of Alu elements, the
majority of which possess an RNA polymerase III promoter which is functional in
vitro, there is very little transcription of Alu family members in vivo. A number of
explanations for this phenomenon have been proposed: absence of the 37bp
upstream sequence required for the 7SL gene to be actively transcribed;
methylation; and accumulation of inactivating mutations (Deininger et al., 1992,
Liu et al., 1994). The fact that some disease related de novo mutations have been
shown to have resulted from Alu element retroposition indicates that some
members are still transcriptionally active (Vidaud et al., 1993). There are two
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different schools of thought on the retroposition of Alu repeat elements, each of
which is based on specific nucleotide variations in individual Alu elements. In the
'master gene' model all subfamilies are serially related due to their origin from the
same master source gene. The subfamilies themselves are not propagated. In the
'transposon model' on the other hand, copies of the source gene may themselves
be transcribed and retropose, and hence subfamilies may share some sequence
changes, but differ in others. Recent analysis of the Huntington disease region
revealed a recently transposed Alu repeat element the sequence of which supported
the latter transposon model (Hutchinson et al., 1993) since it was not serially
related to previously defined subfamilies.
What is the nature of the material produced by Alu PCR? As previously
mentioned, Alus are clustered in R bands. Investigation of R bands (Holmquist
1992) has shown that they are not all homogeneous and some R bands are known
as T bands. T bands are particularly GC and Alu rich and although they represent
just 15% of all R bands they have been shown so far to accomodate 65% of all
mapped genes. This could be related to the fact that two thirds of all genes are
associated with GC-rich CpG islands (Craig and Bickmore 1993). This
concentration of Alus in gene rich locations makes it possible to postulate that inter
Alu PCR products must often span exon sequences and thus can be used as probes
to screen cDNA libraries, allowing the isolation of an expressed gene from a
specific chromosomal region (Klein et al., 1993). It has, however, been shown that
the majority of inter-Alu sequences are derived from within introns and 3'
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untranslated regions (Adams et al., 1991) hence this is unlikely to be a very useful
technique. Some exceptions do exist, for example the LDL-receptor gene where
Alu sequences were located in the nontranslated part of the last exon (Sildhof et
al., 1985). Analysis of this gene also shed light on the ability of Alu elements to
promote genomic rearangements. The gene contains Alu elements in most of its
17 introns, and eight out of nine rearrangements characterised at the sequence level
involve Alu elements. Further investigation led to the identification of a conserved
26bp core sequence which it was proposed could function as a recombinational
hotspot (Rtidiger et al., 1995). Thus, as well as helping in the identification of
candidate genes, Alu elements in a few cases may be responsible for the actual
defect. In the main, however, Alu-PCR has been used to increase the density of
markers for a specific region. The A rich extensions at the 3' end of Alu repeats
are potential VNTRs since it is thought that the majority may be polymorphic
(Charlieu et al., 1992). A significant proportion (6.7%) of these extensions consist
of microsatellites such as (CAA)n, (CAAAA)n, (TAA)n...in which polymorphisms
are easier to detect than in polyA runs (Economou et al., 1990). Thus if a
polymorphic marker is required for linkage analysis of a specific region it is
advisable to sequence the ends of any Alu repeats which map to that region.
1.1.5 Isolation and mapping of repeat free clones
A number of groups (Meese et al., 1992 , Bull et al., 1993) have carried out
regional assignment of Alu-PCR products using the primers and methodology
suggested by Brooks-Wilson et al (Brooks-Wilson et al., 1990). The primer used,
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Al, hybridises to the extreme 3' end of the consensus sequence and can therefore
be used to create probes that do not require preannealing. This primer, however,
produces fewer products than other primers located more internally in the Alu
consensus sequence, probably because it is unable to prime from the more anciently
inserted and hence sequence diverged Alu elements (Tagle et al., 1992). Thus to
produce the maximum number of products, more internally located primers must
be use. This, however, results in products which are flanked by Alu repeat
sequence and this has to be efficiently competed out before they can function as
unique or low copy probes. Frequently this has meant the use of rigorous
competition and stringent washing conditions, which often led to considerable
depletion of the amount of functional probe (Monaco et al., 1991). However,
methods have been devised which allow extensive competition of pooled Alu -PCR
products while minimising this depletion (Cole et al., 1992b). To function as
markers Alu-PCR products have to be mapped individually. Thus a method was
required which produced the maximum number of products and which involved the
least complicated hybridisation protocol. This was achieved by using a two stage
amplification procedure: first an internal primer (614) was used under conditions
which gave the maximum number of products; then a primer designed to hybridise
to the extreme 3' end (Alu 18) of the Alu consensus sequence was used to reamplify
these products, so the resultant products contained minimal Alu sequence and were
available at a high enough density to make them a useful mapping resource. The
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next important stage was to optimise the efficiency of cloning these products and
hence maintain the number and diversity of Alu-PCR products.
1.1.6 Cloning PCR products
PCR products are largely blunt ended, and the cloning of such DNA is often very
inefficient, resulting in a high background of non recombinants. Blunt-end cloning
is hampered by the addition of an extra nucleotide, almost exclusively dATP, to the
3' ends of PCR products by Taq polymerase (Clark 1988). This template
independent terminal transferase activity of Taq polymerase has been used to
advantage in the T-vector technique (Marchuk et al., 1991). Here the vector is
digested at a unique site using a blunt end cutter, Taq polymerase is then used to
add a single thymidine to the 3' ends of the linearised vector. Thus the single base
overhangs on the vector and PCR product are complementary and therefore can be
ligated efficiently. Another widely used approach, cohesive end cloning by virtue
of restriction sites intrinsic to or designed into the 5' regions of PCR products, is
inefficient and tends to generate a high background of non recombinants. Both
methods rely on T4 DNA ligase which under some conditions has been shown to
aberrantly cause frame-shift mutations in the vector during the cloning process
(Wu et al., 1989). This results in lacZa inactivation in the absence of an insert, and
consequently produces white colonies which are termed pseudorecombinants.
Thus a method which gave a higher cloning efficiency and lower background of
pseudorecombinants than those then available was desired. Initially a method for
ligation independent cloning of PCR products was devised. The efficiency of this
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method was compared to conventional cohesive end cloning, and an 'in-house'
method devised by Chris Boyd for the efficient cloning of blunt ended molecules
called 'turbo cloning' (Boyd 1993).
Ligation independent cloning (LIC) is a cloning method which both obviates the
need for T4 DNA ligase and increases the specificity of the cloning process. Such
a method has previously been successfully used by Aslanidis and deJong, although
they modified both vector and inter-Alu fragments by PCR amplification using
primers incorporating specially adapted ends (Aslanidis and Dejong 1990). No
pseudorecombinants produced by rearranged vector were observed. In the method
I used, the vector had already been modified, so a stock could be made in the
conventional manner alleviating the need for vector amplification. Both methods
rely on the creation of long single stranded tails at the end of Alu PCR products
and of the plasmid vector. This permits non-covalent bi-molecular associations via
base pairing, allowing circulization between two molecules in the absence of DNA
ligase. The vector ends are non-complementary, preventing self annealing, and
since linear molecules transform E.coli poorly, recombinant molecules can be
selected by transformation.
Turbo cloning is a method devised to efficiently clone blunt-ended DNA molecules
into plasmids (Boyd 1993). It is simple, rapid (1-2 hours), works with minute
amounts of insert, and shows lack of selectivity for small inserts. Essentially the
method uses any plasmid vector containing the 34 bp site-specific recombination
sequence lox and the cognate Cre recombinase system of bacteriophage PL Here
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a derivative of pBluescribe (Stratagene), pBSLox, was used. This vector permits
turbo cloning and retains the blue/white screen for recombinants. There are two
stages. Firstly, linear vector and fragment DNAs are ligated intermolecularly under
conditions of macromolecular crowding (15% polyethylene glycol 6000) which
accelerates blunt-end joining 1000 fold. Secondly, circular recombinant molecules
are efficiently excised from the ligation products by Cre recombinase acting on
pairs of lox sites within directly repeated vector molecules flanking insert DNA.
In addition to isolating and mapping new markers from chromosome 1 lq 12-13,
mutational analysis was carried out on a gene which was a candidate for Usher
syndrome IB. The olfactory marker protein gene had been mapped to the region
linked to the disorder by Kathryn Evans (Evans et al., 1993) using the somatic cell
hybrid panel previously described (section 1.1.1). The expression pattern of the
gene, and the fact that the mouse Omp gene mapped to the region linked to
Shaker-1, the putative mouse homologue of Usher syndrome type I, made it a
good candidate for the disorder. These factors and the disorder itself are explained
in more detail in the following sections.
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1.2 Usher syndrome
1.2.1 Historical background and clinical description of Usher syndrome
The disorder was named after C.H.Usher who recognised in 1914 that it an
autosomal recessively inherited condition (Usher 1914). Usher syndrome is
characterised by deafness and retinitis pigmentosa, which causes progressive night
blindness and peripheral vision loss, and is the sine qua non for diagnosis of this
disorder. Both hearing problems and retinitis pigmentosa are relatively common in
the general population (1 in 1000 and 1 in 5000 respectively), thus a certain
number of patients can be expected to have both by chance alone. Usher
syndrome, however, is a specific constellation of audiologic, vestibular, and
ophthalmic findings and can be clearly distinguished from other conditions. Usher
syndrome accounts for about 15-20% of patients with retinitis pigmentosa and
50% of patients with combined deafness and blindness (Rosenfield et al., 1994).
The prevalence of Usher syndrome in the general population is fairly constant. In
Colombia it is estimated at 3.2/100,000 (Tamayo et al., 1991). In Nordic countries
the frequency of Usher syndrome is 3-3.6/100,000 (Grpndahl 1987). In the United
States estimates are slightly higher at 4.4 per 100,000 (Boughman et al., 1983).
These figures are typical for an autosomal recessive single gene disorder. Usher
syndrome is clinically and genetically heterogeneous and several different subtypes
have been described. Subtypes are distinguished clinically by phenotypic
variabilities in auditory acuity and vestibular function as described later. First I will
discuss the phenotypic features associated with Usher syndrome.
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1.2.1.1 Sensorineural deafness and vestibular dysfunction
Hearing loss is the most common form of sensory impairment (Duyk et al., 1992).
About one in every 1000 children is bom with hearing impairment, and about half
of these are due to genetic factors (Steel and Brown 1994). The vast majority of
cases of severe or profound congenital deafness result from inner ear defects.
Other causes are middle ear defects and central auditory abnormalities. Late onset
hearing loss is also frequently due to genetic factors which presumably make the
ear more sensitive to environmental damage. Many different genes appear to be
involved in the development and function of the mammalian inner ear.
Abnormalities of the inner ear have been classified into three major groups:
morphogenetic defects, where gross structural deformities of the labyrinth result
from early developmental abnormalities; cochleo-saccular abnormalities, where the
primary defect is to the stria vascularis, a secretory epithelium on the lateral wall of
the cochlea duct that controls the composition of the endolymph in the lumen of
the duct; and neuroepithelial abnormalities, affecting the sensory epithelia of the
inner ear, which fail to complete maturation and subsequently degenerate (Steel
and Bock 1983).
In contrast to morphogenetic defects, cochleo-saccular abnormalities, and late-
onset hearing loss each of which have had a small proportion of genes responsible
for individual disorders identified (Steel and Brown 1994), none of the genes
resulting in neuroepithelial deafness have been identified. In the mouse, many
genes involved in neuroepithelial deafness have been localized, but none identified
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(Lyon and Searle, 1989). This type of pathology is usually autosomal recessive in
inheritance, and not part of an obvious syndrome. Thus the identification of the
responsible genes in humans becomes extremely difficult due to the heterogeneity
involved in neuroepithelial deafness and mouse models are used wherever possible.
Usher syndrome is one of the few examples of syndromic neurosensory deafness.
Recently some major advances have been made in the localisation of nonsyndromic
recessive deafness (Guilford et al., 1994) and of course Usher syndrome.
Neurosensory defects are likely to represent the major cause of heritable deafness
in humans (Steel and Brown 1994). Such defects result in structural and functional
abnormalities of the organ of Corti, which consists of neurosensory epithelium,
leading to progressive secondary sensory hair cell degeneration. The high
susceptibility of this organ to developmental abnormalities might be explained by
its particularly complex and precise arrangement of a variety of types of sensory
and supporting cells.
Another part of the inner ear is the vestibular apparatus, which comprises the three
semicircular canals, the sacculus, and the utriculus. Known also as the labyrinth, it
is a complex sense organ stimulated by gravity and rotational movements. It plays
an important role in postural activity, giving rise to impulses which reflexly adapt
the position of the trunk and limbs to that of the head and enables erect positioning
of the head and normal attitude of the body to be maintained. Impulses from the
vestibule also reach the cerebral cortex and subserve the recognition of the position
and movements of the head (Keele et al., 1993). Vestibular dysfunction is
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commonly associated with deafness. In mice vestibular abnormalities are manifest
as hyperactivity, head shaking and circling. Humans, in contrast, are able to use
other cues, such as well-developed proprioreceptors and stereoscopic vision to
maintain their balance (Steel 1991). Thus more complicated tests are required to
detect vestibular areflexia in humans.
1.2.1.2 Retinitis pigmentosa
Retinitis pigmentosa has a prevalence of 1 in 5000 in the United Kingdom and is a
significant cause of blindness in old age (Kajiwara et al„ 1994). Typically retinitis
pigmentosa (RP) causes progressive loss of the peripheral visual fields (tunnel
vision) and impaired vision under conditions of reduced illumination, generally
leading to complete blindness. This is due to the preferential devastation of rod
versus cone receptor cells (Heckenlively 1988). The primary defect in RP lies in
the rod photoreceptor; rod electroretinograms (ERGs), a measure of the electrical
activity of the photoreceptor cells, are invariably reduced or absent in patients with
RP (Humphries et al., 1994). Retinitis pigmentosa is genetically heterogeneous,
with most cases being due to autosomal dominant, autosomal recessive or X-linked
genes (Wright 1992). Already more than 60 molecular mutations are known to
cause RP and these result from mutations in four different genes (rhodopsin,
peripherin/RDS, the beta subunit of cyclic GMP phosphodiesterase, and the rod
cyclic GMP activated channel protein) (Goldberg 1994). A novel genetic
transmission pattern has also been identified in RP. Three families have been
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isolated in which RP is caused by mutations in the unlinked loci peripherin/RDS
and ROM1, indicating digenic inheritance (Kajiwara et al., 1994).
1.2.1.3 Mental retardation
A review of early reports of Usher syndrome (Hallgren 1959) suggests mental
retardation is a component of the disorder, subsequent investigations, however,
failed to confirm this association (Kimberling et al., 1991). Early diagnoses were
not based on standardised modern criteria, but on educational and social
performance. In addition, mental retardation was not a consistent feature of sibs
concordant for Usher syndrome, suggesting problems with diagnosis, or an unusual
association between the two. Vestibular dysfunction leads to a delay in motor
functions and this could have led to over diagnosis of mental retardation. MRI and
CAT scanning have, however, revealed cerebellar and cerebral abnormalities
supporting the hypothesis of a CNS effect of the Usher genes (Piazza et al.,1987,
Schaefer et al., 1991). Further study of this potential facet of the disorder is
required.
1.2.2 Clinical subtypes of Usher syndrome
In order to identify the affected loci it was important to reliably separate
individuals into subtypes. The difficulty in trying to do so has hampered genetic
linkage approaches. The fact that USH I and II were consistent within families
made it likely that they resulted from separate genetic entities. Miscategorisation
across clinical subtypes, which could well result from mutations at separate loci,
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could easily prevent identification of true linkage, hence a simple classification
scheme was adopted as outlined below (Kimberling et al., 1989).
1.2.2.1 Usher syndrome type I
Type I is clinically the most severe and also the most frequent subtype, accounting
for approximately 90% of Usher patients (Kimberling et al., 1991). It has been
described in a number of different populations (Acadian: Smith et al., 1992b;
Scandinavian: Hallgren 1959; U.S.: Boughman et al.,1983; Colombian: Tamayo et
al., 1991; Norwegian- Grqndahl and Mjpen 1986). It is characterised by profound
congenital hearing loss and vestibular dysfunction. The latter manifests clinically as
a delay in psychomotor development: babies cannot sit without support until
around 10 months (normal range 4-5 months), or begin walking before 27 months
(normal range 9-12 months). Common motor activities usually learnt later in
childhood such as running and cycling are also performed with some difficulty
(Smith et al., 1992b). Hearing aids are ineffective and speech is usually
unintelligible, so sign language is the normal form of communication
1.2.2.2 Usher syndrome type II
This is the second major type of Usher syndrome, and has also been described in a
number of different populations (Acadian: Smith et al., 1992; Scandinavian:
Hallgren 1959; U.S.: Boughman et al.,1983; Colombian: Tamayo et al., 1991;
Norwegian: Grpndahl and Mjpen 1986). Estimates of the frequency of USH2
vary, but it is probably around 10% of the total (Kimberling et al., 1991). Here
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individuals have mild hearing loss in the lower frequencies sloping to a profound
loss in the higher frequencies and normal vestibular function.
Studies have shown that although Types I and II cannot strictly be distinguished by
the age of onset of retinitis pigmentosa or its rate of progression, although a
general pattern is observed. Usher type I individuals have an earlier onset of retinal
degeneration, in childhood or early adolescence, and more rapid progression, while
Usher type II individuals have an onset in adolescence or early adulthood, and
slower progression.
1.2.2.3 Usher syndrome type III
This is a much less frequent subtype representing only 2% of all Usher syndrome
affected individuals. It is defined by a congenital or early onset progressive hearing
loss that leads to profound deafness. Like the other two subtypes it appears to be
mainly found in a particular region: several cases have been reported in studies of
Nordic countries (Grpndahl and Mjpen 1986). A few other isolated cases have
been identified in other populations (Smith et al., 1992b). A recent study showed
that almost 20% of Usher patients in Eastern Finland have USH3, including a
number of affected sib pairs (Sankila et al., 1993). A founder effect may explain
why this subtype is higher in this particular population. Grpndahl and Mjpen
(1986) also proposed that it may be impossible to differentiate between type 2 and
3 without comparing audioradiograms for a series of years, or having data available
for other family members. They felt that some studies were carried out over too
short a period of time to detect progressive deafness.
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1.2.2.4 Usher syndrome type IV
This type is clinically similar to type II, but with X linked inheritance. The
classification exists, but no convincing evidence for an X-linked inheritance pattern
has so far been shown, in this potentially extremely rare subtype (Kimberling et al.,
1989).
1.2.3 Carriers ofUsher syndrome
Electrooculographic (EOG) studies of carriers with tapetoretinal dystrophies which
had been matched for sex and age with normal controls revealed that for some
dystrophies an abnormal EOG may indicate a carrier state (Pinkers et al., 1994).
EOG is a non-invasive method of assessing the function of the retinal pigmented
epithelium. Results were statistically significant for type I and II, although more
pronounced for type II. Overall a subnormal EOG Lp/Dt ratio (light peak and
dark trough- these measure the adaptation of the eye to light and dark) was present
in 30% of the carriers.
Even if carriers could be identified the overall risk of a child being born with Usher
syndrome is so small that a screening programme would be hard to justify. In the
US there is estimated to be 1 carrier per 100 inhabitants so that the chance that
both parents carry the mutated gene is 1/10,000, and the risk of producing an
affected child (25%) is then 1/40,000. By the time an affected child is diagnosed
most couples will have completed their families, and even unaffected sibs of the
affected individual have a very low chance of themselves producing an affected
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child. The problems with an autosomal recessive disorder like Usher syndrome
come to the fore in a consanguineous population.
Normally consanguinity occurs for religious and geopolitical reasons. In such a
reproductively isolated population, a large number of individuals affected with
what is normally a relatively rare disorder, indicating the presence of a recessive
deleterious allele, can result from the marriage of normal but not distantly related
parents (Bonnd-Tamir et al„ 1994). This is because when one marries "within the
family", for example, a cousin marriage, the probability that the individual and
his/her cousin carries the same specific rare gene (and that their child be
homozygous) is much higher than if the marriage is "outside the family" (Bittles
and Neel 1994). Studies have shown that consanguinity is higher among parents of
deaf children than in parents of their normal hearing counterparts (Reardon 1992).
In a normal population the preference of a deaf individual for a deaf partner may
inadvertently increase the risk of a particular deafness disorder. The risks here,
however, are potentially less than in a consanguineous population due to the many
different causes of genetic deafness and the fact that half the cases of deafness
cannot yet be linked to a genetic cause. Perhaps understandably the deaf are often
hostile to the proposition of genetic counselling to prevent them having deaf
children (Reardon 1992).
The point at which most help can be given is in the early diagnosis of Usher
syndrome. With intact vision, deaf individuals can lead a relatively normal life.
However, with visual loss their ability to cope is severely restricted. Timely
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identification of affected individuals (e.g. by screening children attending speech
and hearing clinics and schools for the deaf) will result in their placement in the
proper rehabilitative programme to allow them to acquire skills to prepare for the
ensuing loss of vision (Samuelson and Zhan 1990).
Hope also comes from the fact that it is now possible to implant a normal cochlea
in USH1 affected children. Initial studies have shown that Usher's patients
required very little extra effort in rehabilitation compared to other prelingually deaf
patients, and all patients reported considerable advantages in hearing abilities and
social life (Hinderink et al„ 1994).
1.2.4 Genetic subtypes of Usher Syndrome
1.2.4.1 Genetic heterogeneity
The higher frequency of types 1 and 2, and hence greater availability of families,
has meant that gene mapping of the Usher syndromes has concentrated on these
two clinical subtypes. The differences in phenotype which are consistent within
individual families pointed to heterogeneity. It could not be ruled out, however,
that the subtypes themselves could result from mutations in a number of genes.
Individuals affected by Charcot-Marie-Tooth type I disease (CMT-I), a common
form of genetic neuropathy with slow neural conduction, phenotypically gave no
indication that they were in fact the result of mutations of more than two genes.
Genetic linkage analysis has however indicated that mutations at a locus on the X
chromosome and at least three different autosomal recessive loci can result in
CMT-I (Chance et al., 1990). Herein lies the problem with autosomal recessive
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disorders. Because each family is unlikely to have more than one or two affected
individuals, pooling of data across families is necessary to establish statistical
evidence for linkage to a marker. If the disorder is heterogeneous then different
families will show linkage to different markers and the end results could be
inconclusive. The inability to say with certainty that all families included in a
linkage study have mutations at the same locus being analysed means that families
showing critical crossovers cannot be accepted with total confidence. The problem
can be circumvented by using data from large consanguineous pedigrees, but these
are seldom available. Alternatively, as was the case in USH2, as large a sample
size as possible can be used in the hope that the likelihood distribution calculated
would be less sensitive to effects of heterogeneity (Kimberling et al„ 1995). The
results of linkage studies to date are given below. Six different genetic loci have
been linked to Usher syndrome- one coding for Usher Type III, two coding for
Usher Type II, and three coding for Usher Type I.
1.2.4.2 Usher Syndrome Type II
The mapping of Usher syndrome type II to chromosome lq in 1990 (Kimberling et
al., 1990) was a significant breakthrough. USH II was the first autosomal
recessive form of retinitis pigmentosa to be localized, as well as being the first
autosomal recessive gene causing deafness. Informative members from 8 type II
families were typed for three loci previously mapped to chromosome 1. A
maximum pairwise LOD score of 6.04 was obtained for the marker THH33
(D1S81), which placed the gene in the distal one third of the long arm of
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chromosome 1. Similar analysis of Type I families showed no linkage to any of the
three loci. Lewis et al (1990) confirmed the assignment of USH2 to Iq32-q44, and
provided further support for heterogeneity of USH1 and 2 (USH1 families again
failed to show linkage), using different families. This demonstrated that the
observed clinical heterogeneity of Usher syndrome is due to the effects of
mutations in two or more separate and distinct loci. Using additional markers from
the lq32-lqter region the map location of USH II was further refined in the
original families by Kimberling et al. Significant linkage was observed with the
marker D1S48 and the favoured order was USH2-D1S81-D1S48, although this
may have been biased by the low level of heterozygosity of surrounding markers
and the fact that more information was gained from D1S81 than D1S48 (Weston et
al., 1991). Efforts to isolate and clone the gene were complicated when typing and
linkage analysis of an USH2 family failed to show linkage to markers from lq32-
44 (including D1S81) suggesting a second different gene was affected in this family
(Pieke Dahl et al., 1991, 1993). The locus at Iq32-q44 has been termed USH2A
and the new unlinked locus designated USH2B. There was no obvious clinical
distinction between this new family and previous families, but clearly it would be
useful if some differences could be defined.
There are two main approaches to take when a disorder has been mapped to a
specific chromosomal region, either a) mutational analysis of an appropriately
expressed gene which has previously been mapped to the region (the candidate
gene approach) or b) in the absence of any suitable candidates, refine the linkage
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analysis to cover as small a region as possible then look for genes located in this
region which would make suitable candidates (the positional cloning approach).
Two genes, phosducin and hCHML, which mapped to the appropriate region made
suitable candidates for USH2
The gene for human phosducin was mapped to Iq25-q31.1 (Ding et al., 1993).
Phosducin is known to have a role in regulating phototransduction in retinal rod
cells and is abundantly expressed in the retina and the brain. These two facts made
it a good candidate for Usher syndrome type II. The gene is 18kb in length, has
four exons and three introns (Abe et al., 1994). Denaturing gradient gel
electrophoresis was carried out on PCR amplified exons from Usher patients which
had shown linkage to D1S81 (Ara et al., 1992). No mutations in the gene causing
an amino acid change were found, but two polymorphisms were identified which in
combination produced a specific haplotype (Ara et al., 1993). The frequency of
the polymorphisms was different between individuals affected by USH2 and
autosomal dominant retinitis pigmentosa, as compared to controls, suggesting that
a gene involved in these two disorders was located in the vicinity of the phosducin
gene.
Choroideremia is an X-linked disorder characterised by progressive dystrophy of
the choroid, retinal pigment epithelium and retina. The gene responsible for this
disorder has been identified (hCHM), and in the process of analysing this gene a
new gene showing a high degree of homology to hCHM was identified (Cremers et
al., 1992). This new gene was called hCHML (choroideremia-like) and although
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the deduced amino acid sequence showed 95% similarity to hCHM, hCHML
contained no introns. This suggested that hCHML had originated by reverse
transcription of hCHM mRNA and subsequent integration into the genome.
Analysis of somatic cell hybrids allowed the assignment of hCHML to
chromosome lq31-qter. This chromosomal localisation and the phenotypic
similarities between choroideremia and USH2 made hCHML another good
candidate for this disorder. The DNA of USH2 patients was analysed by
polymerase chain reaction single-strand conformation polymorphism analysis and
direct sequencing (van Bokhoven et al., 1994). No mutations were detected.
Thus it would appear that we have gone from two potential candidates to none. It
is worth considering however the reliability of the methodology used to identify
mutations and extent of each gene which was actually analysed. DGGE is highly
reliable and able to identify 95% of mutations. SSCP is less reliable and the
conditions used to analyse CHML would miss 20% of all possible mutations. It is
also important to note that neither the 5' nor the 3' untranslated regions, which
could contain important regulatory sequences, were analysed. Similarly the introns
in the phosducin gene were not screened for mutations. The formal exclusion of
both genes therefore awaits either more complete mutation analysis; detailed RNA
and protein analysis from B-cell lines of patients; more detailed linkage analysis; or
of course, the identification and confirmation of a new candidate gene.
Recently more detailed linkage analysis has placed the USH2A gene into a 2.1-cM
region between the markers D1S237 and D1S229 on chromosome lq41
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(Kimberling et al., 1995). This localisation rules out phosducin as a candidate,
since it was mapped to Iq25-q31.1. Linkage analysis was carried out on a large
sample of 68 informative families in order to reduce the effects of locus
heterogeneity: approximately 12.5% of the families studied were estimated to be
unlinked to lq41. Cytogenetic analysis of a member from each of 38 families failed
to identify any deletions, inversions or translocations. No suitable candidates have
been shown to lie within the linked region, hence work has been initiated to
construct a YAC contig and physically map the region.
1.2.4.3 Usher Syndrome Type III
It was Sankila et al (1993) who observed an increase in the prevalence of USH3 in
Finland. The most recent studies by this group have shown that this proposed
enrichment of the USH3 gene is even higher than at first anticipated (Sankila et al.,
1995), and may be as much as 42%. Sankila et al excluded the four regions
previously linked to Usher Syndrome (Sankila et al in preparation), then carried
out a systematic search by genetic linkage analysis in 10 multiple affected Finnish
families using polymorphic microsatellite markers. This led to the assignment of
USH3 to the 5-cM interval between the markers D3S1555 and D3S1279 in 3q21-
25. This confirms the existence of Usher Syndrome Type in as a distinct entity. A
number of eye-related genes have been mapped to 3q21-25 (rhodopsin (RHO) in
q21-24, cellular retinol binding protein 1 (CRBP1) in q21-22, and CRBP2 in 3pl 1-
qter - Naylor et al., 1995), but further refinement of the region is necessary before
candidates can be confidently identified.
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1.2.4.4 Usher Syndrome Type I
There was strong evidence that the clinical heterogeneity in Usher syndrome was
due to genetic heterogeneity (Kimberling, et al., 1990, Lewis et al., 1990), and
although no alternative location for USH1 was suggested, lq was excluded since
USH1 families failed to show any linkage to markers from this region (Weston et
al., 1991). The first evidence of linkage to USH1 came from Kaplan et al in 1992
when they showed linkage of 10 out of 15 families to the marker WLJ14
(DS14S13) at chromosome 14q32 (USH1A). Notably 8 of the 10 linked families
came from the Poitou-Charentes region in Western France, suggesting a founder
effect. There were no obvious candidate genes in the linked region, although a
mouse gene controlling heart position has been mapped to the region homologous
to human 14q32. This is termed the iv locus, which lies 3-cM from the
immunoglobulin heavy-chain constant-region complex (Igh-C) on distal
chromosome 12 (Brueckner et al., 1989). Normal ciliary function during foetal
development is required for the asymmetric left-right position of heart and viscera
in higher vertebrates which links in with the fact that the proposed defect affecting
the 3 different sensory systems in USH1 individuals is a congenital abnormality of
the cilia (see later). Thus a cluster of genes on 14q involved in ciliary motility has
been proposed (Kaplan et al., 1992). This proposition is strengthened by reports of
two independent cases of Kartagener syndrome (abnormal heart position and
deficient ciliary function in respiratory epithelium and sperm) in association with
retinitis pigmentosa and deaf-mutism (Lake and Sharma 1973).
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In the meantime, extensive linkage analysis (Keats et al., 1992) using affected
individuals from 36 families from the United States, England and Sweden, and 206
markers allowed the exclusion of 39% of the genome. No linkage was observed to
14q32 indicating that there were at least two loci responsible for USH1. The next
major breakthrough came when Smith et al (1992a) localised two regions linked to
USH1 to chromosome 11. The analysis was carried out on British and French-
Acadian families, and demonstrated further locus heterogeneity. Each was linked
to a separate marker and both failed to show linkage to the region linked to the
other geographically defined family set. The French-Acadian families gave a
maximum LOD score with the locus D11S419 which had been localised to 1 lp 15-
pl3 (USH1C). The British families, on the other hand, gave a maximum LOD
score for the locus D11S527, which had been localized to llql3.5 (USH1B). The
most common Usher Type I mutation is that found at the llql3.5 locus
(Kimberling et al., 1995).
The localisation of the Acadian Usher syndrome type I locus (USH1C) was further
refined to a 2-3cM interval in the pl5.5-pl4 region of chromosome 11 by Nouri et
al in 1994. The results obtained showed evidence for a founder effect. No
recombination events were found between USH1C and three microsatellite
markers (D11S419, D11S921, and D11S899), and all of the 54 chromosomes with
the abnormal allele at the disease locus had a specific haplotype for
D11S419/D11S921. The Acadians are the descendants of French immigrants who
colonized the Canadian territory known as Acadia (now Nova Scotia and
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surrounding areas) in 1604. After being expelled by the British in 1775, many
Acadians made their way to Louisiana. They settled on the plains among the
Bayous and remained relatively isolated because of linguistic, religious, and
cultural cohesiveness, as well as geographic isolation. Thus, a strong founder
effect would be anticipated. No obvious candidate genes are known to map to the
region delineated by this study. Recently, however, a possible mouse model for
USH1C has been identified (Heckenlively et al., 1994). The tub/tub strain of mice
were determined to have progressive retinitis pigmentosa and deafness. Crossing
with known types of retinal degeneration showed that the tub/tub strain had a
unique retinal degeneration and mapping indicated linkage between Hbb and tub on
mouse chromosome 7. This region is syntenic to human 1 lp 15, making the mouse
strain a good candidate for the human Acadian Usher homologue.
1.2.5 Ciliary defect
I have already hinted at the possible involvement of a ciliary defect in Usher
syndrome. There are a number of characteristic defects observed in Usher
syndrome affected individuals which led to this theory, which I will now discuss. I
will then explain how the olfactory marker protein through its expression in
olfactory cilia and its map position in mouse and man became a candidate for
USH1B.
The presence of a congenital abnormality of the cilia in Usher syndrome affected
individuals could explain how a single gene defect could affect three different
sensory systems. This is because photoreceptors, auditory hair cells, and vestibular
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hair cells all develop from ciliated progenitors. In addition, primary ciliary
dyskinesia due to generalised abnormality of the axoneme structure could account
for the non progressive nature of the hearing loss, since axonemes are present in
auditory hair cells only during their development (Kaplan et al.,1992).
Several lines of evidence indicate that such a generalised abnormality of the
axoneme structure has occurred in the cilia of Usher syndrome affected individuals.
Many of the studies to date have concentrated on nasal cilia and sperm, which are
more accessible sources of human material then the inner ear and the eye, in order
to study the basic pathological process. Arden and Fox (1979) found an increased
incidence of abnormal ultrastructure of axonemes in nasal cilia. Difficulties in
biopsying photoreceptors has also led to the study of sperm in Usher syndrome
affected males. It is possible to assess the functional capabilities and three-
dimensional structure of cilia in sperm. Hence, Hunter et al (1986) were able to
demonstrate that as well as the presence of a number of sperm tail abnormalities,
both sperm motility and velocity were decreased in the patient group. Electron
microscopic examination revealed abnormal axonemes in not only the sperm, but
also the photoreceptors of these patients. Further evidence for the presence of
abnormal photoreceptors came from Berson and Adamian's (1992) study of the
eye of an USHII affected individual, which led them to conclude that the majority
of the connecting cilia of the photoreceptors were abnormal. In an attempt to
explain the progressive nature of the Retinitis Pigmentosa they proposed that
abnormalities in the cilia might affect the microtubule membrane crosslinker
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leading to impairment of the process of outer segment renewal. Alternatively,
disruption of the pattern of microtubule doublets could be preventing actin from
carrying out its essential role in the process of outer segment renewal. Transport
of soluble proteins such as arrestin from the inner to outer segment may also be
disrupted due to abnormalities in the structure of the cilia and therefore affect
photoreceptor function and viability. The connecting (sensory) cilium of rods and
cones is the stalk that separates the outer segment that contains visual pigment in
stacks of membrane discs from the inner segment that contains cytoplasmic
organelles involved in protein synthesis. Morphological defects in the connecting
cilia in photoreceptors belonging to an USH2 affected individual were also
observed by Barrong et al (1992).
Shinkawa and Nadol (1986) were able to carry out a histological examination of
the inner ear of an USH3 affected patient. They observed significant primary
neuronal degeneration throughout the cochlea, leading to a decrease in outer ciliary
cells. This finding was supported by earlier work by Buch and Jorgenson (1963)
who also observed cochlear degeneration, but this time in USHI affected
indviduals. The most recent evidence for a generalised abnormality of cilia in
patients with Usher syndrome came from Bonneau et al (1993) who observed
bronchiectasis, chronic sinusitis, and reduced nasal mucociliary clearance in two
USHI affected sibs.
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1.2.6 Olfactory marker protein as a candidate
1.2.6.1 Olfaction
The sense of smell arises from stimulation of receptors in the olfactory mucosa.
The olfactory mucosa is above the main respiratory stream and sniffing is often
required to stimulate receptors. In man the olfactory mucosa contains about 10-20
million special sensory cells each of which is a bipolar neuron (Keele et al., 1983).
The receptor cells lie between supporting cells and their dendrites extend as naked
rods which end in fine cilia (6-12 to each rod) which lie in the mucus covering the
olfactory mucosa. The supporting cells end in microvilli which secrete mucus.
The axons from the olfactory receptor cells are fme unmyelinated fibres, which run
in bundles or fascicles containing 20-100 fibres; each fascicle is enclosed in one
mesaxon or Schwann cell process. The fascicles run together in the fila olfactoria
which pierce the cribriform plate and enter the olfactory bulb. Within the outer
layers of the bulb the axons of the olfactory nerves enter the glomeruli and these
form synapses with dendrites from mitral and tufted cells. The latter forming the
second-order neurons on the olfactory pathway. Olfactory neurons are unusual in
that they are continually replaced throughout adult life. Neurons lost as a result of
normal neuronal turnover in mature animals or in response to experimentally
induced chemical or surgical insult, are replaced by stem cells which are part of the




In many cells e.g. those lining respiratory epithelium the major function of cilia is
concentrated in the cytoskeletal core, and cilia appear as motile cellular elements.
Olfactory cilia are much more highly specialized and have acquired a secondary
function whereby a key role is played by the enclosing lipid bilayer and the
axoneme becomes an inert scaffold. This modification of ciliary function and
structure has also occurred in other sensory cells i.e. the development of the
elaborate membraneous disc structures of retinal rod outer segments. The cilia of
both olfactory and visual sensory cells appear to have evolved to give increased














Figure 1A Olfactory and visual sensory cells
Schematic representation of the structures involved in transmission of sensory
signals in the peripheral olfactory and visual sensory systems, drawn
approximately to scale. In both, transduction occurs in modified ciliary structures,






1.2.6.3 Odorant induced signal transduction
In the predominant model of the initial events underlying odorant-induced signal
transduction the initial event is when odorants bind to receptors on the surface of
the cilia that emanate from the extended dendritic process of olfactory neurons.
This then activates either one or both of the second messenger pathways in the cilia
where either; a) G proteins are activated to interact with membrane bound adenylyl
cyclase, resulting in an increase in cAMP which opens a cyclic nucleotide
responsive cation channel, depolarizes the cell and initiates an action potential; or
b) binding causes the generation of inositol 1,4,5-triphosphate (IP3) which leads to
the activation of an IP3 receptor-channel complex in the cilial membrane. Thus the
large family of receptor molecules seems to rely on just two secondary messenger
systems emphasizing how much the olfactory sensory neuron has evolved to deal
with a multitude of diverse ligands while using the components of a simple
transduction cascade (Cunningham and Reed 1992). Having outlined the major
features of the olfactory system and olfactory cilia, it is necessary now to look at
the expression pattern and putative function of OMP to see why it became a
candidate for Usher syndrome Type IB.
1.2.6.4 Olfactory markerprotein
Olfactory marker protein (OMP) was originally observed as a band on acrylamide
gel electrophoresis of native mouse olfactory tissue cytoplasmic extracts. The
protein was subsequently purified and characterised from both mouse and rat
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olfactory tissue, and specific antibodies prepared. OMP has a molecular mass of
19,000Da and an isoelectric point of approximately 5. Purified OMP protein
contains no carbohydrate, or the amino acid cysteine. It represents about 0.1-1%
of the olfactory tissue cytoplasmic protein, and antisera directed against rat OMP
has been shown to cross react with extracts from olfactory epithelium of many
species including humans. In common with other cytoplasmic proteins the amino
terminus of OMP is acetylated. No homology has been shown between OMP and
any other proteins in the database, and there is no evidence of it exhibiting any
common enzymatic activity, suggesting that it plays a unique role in olfactory
neuron function (Margolis 1988).
How does olfactory marker protein fit in with the overall picture of odorant-
induced signal transduction? In rats immunohistochemistry has been used to show
that OMP is restricted to olfactory neurons. It is present in the cytoplasm of the
cell body, the peripherally directed dendritic knob, in the proximal portion of the
cilia, as well as in the axon and synaptic terminals in the olfactory bulb. It is not
expressed in any other cell type in the olfactory mucosa and disappears at the
boundary between the olfactory and respiratory mucosa. OMP is synthesised in
the mature olfactory receptor perikaryon from which it is transported to the entire
cytoplasmic compartment of the neuron in association with the slow component of
axoplasmic flow. OMP turnover has a biphasic half-life with a rapid component of
about a day and slower component of about a week. Since OMP is absent from
the neural precursor basal cells in the olfactory neuroepithelium, it has been used as
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a marker for the mature, functioning receptor cells whose axons comprise the first
cranial nerve. In rodents, expression of OMP has also been observed in olfactory
neurons of the vomeronasal organ (Farbman and Margolis 1980). Less OMP
expression is observed in the vomeronasal organ than in cells of the nasal cavity;
the major morphological difference between olfactory receptor cells from the two
sites is the absence of cilia in the cells of the vomeronasal organ. This indicates
that OMP may be involved in sensory transduction in the cilia, although it could
also be involved in a more basic function in this specific cell type.
Expression of OMP is first observed in olfactory neurons early in the last trimester
of gestation at about the time when innervation of the olfactory bulb begins. In the
mouse, expression of OMP in receptor cells is observed one day after
synaptogenesis, and evidence in rodents is consistent with the theory that
formation of a synapse induces receptor cells to synthesize OMP. In humans,
however, OMP is not synthesized until approximately two months after
synaptogenesis has occurred (Meng and Zheng 1992). Another difference between
humans and rodents is that unlike the latter, where OMP expression is seen as an
indication of mature olfactory neurons, human OMP is found in selected groups of
cells of various ages and more likely serves as an indicator of the metabolic state of
the cell.
The function of OMP remains unknown although study of its expression
throughout vertebrate classes could led to fundamental insights regarding its role,
as indicated above. In addition, identification of OMP expression in amphibians,
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which are extensively utilised as a model system for innovative studies of sensory
transduction in isolated olfactory cell preparations, could be very useful. Thus the
demonstration of OMP expression in olfactory receptor neurons of frogs and
salamanders was seen as a major breakthrough (Krishna et al., 1992). The
distribution of OMP in olfactory receptor neurons of amphibians is characteristic of
that already reported in mammalian species. The presence of OMP in the primary
olfactory system of a wide variety of species that range from fish to human
(Margolis 1988), and the phylogenetic conservation of cellular localization to
olfactory receptor neurons strongly supports the supposition that this protein plays
an important role in the function of ORNs. The evidence presented so far indicates
that OMP is selectively expressed in olfactory receptor cells, but no olfactory
defects have been observed in Usher syndrome patients. There is however
immunohistochemical evidence for low levels of OMP in discrete neurons in the
cerebellum, hypothalamus, and spinal cord of rat and hamster, indicating that OMP
might be a more ubiquitously distributed neural protein (Baker et al.,1989). This
supports the hypothesis of a CNS effect of the Usher genes due to the observed
cerebellar and cerebral abnormalities (Piazza et al.,1987, Schaefer et al., 1991).
Equally as important as the ability to observe the expression of OMP in its normal
cellular context is the ability to manipulate the expression of OMP both temporally
and spacially. Thus it became essential to clone and characterise the mRNA and
gene for OMP in order to determine how expression of the gene was controlled.
This was done initially in the rat. Rogers et al (1987) isolated a very large
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polyadenylated mRNA and were able to show that the primary translation product
was indistinguishable from OMP isolated from olfactory tissues. The isolated
mRNA and resultant cDNA allowed confirmation of the amino acid sequence of
the protein, and showed the gene to be composed of a 486 nucleotide coding
region followed by 1630 nucleotides of the 3' untranslated region. The absence of
the initiator codon and the cap site from the cDNA indicated that a portion of the
5' noncoding region was missing from the cDNA, although the presence of a
poly(A) tail suggested that the cDNA insert was complete at the 3' end. Danciger
et al (1989) then isolated a phage clone containing the whole gene including the 5'
untranslated region. They were able to show that the coding region was colinear
to that previously observed by Rogers in the cDNA clone, indicating that OMP is
intronless. The gene lacked both CAAT and TATA boxes in the flanking region.
These features are normally characteristic of a pseudogene so it was necessary to
prove that the isolated gene was capable of being expressed. This was done by
making an llkb chimeric gene where the coding region was replaced by Thy 1.1.
Immunohistochemical localisation of THY 1.1 transgenic mice showed the
expression of the chimeric gene to be restricted to olfactory receptor neurons and
their axons, consistent with the presence of regulatory sequences controlling the
olfactory specific expression of the OMP gene. The position had now been
reached where it was possible to identify the minimal sequence information
necessary to achieve biological specificity of OMP expression and determine the
method by which this is achieved.
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The rodent OMP promoter was analysed by electrophoretic mobility shift assay
(EMSA). Here radiolabeled OMP gene DNA fragments were incubated with
nuclear protein extracts and the extent of gel retardation in the presence and
absence of inhibitors assessed. DNasel footprinting was also carried out.
Together these methods allowed the identification of two elements that interact
with an olfactory neuron specific factor(s) (Kudrycki et al., 1993) and an additional
region (upstream binding element-UBE) involved in binding of nuclear proteins in
extracts from all tissues tested. The former two elements were shown to be
located approximately 0.5Kb apart and share a common motif that binds the novel
olfactory neuron specific factor Olf-1 (Kudrycki et al., 1993). A cDNA clone
encoding the Olf-1 binding activity has recently been identified by genetic selection
in yeast (Wang and Reed 1993). The deduced amino acid sequence of Olf-1 is
predicted to contain two helical repeats with similarity to the helix-loop-helix class
of transcription factors, and may represent the first identified member of a novel
subclass containing this protein motif. Danciger et al identified two transcription
initiation sites at 55 and 58bp upstream of the ATG and using this information
Kudrycki et al (1993) designed an OMP-ZacZ transgene, where the lacZ gene was
under the control of a fragment of the rat OMP gene spanning nucleotides -239 to
+55 (here 0 was the transcription start point and hence +55 marked the translation
initiation codon). This fragment included the proximal Olf-1 binding site and was
sufficient to confer olfactory tissue specific expression of a reporter gene in
transgenic mice (Grillo et al., 1992; Servenius et al., 1994).
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1.2.6.5 A mouse model for Usher syndrome Type IB
Mice have been called the experimental surrogate of humans. The physiological
similarities between mouse and man mean that mutations in a mouse gene affecting
a specific biological process such as hearing may either give insights into
development and function of the ear or serve as candidates for specific human
hearing disorders (Nadeau et al., 1991). Support that human and mouse disorders
which are physiologically similar may result from mutations in a homologous gene
can also be gained on the genetic level. Comparative mapping has demonstrated
that loci that are closely linked in one species tend to be closely linked in the other,
whereas loci that are loosely linked in one species tend to be unlinked in the other
(Lalley et al., 1978). These linked loci therefore mark homologous chromosomal
segments, also known as syntenic groups of genes, and have been used to identify
candidate homologues between mouse mutations and human hereditary hearing
disorders (Nadeau et al., 1991).
These similarities between mouse and man are particularly advantageous when it
comes to hearing disorders. Analysis of the development of the human inner ear is
not possible in humans, and temporal bone specimens on the rare occasions when
they are obtained have undergone further degeneration due to environmental
factors such as noise and drugs, over and above the initial genetic defect (Steel
1991). Most functional development of the ear occurs postnatally making it
relatively easy to draw conclusions about normal auditory function by observing
defects in the mouse (Steel and Harvey). The normal structure of the human and
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mouse ear differ in only a few minor features, even the structure of the highly
complex organ of Corti is preserved. Thus it is likely that there will be a similar
array of genes controlling its development in the two species. Cloning genes for
deafness, even autosomal recessive deafness, is a realisable goal in mice because
large mouse backcrosses can be constructed that are known to carry the same
mutation and that give a high density of recombination breakpoints around the
gene of interest. Indeed several groups have assembled large backcrosses of
selected mouse strains to facilitate high-resolution gene mapping. For example the
European Backcross Consortium has a mapping panel of 1000 mice typed for 78
anchor loci, which provides an informative panel of recombinants.
One of the many mouse mutations implicated in hearing impairment is shaker-1
(sh-1), a spontaneous mutation which has a characteristic phenotype consisting of
sensorineural deafness, hyperactivity, head shaking, and circling (Lord and Gates
1929). These behavioural abnormalities are attributed to vestibular dysfunction
because of associated structural anomalies in the vestibular part of the labyrinth
(Steel 1991). Considerable electrophysiological research has been carried out to
characterise the nature of the deafness in sh-1 mice and this implicated either the
inner hair cells or their innervation as the primary site of the lesion (Steel and
Harvey 1992).
The mutation is autosomal recessive and shows complete penetrance. This
disorder was localised to the distal region of mouse chromosome 7 (Lyon and
Searle 1989) where it is flanked proximally by the gene tyrosinase (Tyr at the c
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locus) and distally by the gene for (3-globin (Hbb). This mapping result was
fortuitous, since the locus c is a well-known coat-colour locus, 'null' mutations at
which produce albino (or chinchilla etc.) mice. The fact that it is a visible marker
led to the c locus being used in specific locus mutation-rate experiments and as a
result a large number of mutations were induced at this locus (Doolittle et al.,
1990). Many of these mutations were chromosomal deletions of varying lengths
that affected neighbouring genes in addition to the primary selected locus and as
such facilitated mapping of other mutations, in this case sh-1, linked to this region.
Thus Rinchik et al (1991) were able to localise the sh-1 locus within the albino (c)
deletion complex by looking for deletions which could elicit pseudodominance
over sh-1 i.e. crossing mice heterozygous for the lethal albino deletions to sh-1
homozygous mice resulted in animals exhibiting the sh-1 phenotype hence the
deletion must include the sh-1 locus. The proximal border of the sh-1 interval was
refined by the mapping of an N-ethyl-N-nitrosurea (ENU) induced lethal mutation
within the deletion complex. In addition, two loci defined by molecular clones,
Omp and D70R1 (an anonymous clone) were mapped to the distal region of non
overlap. An intraspecific backcross segregating for the sh-1 mutation
[(C57BLV10+/+ x sh-l/sh-1) x (sh-l/sh-1)] was then set up and yielded a total of
1066 progeny mice, 67 of which were identified as recombinant in the vicinity of
the sh-1 mutation (Brown et al., 1992). This panel was then used to generate a
detailed genetic map of the region and identify markers closely linked to the sh-1
locus. Thus only one recombinant was identified between Omp and the sh-1 locus.
61
Therefore the two loci were separated by a genetic distance of O.lcM which in the
mouse genome represents an approximate physical distance of 200kb. Subsequent
genetic mapping of a number of other genetic markers through the recombinant
panel indicated that the Omp/sh-1 recombinant mouse had been mis-scored
(Brown,K.A.,Steel,K.P., and Brown,S.D.M., unpublished data).
At this point the OMP gene was mapped in humans (Evans et al., 1993) to
llql3.5, identifying a new region of homology between mouse chromosome 7 and
human 11. The gene was mapped using a subfragment of a human cosmid, which
encompassed the OMP gene, as a hybridisation probe on a somatic cell hybrid
panel carrying various portions of chromosome 11. This allowed the gene to be
placed on the long arm of chromosome 11 centromeric to TYR. This position was
further refined using fluorescently labelled cosmid as an in situ hybridisation probe
on banded human metaphase chromosomes. Hence human OMP was mapped to
the region linked to Usher syndrome type lb. The similarities in the mode of
inheritance, penetrance, and the basic pathology between Usher syndrome and sh-1
led to the conclusion that the two disorders may be homologous. Retinitis
pigmentosa had not been observed in sh-1 mice, but examples do exist where
mutations in homologous genes result in similar but not identical phenotypes in
mouse and man. Mutations in the human PAX3 gene causes varying degrees of
deafness in association with dystopia canthorum and variable degrees of
pigmentary disturbance. In contrast, mutations in the homologous mouse gene
Pax-3, which is located in a region syntenic to that wherein the human gene is
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located, cause pigmentary anomalies, cranofacial abnormalities, but no auditory
defects (Steel and Smith 1992). It was proposed that the difference in phenotype
may be due to different parts of the gene being mutated, or variations in modifying
influences yet to be identified. In the same manner, therefore, USH1B and sh-1
could be true homologues, and result from mutations in the olfactory marker
protein gene. Thus the comparative mapping results and the observed ciliary
defects in USH1B patients made the OMP gene a strong candidate for both
disorders.
The possibility that mutations in Omp resulted in the sh-1 phenotype was
investigated by direct sequencing of the coding region in the original sh-1 mutation
and five new mutations recovered following ENU mutagenesis (Rinchick et al.,
1990). No sequence variants were detected in the coding region of any of the sh-1
mutants, and expression of Omp in the original spontaneous sh-1 mutant was
apparently normal. Therefore it was concluded Omp was not the shaker-1 gene
(Brown et al., 1994). While this result lessened the confidence in the OMP gene as
the locus responsible for USH1B there were a number of reasons why OMP
remained a candidate. It was possible that sh-1 and USH1B were not true
homologues and mutations in OMP result in USH1B. Alternatively neither
disorder could involve OMP directly, but OMP could occasionally be involved in
USH1B as a result of a contiguous gene deletion. The third possibility of course
was that OMP is not involved in either defect. The only way to confidently resolve
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this issue was to characterise the OMP gene in normal individuals and families
carrying the Usher Type IB defect.
In the meantime, Steve Brown and his group, who had formally excluded Omp as a
candidate in sh-1, began to construct a 1.4Mb YAC contig across the sh-1 region
using Omp as a start point. Microsatellites were isolated from two YAC clones
which contained Omp, and used to analyse backcross progeny from the original sh-
1 cross in order to delimit the sh-1 non-recombinant region to approximately
500kb. Exon trap products were then recovered from one of the YACs which lay
within the non-recombinant region (Gibson et al., 1994). Those products with
open reading frames in the correct orientation and showing no homology to
repetitive sequences were hybridised to zoo blots. Two exon trap clones-ET17
and ET58- clearly detected sequences conserved across a wide variety of species,
which were mapped in humans during the course of this project. If they mapped to
1 lql3.5 then the gene from which they had originated would be a strong candidate
for both disorders. In parallel the Brown group also mapped a potassium channel
gene to the non-recombinant region, and an attempt was also made to map this in
human.
1.2.7 Mutational analysis of OMP
To confirm that a candidate gene is responsible for a disorder it is necessary to
carry out mutational analysis. Once mutations have been observed in a candidate
gene, these or other mutations in the same gene must be seen in a number of other
affected individuals for their role in the disease phenotype to be confirmed and
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understood. The method chosen to carry out mutational analysis on a particular
gene depends on a number of factors, and no single method is applicable for all
situations. Primarily the procedure selected depends on whether one is screening
for known mutations (e.g. in prenatal diagnosis of a common genetic disorder such
as cystic fibrosis), or scanning a candidate gene for previously unknown mutations.
The latter was the situation applicable to analysis of the OMP gene, hence I will
only consider methods relevant to this. The method chosen depends on: the
expected nature of the mutation; the size and structure of the locus being analysed;
the availability of mRNA; the degree of sensitivity needed; and the equipment
available. Candidate genes can be anything from a few hundred to hundreds of
thousands of bases long, and may be composed of many exons. Thus the search
for a disease causing mutation may require screening thousands of nucleotides. A
number of different techniques have been developed which show varying degrees
of accuracy and ease of use. If a gross chromosomal structural alteration has
occurred this can be readily identified using cytogenetic techniques. If a disorder is
caused by a large deletion, insertion, duplication, or inversion in the gene under
analysis this may be detectable by Southern blot hybridisation and restriction
mapping or multiplex PCR. These, however, are relatively rare compared to
alterations in one or a few bases. The most common methods used to detect single
base changes are SSCP, DGGE, HOT, and direct sequencing; I will discuss each of
these in turn. All of the methods require prior amplification of the gene from
genomic DNA and as such are PCR based.
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1.2.8 Comparison ofmethods to detect single base changes
1.2.8.1 Single-strand conformation polymorphism (SSCP)
Overall, this is the fastest and simplest technique. Wild type and mutant DNA are
amplified by PCR, denatured, then electrophoresed adjacent to each other in a non-
denaturing polyacrylamide gel containing glycerol. The single stranded DNA
molecules from each denatured product assume a 3-D conformation dependent on
their primary sequence. If there is a difference between wild type and mutant DNA
differential migration may result. The major disadvantages of this technique are
that it only detects up to 90% of mutations and screening must be carried out on
small fragments (less than 400bp) (Condie et al., 1993). It has nevertheless been
used very successfully to identify mutations (Berger et al., 1992) and has the
advantage that due to its simplicity a large number of samples can be screened in
parallel.
1.2.8.2 Denaturing gradient gel electrophoresis (DGGE)
Once the correct conditions have been established, DGGE is also relatively simple
and can be carried out on a large number of samples in parallel. Here PCR
products are electrophoresed through an increasingly stringent gradient of the
denaturing agents urea and formamide. When the denaturation stringency becomes
high enough strands of DNA dissociate in discrete sequence dependent domains of
low melting temperature. Again sequence differences between wild type and
mutant DNA can cause each to migrate differently due to different degrees of
'melting'. The sensitivity of the method is greatly enhanced if heteroduplex DNA
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formed between wild type and mutant DNA is analysed. To ensure the sequence
heterogeneity lies within a domain of relatively low melting temperature a 30-50bp
high melting temperature GC rich sequence (GC-clamp) is attached to one of the
primers, and primers are designed using a computer program to predict theoretical
melting profiles. The fragment sizes screened depend on the melting profile of the
DNA, but are normally in the range of 500bp. This technique has also been used
very successfully in the identification of mutations (Fodde et al., 1992). The
denaturing concentration which gives maximal separation between the wild-type
and mutant DNA fragments can be selected experimentally, once a particular
mutation is known, and this can then be used instead of a denaturing gradient
(CDGE- constant denaturing gradient gel electrophoresis). Theoretically
DGGE/CDGE has the potential to pick up 100% of mutations, although in practice
the figure is more like 90% (Condie et al., 1993). DGGE/CDGE requires quite a
lot of effort to set up although commercial equipment and software are now
available.
1.2.8.3 Chemical mismatch or hydroxylamine and osmium tetroxide (HOT)
The chemical mismatch or HOT (because of the use of the chemicals osmium
tetroxide and hydroxylamine) technique is the most accurate, but most demanding
of the mutation detection techniques. A heteroduplex is created between wild type
and mutant PCR products by boiling and reannealing. Mismatched bases in the
heteroduplex molecules are then modified using Maxam-Gilbert sequencing
chemistry; osmium tetroxide is used to modify mispaired thymines and
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hydroxylamine for mismatched cytosines. The DNA is cleaved at modified bases
by piperidine. In order to detect the point at which cleavage has occurred, either
wild type or mutant DNA is labelled, and the products run out on a denaturing
polyacrylamide gel which is autoradiographed. The precise distance from the end
of the molecule where the sequence alteration has occurred is indicated by the size
of the cleavage band and the cleaving reagent. Only a small proportion of the
mutant gene needs therefore to be sequenced. The HOT technique has also been
used very successfully (Prosser et al., 1990) and is capable of picking up all
mutations (Condie et al., 1993). Moreover this method has the lowest size
constraints of the three mutation scanning techniques and products of up to 1.7kb
have been accurately screened (Saleeba et al., 1992).
Both SSCP and DGGE7CDGE are simple to carry out, and can be used to screen a
large number of samples. The HOT method is very accurate and can be used to
analyse large fragments, but involves the use of hazardous chemicals, and is much
more labour intensive than the other two. In all cases the final step is to sequence
the fragment under analysis to confirm the presence of a mutation. The HOT
technique has the added advantage that the position and nature of the mutation is
produced and therefore only a defined region needs to be sequenced.
1.2.8.4 Recent advances
A number of advances have recendy been made to the DGGE, SSCP, and HOT
techniques. These were made after I had developed an experimental strategy for
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OMP mutation analysis, but are worthy of consideration for future candidate gene
analysis.
DGGE
A technique has been developed which overcomes the size limitation of DGGE.
Guldberg and Guttler (1994) were able to show that multiple DNA fragments can
be scanned for mutations by heteroduplex analysis in a 0-80% denaturing gradient
gel, where the running time is determined as the time it takes for the shortest
migrating fragment to reach its final position in the gel. Thus by using one 'broad-
range' gel and protocol they were able to analyse simultaneously all 13 PCR
products covering the human phenylalanine hydroxylase gene and detected all of
the 75 expected point mutations.
SSCP
SSCP has also undergone recent improvements due to the advent of automated
fluorescent sequencing technology. A new technique called the multiple
fluorescence-based polymerase chain reaction single-strand conformation
polymorphism (MF-PCR-SSCP) has been developed (Iwahana et al„ 1994). It
takes advantage of the fact that the ABI Model 373A DNA sequencer can detect
up to four types of fluorescence in one lane, so each sample can include an internal
control and lane to lane differences in mobility can be standardised. In addition, a
gel temperature controlling apparatus has been developed which allows strict
temperature control. This in combination with a higher percentage gel, than used
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in standard SSCP analysis, enables better separation and can result in 100%
detection of mutations often under one set of electrophoresis conditions.
HOT
Similarly the HOT technique has been adapted to make use of fluorescence
technology, and a new technique called FAMA (fluorescence assisted mismatch
analysis) has evolved (Verpy et al., 1994). The wild type and putative mutant
allele which form the heteroduplex are end labelled with strand specific
fluorophores prior to the formation of heteroduplex. This further increases the
sensitivity of detection, because fluorescent differential labelling allows the
identification and measurement of strand-specific background cleavages at matched
cytosine or thymine residues. The technique is less time consuming than
conventional HOTs and produces a high signal-to-noise ratio indicating that it may
be applicable to the detection of somatic mutations.
1.2.8.5 Direct sequencing
Direct sequencing is the final step in mutational analysis of candidate genes, but for
a number of reasons it is used to confirm rather than initially identify mutations.
Sequencing is more effective when the template is made single stranded. This may
be achieved by carrying out an initial PCR in which one of the primers is
biotinylated. The DNA fragment is then selectively immobilised to streptavidin
coated magnetic beads and after strand-specific elution, the eluted strand as well as
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the remaining immobilised strand, is used for bidirectional dideoxy sequencing
(Hultman et al., 1991). An alternative method is cycle sequencing which involves
the simultaneous amplification and sequencing of template by the addition of
dideoxy terminators to a secondary PCR reaction. This has the advantage of
requiring minute amounts of template, and the use of vast excess of sequencing
primer and the high temperature of the reaction permit analysis without prior
preparation of single stranded template (Ruano and Kidd 1991). The recent
availability of automated sequencing apparatus for analysis of fluorescently labelled
sequencing products has greatly increased the efficiency of direct sequencing.
Expensive specialised equipment is required so this technology is not at present
available to all laboratories, but after an initial investment the returns are great
since a large number of samples can be processed and directly analysed by a
computer. It is however still time-consuming to detect mutations by comparing
large numbers of sequencing reactions, and sequence ambiguities may be falsely
mistaken for mutations. Consequently new methods have been designed which
allow more direct comparison of sequencing reactions. An example of one of these
is orphan peak analysis.
1.2.8.6 Orphan peak analysis
Orphan peak analysis is a fluorescent adaptation of dideoxy fingerprinting (Sarkar
et al., 1992) where Sanger sequencing reactions of multiple samples using one
dideoxynucleotide are run out alongside each other on a non-denaturing gel. A
sequencing ladder results and mutations are detectable as shifts of individual bands
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in the ladder. Similarly in Orphan Peak analysis, PCR amplified DNAs from four
different individuals are subjected to a single base-specific sequencing reaction and
the products are applied to a set of four lanes of a Pharmacia automated DNA
sequencer. The computer software then applies a different colour to each lane, and
a base substitution in an individual is clearly visible as an individual-specific peak
with a colour specific for the individual. The intensity of the resultant signal is high
enough that a mutation can be detected even when several individuals are applied
to the same lane (Hattori et al., 1993). Obviously for both ddF and Orphan Peak
analysis to search for unknown mutations the patterns of all four (A,C,G,T) bases
must be analysed. The method may also be applicable to an ABI-type automated
sequencer, where four primers labelled with a different fluorochrome would be
employed.
1.2.8.7 Enzyme mismatch cleavage
A new method has been devised for the detection of mismatches in heteroduplex
molecules formed between wild type and mutant DNA (Dean 1995). It takes
advantage of the ability of bacteriophage resolvases, whose function in vivo is to
cleave branched DNA, to recognise and cut DNA at mismatches. This has been
tried successfully by two groups, and while there are still some problems with the
method it has great potential (Youil et al., 1995; Mashal et al., 1995). Basically,
PCR products from the two DNA resources are combined to form heteroduplex.
Youil et al (1995) end labelled wild type DNA and combined it with 10 x excess
unlabelled mutant DNA, Mashal et al (1995) on the other hand combined the two
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DNAs in equimolar proportions then carried out end labelling after the formation
of heteroduplex or after incubation with resolvase. Products are then incubated
with resolvase. Youil et al (1995) used T4 endonuclease VII, whereas Mashal et al
(1995) used T4 endonuclease VII and T7 endonuclease I, both in combination and
separately. Fragments are finally resolved on a polyacrylamide gel. Fragments of
up to lkb can be screened, no toxic chemicals are involved, and it can be set up in
any laboratory without the need for expensive equipment. Reactions are identical
for all DNA fragments, and resolvases recognise all four classes of nucleotide
mismatch. Overall the method is simple and rapid, but does require some fine
tuning. In some sequence contexts certain mismatches are not cleaved, and there is
a high degree of nonspecific background cleavage. Both problems may be solved
by the use of highly purified commercially available resolvases. Alternatively,
resolvases from other viruses or organisms may be discovered which show a
preference for presently uncleaved mismatches and indeed give a lower
background.
1.3 Experimental strategy
The aims of this project were to develop a rapid and simple method of cloning inter
Alu PCR products which were readily mappable. The cloning resource was a
somatic cell hybrid which contained the chromosomal subregion llql2-13. PCR
conditions were optimised to give the maximum number of inter ALu products
from the hybrid, and the capabilities of three different cloning methods were then
compared. Finally clones were mapped on a somatic cell hybrid panel which
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subdivided 1 lql2-13, and used to isolate YACs for the region. In parallel, the
human olfactory marker protein gene, which maps to 1 lql2-13 and was a
candidate one of the subtypes of the sensorineural deafness syndrome Ushers IB,
was cloned and sequenced. The sequence was then used to design primers and the
best method of mutation analysis selected before carrying out mutation analysis on
affected individuals.
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2. Materials and Methods
2.1 Cell culture
2.1.1 Bacterial cells
2.1.1.1 Media and additives
All media was sterilised by autoclaving.
L-broth and L-agar
2.46g MgSO*, lOg tryptone (Difco), 5g yeast extract (Difco) and lOg NaCl were added per litre of
distilled water. To make plates 15g agar (Oxoid) was added per litre of L-broth.
Terrific broth
12g tryptone, 24g yeast extract, 4g glycerol were added per 900ml of distilled water. After
autoclaving, 100ml autoclaved phosphate buffer (0.1M KH2P04and 0.72M K2HPO4) was added.
2 YT medium
16g bacto-tryptone, lOg bacto-yeast extract, and 5g NaCl were added per litre of distilled water.
The pH was adjusted to 7.0 with 5n NaOH
Ampicillin
Ampicillin was added to agar and broth in order to select for bacteria carrying plasmids which
confer resistance to this antibiotic. A stock solution of ampicillin (Sigma) was made up at a
concentration of 50mg/ml in dH20. This solution was filter sterilised and stored at -20°C. It was
added to melted broth and agar (cooled to 60°C) to give a final concentration of 50(j.g/ml.
5-Bromo-4-Chloro-3-Indolyl {3-D-Galactopyranoside (X-gal)
X-gal (Sigma) acts as a substrate for P-galactosida.se. It was added to agar to enable blue/white
colour screening for recombinants. A stock solution of X-gal was made up at a concentration of
20mg/ml in dimethylformamide (Sigma) and stored, protected from light at -20°C. It was added
to agar to give a final concentration of 40(ig/ml.
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Isopropyl fi-D-Thiogalactopyranoside (IPTG)
IFrG is a derepressor of the Lac operon. It was added in addition to X-gal to agar to enable
blue/white colour screening for recombinants. A stock solution of IPTG (Sigma) was made up at
a concentration of lOOmM in dH20 and stored at -20°C. It was added to give a final
concentration of 0.5mM.
2.1.1.2 Bacterial cell culture
Escherichia coli (E.coli) is the most widely used host organism for molecular cloning of DNA
and a diverse set of assays involving cloned genes. There are two major parameters involved in
efficiently transforming a bacterial organism: the method used to induce competence; and the
genetic constitution of the host strain of the organism being transformed.
2.1.1.3 Bacterial strains
The recA gene is the master regulator of recombination in E.coli (Hanahan et al„ 1991) It is
important that the cloned DNA is not rearranged within the bacterial cell, hence recA mutants
are used for the propagation of vectors containing cloned inserts. Another necessary genetic
component of the host strain is the lacZAM15 mutation. The multiple cloning site (MCS) in
appropriate plasmid cloning vectors is incorporated in-frame into the amino terminal DNA
fragment of lacZ carried by the vector. When such a vector is transformed into a host strain
carrying the lacZAM15 mutation, active P-galactosidase is produced and colonies turn blue on
indicator plates containing X-Gal (5-bromo-4-chloro-3-indoyl-P-D-galactosidase). If DNA
fragments cloned into the MCS of the vector cause the a subunit to be disrupted such that it
cannot combine with the P subunit to restore P-galactosidase activity, white colonies develop.
Thus blue-white colony screening can be performed to identify vectors containing cloned inserts.
Strains can carry the lacZAM15 by two different means : on an F (JM101); or on the
chromosome as part of the (|>80dlacZAM15 transducing phage (JM83,DH5a, DHSaMCR,
DH10B). The genotype of the three strains used is given below:-
DH5a - supE44 A/acU169 (<)>80 /acZAM15) hsdRll recAl eruJAl gyrA96 thi-l relAl
XLl-Blue - supE44 hsdR 17 recAl endAl gyrAA6 thi relAl lac' F [proAB+ /aclq /acZAM15
Tn lOttefJ]
DH10B - araD139 A(ara-leul691) galU galK mcrA A(mcr-hsdRMS-mcrBC) rpsl deoR <f>8CW
lacZV A(M15) endAl nupG recAl
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2.1.1.4 Plasmid vectors
The cloning vectors used were pBS (formerly Bluescribe) and pBS-SK, both of which are
produced by Stratagene™.
2.1.2 Yeast artificial chromosomes
YACs are currently the cloning system of choice for long range physical libraries. This is
because of their ability to clone large inserts (up to about 2Mb), which means that fewer markers
are required to assemble a contiguous array of YACs representing a multimegabase genomic
region. Yield of insert DNA from YACs is typically low. YACs are carried primarily as single
copy chromosomes in a yeast host, and yeast cell densities in overnight cultures are significantly
lower than E.coli cell densities. About lOptg of yeast DNA may be obtained from a 5ml overnight
culture of a YAC clone, but only 2% to 8% of that is YAC DNA. The rest is yeast chromosomal
DNA, which so resembles the YAC in physical properties that neither alkaline lysis procedures
nor cesium gradients can separate them. Preparative pulsed field gel electrophoresis (PFGE) can
be used to separate the YAC from the endogenous yeast chromosomes on a size basis, if the YAC
does not comigrate with one or other of the yeast chromosomes, but yields are low by comparison
with E.coli plasmid DNA preparations. The most common way to use YACs in mapping is to
use ordered overlapping YACs or single copy markers ordered using those YACs to identify
overlapping clones from a smaller insert, chimera free library e.g. in cosmids, for a region of
interest (Dracopoli et al„ 1995).
2.1.2.1 Media and additives
AHC broth and agar
AHC (Acid Hydrolysate of Casein) is a rich selective medium which lacks uracil and trytophan.
It was used for selective growth of YAC recombinants prior to production of plugs and isolation
of DNA. Combine :-
1.7 g yeast nitrogen base (without amino acids and ammonium sulphate- DIFCO), 5 g
ammonium sulphate, and 10 g acid casein hydrolysate (low salt) were added to 1 litre of distilled
water and the pH adjusted to 5.8. For AHC agar 17-20 g of Bacto agar (Difco) were then added.
Autoclave, and when cooled to 60°C add 50ml filter sterilised 40% glucose and 10ml 2mg/ml
sterile adenine sulphate
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2.1.3 Somatic cell hybrids
2.1.3.1 Cell tines
The following cell lines were analysed. The translocation chromosome MAR1 which carries the
derived 11 translocation chromosome, in the absence of any normal chromosome 11 material.
Four X irradiation hybrids, WJX3.4, WJX5.4, WJX7.4, and WJX11.2, which contain fragments
of chromosome 11 in the background of a Chinese hamster ovary cell line WG3H, were also
analysed. These fragmentation hybrids were produced by X irradiation of a chromosome 11-only
hybrid J1 C14 (Jones et al„ 1984), followed by rescue of the fragments produced, by fusion with
WG3H cells, and finally, cell surface marker selection to isolate those cell lines which contained
fragments of chromosome 11 (Fletcher et al„ 1993). Two additional chromosome 11
fragmentation hybrids, E67.1 and E67.4, were studied. These were derived by transfer of
metaphase chromosomes from a human EJ bladder carcinoma cell line to the murine CI27 cell
line. This was followed by selection for HRAS1 mediated transformed growth, in addition to
selection for the HRAS locus and other markers on lip (Porteous et al„ 1986). E67.1 and E67.4
had been analysed previously for lip markers (Porteous et al„ 1987) and a limited number of llq
markers (Spurr et al., 1988). Two other translocation cell lines were also analysed. CF52, which
has a well characterised t( 11; 16)(q 13;p 11) translocation chromosome as its sole human
component in the background of a murine cell line, A9 (Koeffler et al., 1981). MAFLI, which is
a permanent B lymphoblastoid cell line established from a patient with schizophrenia and bearing
the t(l;ll)(q42.2;q21) translocation (Fletcher et al., 1993). J1 C14 (Jones et al., 1984) was used
as a positive control and WG3H and RAG (murine background) were negative controls. Cells
were available as a cell pellet from which DNA was extracted.
2.2 Transformation and isolation of DNA
2.2.1 Reagents and protocols for the transformation of competent bacteria
Bacterial cultures should always be initiated from a fresh agar plate derived from a stock stored at
-70°C, or cells maintained in slow anaerobic growth in an agar stab stored in the dark at room
temperature. These methods will always produce reliably competent cells whereas cells
maintained in suspension in glycerol or on plates at 4°C produce erratic competence. There are
two major methods used to induce competence in cells (Hanahan 1983; Hanahan et al., 1991).
Several different methods using chemicals exist to do this, with the degree of simplicity of the
method directly reflected in the degree of competence achieved. These methods all ultimately
involve a heat shock step and hence are also referred to as heat shock transformation. The other
major method is electroshock transformation. Transformation efficiency can be roughly
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measured as the number of colonies formed per unit mass of DNA. Not every cell is competent
so a limited number of transformed cells will be obtained irrespective of how much DNA is
added. Electrocompetent cells have 10 fold higher transformation efficiency and the fraction of
competent cell is also 10 fold higher, so they can be expected to produce 10-100 times more
colonies than chemical methods. The method chosen is determined by the nature of the DNA to
be transformed i.e. whether it just retransformation of a plasmid clone, transformation of an
efficient or inefficient ligation, or transformation of cloned high complexity cDNA and genomic
cloning. The other major parameter, which also requires consideration of the nature of the DNA
to be transformed, is the genetic constitution of the host cells as discussed above (section 2.1.1.3).
2.2.1.1.1 Preparation of bacteria for heat transformation
Standard laboratory method
• Inoculate 100ml of pre-warmed L-broth (containing lOmM MgS04, 10 mM MgCl2, lOmM NaCl,
25mM KC1) with 2ml of an overnight culture
• Incubate cells in a 37°C shaking incubator until the A50onM = 0.48
• Incubate 15min on ice
• Centrifuge 5000rpm 15min, in sterile Falcon tubes at 4°C
• Take up pellet in 33ml of RF1 (lOOmM RbCl, 50mM MnCl2.4H20, 30mM KOAc, lOmM
CaCl2.2H20 15% w/v Glycerol pH to 5.8 with 0.2M acetic acid. Filter sterilise.)
• Incubate 15min on ice
• Centrifuge 5000rpm 5min, in sterile Falcon tubes at 4°C
• Take up pellet in 25ml of RF2 (lOmM MOPS, lOmM MgCl2, 75mM CaCl2.2H20, 15% w/v
Glycerol pH6.8 with NaOH. Filter sterilise.)
• Incubate 20 min on ice
• Freeze in 200pl aliquots in dry ice/methanol bath
• Store at -70°C for up to 6 months
Hanahan method (Hanahan 1991)
• Inoculate 50 ml of prewarmed L-broth with 3ml of a fresh overnight culture
• Incubate in a 37°C shaking incubator until the A50onM = 0.48-0.55
• Incubate 30ml of cells 15min on ice
• Centrifuge 2500xgmax 10 min, in sterile Falcon tubes at 4°C
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• Resuspend pellet in 10 ml of TFB (lOmM K-MES pH6.2, lOOmM RbCl, 45mM MnCl2.4H20,
lOmM CaCl2.2H20, 3mM Hexamine Cobalt (III) Chloride) by gentle vortexing
• Incubate 15min on ice
• Centrifuge 2500xgmax lOmin at 4°C
• Resuspend pellet in 2.4ml of TFB
• Add 97.5|il of fresh DMSO
• Incubate on ice 5 min mixing occasionally
• Add 97.5(il of 2.25M DTT 4mM potassium acetate
• Incubate on ice 10 min
• Add 97.5pl of fresh DMSO
• Incubate on ice for 5 min, then transform immediately
Calcium/Manganese-based method (CCMB - Hanahan 1991)
• Inoculate 50 ml of prewarmed L-broth with 3ml of a fresh overnight culture
• Incubate cells in a 37°C shaking incubator until the absorbance at 550nM reads 0.3
• Incubate 15-30min on ice
• Centrifuge 4000xgmax 15min, in sterile Falcon tubes at 4°C
• Resuspend cells in 1/3 volume of CCMB80 (80mM CaCl2, 20mM Mn Cl2, lOmM Mg Cl2, lOmM
KOAc, 10% w/v glycerol)
• Incubate on ice for 20 min
• Centrifuge 4000xgmax 15min, in sterile Falcon tubes at 4°C
• Resuspend cells in 1/12 volume ofCCMB80
• Freeze in 1ml aliquots in dry ice/methanol bath
• Store at -70°C for up to 6 months
2.2.1.2 Preparation ofbacteria for electro-transformation
• Inoculate 1 litre of L-broth with 10ml of a fresh overnight culture
• Incubate cells in a 37°C shaking incubator until the absorbance at 600nM reads 0.5-1
• Incubate 15-30min on ice
• Centrifuge 4000xgmax 15min, in sterile Falcon tubes at 4°C
• Resuspend pellets in 1 litre cold, low ionic strength buffer, usually dH20
• Centrifuge 4000rpm 15min, in sterile Falcon tubes at 4°C
• Resuspend pellets in 500ml cold, low ionic strength buffer, usually dH20
• Centrifuge 4000rpm 15min, in sterile Falcon tubes at 4°C
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• Resuspend pellet in =20ml cold 10% glycerol
• Centrifuge 4000rpm 15min, in a sterile Falcon tube at 4°C
• Resuspend to a final volume of 2-3ml in 10% glycerol
• Freeze in 40(il aliquots in dry ice/methanol bath
• Store at -70°C for up to 6 months
2.2.1.3 Heat shock transformation of competent bacteria
• Thaw competent cells on ice
• Mix up to 1.5(il of DNA with lOOpl of competent cells
• Heat shock by incubation at 42°C for 1 min
• Incubate on ice 1 min
• Add 1ml of 2YT medium
• Incubate in a shaking 37°C incubator for 1 hour
• Plate out 200(jl on a selective plate
2.2.1.4 Electro-transformation of competent bacteria
• Thaw elctrocompetent cells at room temperature and place on ice
• In a cold 1.5ml eppendorf, mix 40 )il of cell suspension with l-2pl of DNA
• Mix well, incubate on ice 1 min
• Set the Gene Pulser (Biorad) apparatus to 25|iF and 2.5 Kv. Set the pulse controller to 200G.
• Transfer the DNA/cells to a cold 0.2cm electroporation cuvette, shake suspension to. the bottom
• Place cuvette in chilled safety chamber slide. Pulse. The time constant should be 4.5-5msecs
• Add 1ml of L-broth to the cuvette immediately
• Quickly transfer the cells to a 1.5ml eppendorf and incubate in a shaking 37°C incubator for 1
hour
• Plate out on selective media
2.2.2 Frozen stocks of bacterial strains
Frozen stocks were made by freezing down to -70°C an aliquot of an overnight culture in 20%
glycerol.
2.3 Isolation of plasmid DNA from bacterial cells
All of these methods can be found in Sambrook et al„ (1989).
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2.3.1 Small scale plasmid DNA purification
Set up an overnight culture by picking a single colony from a fresh plate into 5ml terrific broth
containing a selective antibiotic for the plasmid which is to be purified, generally ampicillin.
Incubate at 37°C overnight in a shaking water bath Either spin down the full 5ml (5 min) or a
1.5 ml(l min) aliquot. The larger volume gives a higher yield of plasmid without the need to
adjust the volume of other solutions used in the method.
• Add 250|il lysozyme (lOmg/ml) in GTE (50mM Glucose,25mM Tris,50mM EDTA) to pellet,
and incubate 10 min room temperature. This breaks down the cell wall and outer membrane.
• Add 500 pi alkaline/SDS (1% SDS,0.2M NaOH), and incubate 10 min on ice. SDS lyses the
spheroplasts.
• Add 250pl high salt (3M Potassium Acetate, pH to 4.8 with acetic acid),and incubate on ice 10
min. Here the disrupted of the plasmid base pairing is returned to the native superhelical
structure, but the chromosomal DNA remains irreversibly denatured.
• Centrifuge in the cold room 15 min
• Transfer 900pl supernatant to a fresh tube
• Repeat centrifuge and transfer to fresh tube
• Add 540(il of isopropanol
• Centrifuge at room temperature 15 min
• Wash pellet with 70% ETOH
• Dry 3 min under vacuum
• Resuspend in 30pl TE, and run 3pl on a gel to estimate the recovery (typically 3-5pg).
2.3.2 Large scale plasmid DNA preparation
Set up an overnight culture shaking, at 37°C, by picking a single colony from a fresh plate into
5ml of terrific broth containing a selective antibiotic for the plasmid which is to be purified,
generally ampicillin. Use 500pil of the overnight culture to inoculate 500ml of L-broth
containing ampicillin (100pg/pl). This must also be incubated overnight as before.
The DNA is then extracted as described below.
• Centrifuge 5min at 6000rpm
• Resuspend pellet in 20ml GTE + 200mg lysosyme (lOmg/ml)
• Add 40ml alkaline/SDS, and incubate 10 min on ice
• Add 30ml high salt, and incubate on ice 5-30 min
• Centrifuge 30min at 12000rpm
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• Filter through muslin to remove bacterial debris
• Add 55ml isopropanol, incubate 5 min room temperature
• Centrifuge 15min at 8000rpm
• Wash pellet with 70% ETOH
• Centrifuge 5min 800rpm to repellet cells
• Resuspend pellet in 5ml TE
• Add 5g caesium chloride
• Add 5ml EtBr (lOmg/ml)
• Transfer to Quick-seal centrifuge tubes (Beckman) tubes, balance tubes using lg/ml CsCl, then
seal the tops
• Ultracentrifuge at 80,000rpm at 20°C for 4-16 hours
• Plasmid DNA forms a band, just below the bacterial chromosomal DNA near the top of the tube.
RNA and protein are deposited in the bottom of the tube. The DNA band is removed by inserting
a needle in the top of the tube to relieve any vacuum formed, then inserting another needle
attached to a syringe just below the plasmid DNA band which can then be used to draw off the
band
• Remove the EtBr by butanol extraction: add the same volume of butanol, invert several times by
hand, allow the two phases to separate then remove and discard the upper phase. This process is
repeated until the lower layer becomes clear
• The DNA can then be precipitated: add two volumes of dH20 to dilute the salt, then six volumes
of cold absolute ETOH to precipitate the DNA. Incubate -20°C 20min. Centrifuge at 8000rpm
(Sorvall SM24) for 10 min
• Wash pellet with 70% ETOH, centrifuge as above for 5 min
• Resuspend the DNA pellet in 500pl-lml dH20 (yield typically 0.5-2mg)
2.3.3 Sequencing standard DNA preparation
This method yields DNA suitable for use with the ABI cycle sequencing kit i.e. high quality
supercoiled plasmid DNA which is relatively free of contaminating chromosomal DNA and
RNA. The initial steps are very like conventional alkaline lysis mini preps, but there are
additional RNase A and PEG (polyethylene glycol) precipitation steps.
• Incubate 5ml cultures overnight 37°C in terrific broth in a 50ml tube to allow adequate aeration
• Centrifuge 5 min to pellet the cells
• Remove the supernatant by aspiration, resuspend pellet in 200|il GTE
• Add 500(il freshly prepared 0.2M NaOH/1% SDS
• Vortex and incubate on ice 5 min
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• Neutralise by adding 250pl 3M Potassium Acetate pH4.8
• Vortex and incubate on ice 10 min
• Centrifuge 10 min room temperature
• Transfer supernatant to a fresh tube leaving behind cellular debris
• Repeat the last two steps
• Add RNase A to a final concentration of 20pg/pl
• Incubate 37°C 30 min
• Extract supernatant twice with 400pJ chloroform
• Mix layers by hand for 30 seconds after each extraction
• Centrifuge 1 min to separate phases
• Remove aqueous layer to a fresh tube
• Precipitate DNA by adding an equal volume of 100% isopropanol and immediately centrifuging
10 min room temperature
• Wash pellet with 500pl 70% ETOH
• Dry 3 min under vacuum
• Resuspend pellet in 33.6|il dH20
• Precipitate by adding 6.4(_tl NaCl, 40pl 13% PEG8000
• Mix thoroughly, incubate 20 min on ice
• Pellet plasmid DNA by centrifuging 15 min cold room
• Wash pellet with 500|il 70% ETOH
• Dry 3 min under vacuum
• Resuspend in 20pl dH20
• Store at -20°C
2.3.4 Yeast DNA preparation
• A single colony, freshly grown on an AHC plate, was grown overnight in 5ml of AHC medium,
at 30°C, shaking at 200rpm
• centrifuge 3000rpm for 4 min
• resuspend cells in 0.5ml 1M Sorbitol; 0.1M EDTA pH7.5
• add 20(jl of 2.5mg/ml zymolyase 6000 and incubate at 37°C for 1.5-2 hours
• centrifuge 1 minute
• resuspend pellet in 0.5ml 50mM Tris pH7.4; 20mM EDTA
• add 50pl 10% SDS and mix carefully but thoroughly
• incubate 65°C for 30 min
84
• add 200|il 5M potassium acetate
• incubate on ice 1 hour, then centrifuge for 5 min
• transfer supernatant and combine with 1 volume of isopropanol
• mix, incubate room temperature 5 min
• spin 10 sees, take off supernatant with a pastette and air dry pellet
• resuspend in 300(il lOmM Tris; ImM EDTA pH7.4 (TE)
• add 1.5|il lOmg/ml pancreatic RNase
• incubate 37°C for 30 min
• add 15|il NaCl; 900(il 100% ETOH
• centrifuge 15 min, wash pellet with 70% ETOH
• resuspend dried pellet in 100|il TE
• before digesting DNA centrifuge 15 min to remove any insoluble material which may inhibit
digestion
2.3.5 Preparation of agarose plugs for pulsed field gel electrophoresis
This method allows the extraction of intact yeast chromosomes, including yeast artificial
chromosomes (YACs), from cells. It was adapted from Maule (1994). The volume can be
adjusted to suit the number of plugs required.
• A single colony, freshly grown on an AHC plate, was grown overnight in 10ml of AHC medium,
at 30°C, shaking at 200rpm
• Increase the volume of AHC medium to 100ml, and reincubate until cell count reaches - 1x10s
cells/ml (-16 hours)
• Harvest the cells by spinning at 2000g for lOmin at 4°C
• Discard the supernatant, and gently disrupt the pellet with a sterile loop before adding 50ml of
chilled 50mM EDTA pH7.5
• Centrifuge 2000g, 5 min, at 4°C
• Repeat the last two steps
• Discard supernatant, and take pellet up in 3ml of ice-cold 50mM EDTA pH7.5
• Transfer cells to a 20ml universal container, with a fine tipped sterile Pastette, and heat to 37°C
• Add 6ml of 1% low melting temperature agarose (in 0.125M EDTA pH7.5) which has been
cooled to 50°C
• Add 1.2ml of freshly prepared cell wall digestion solution (2ml SCE [1M sorbitol, 0.1M
trisodium citrate, 60mM EDTA pH7- autoclave], 0.1ml 2-mercaptoethanol (Sigma), 2mg
zymolyase (ICN Biochemicals)
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• Immediately mix thoroughly and dispense in lOOpl aliquots into plug moulds and allow to set on
ice
• Eject the plugs into a 50ml Falcon tube containing 25ml of ETM solution ([0.45M EDTA, lOmM
Tris-HCl pH8 - autoclave], 7.5% 2-mercaptoethanol), and incubate at 37°C overnight
• Replace ETM with 20ml 1% NDS solution (0.45M EDTA, lOmM Tris.HCl pH9, 1% SDS)
containing proteinase K (Boehringer Mannheim)at lmg/ml, and incubate at 50°C overnight
• Repeat the last step
• Store plugs in 20ml ETM at 4°C
• Plugs should be equilibrated for at least one hour in gel running buffer before use
2.3.6 Isolation of genomic DNA from cultured cells
• Human genomic DNA was extracted from of a pellet of cultured cells as described below
• Resuspend pellet in 0.5ml of TE buffer (lOmM Tris pH7.5; ImM EDTA), and transfer to a
phenol resistant tube
• Vortex while adding 2.5ml of lysis buffer (0.5% SDS; 150mM NaCl; lOOmM Tris pH8; lOOmM
EDTA)
• Add lOpl/ml RNase
• Incubate 37°C for 15 - 60 min
• Add proteinase K to final concentration of 0.5mg/ml
• Incubate 50°C overnight
• Add and equal volume of water saturated phenol
• Centrifuge at 2500 rpm for 5 min
• Remove upper aqueous layer and add an equal volume of 1:1 phenol/chloroform
• Centrifuge at 2500 rpm for 5 min
• Remove upper aqueous layer and add an equal volume of 24:1 chloroform/isoamyl alcohol
• Remove upper aqueous layer and add half volume of 7.5M Ammonium Acetate
• Add two volumes of absolute ethanol and spool out DNA on a glass pasteur with sealed end
• Air dry then dip in 66% ETOH 0.8M ammonium acetate
• Resuspend DNA in 200|il TE
2.4 Amplification of DNA by the polymerase chain reaction
(PCR)
The PCR (Saiki et al., 1985; Mullis and Faloona 1987) is an enzymatic technique which permits
the cyclic and exponential amplification of a specific ds DNA sequence. The sequence specificity
is provided by a pair of oligonucleotide primers which direct amplification. The primers are
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complementary in sequence to the 5' ends of the sequence to be amplified and are annealed to the
template under conditions where they hybridise only to their exact complement. The PCR is a
series of cycles, each of which consist of three steps. The first is a high temperature step (93-
94°C) which causes denaturation of the template. This is followed by a reduction in temperature
(to that which is optimum for precise annealing of the primers, usually 45-65°C) and finally an
extension step at 72°C (which is the optimum temperature of the thermostable polymerase).
2,4.1 Constituents and conditions
Generally PCRs were carried out in a 50|il volume which contained 5pi of lOx buffer, 3pi 25mM
MgCl2, lpi of each primer at 300ng/pi, 1pi of a 50x dNTP stock where each dNTP (Pharmacia)
is at lOmM, 1 unit of thermostable DNA polymerase, and DNA template the concentration of
which depended on the complexity of the resource being amplified. Initially reactions were
carried out using Promega Taq polymerase enzyme, buffer (lOx buffer= lOOmM Tris-HCl pH8.8,
500mM KC1, 15mM MgCT, 1% Triton X-100) and magnesium chloride. Licensing restrictions,
however, meant that a switch to Cetus Amplitaq, and the corresponding buffer (lOx buffer=
lOOmM Tris-HCl pH8.3, 500mM KC1, 15mM MgCl2, 0.01% (w/v) gelatin), had to be made. It
was found that amplification with Cetus enzyme could be improved to the same level as Promega
by the addition of 5pl of 1% Triton X-100 to the reaction mix. In each case reactions were
overlaid with mineral oil (Sigma).
PCRs were carried out on various different machines; a Perkin Elmer Cetus DNA Thermal
Cycler, Hybaid Thermal Reactors and a Hybaid Omnigene. The temperature and the length of
the different steps was varied according to the primer pair, the machine and the length of the
fragment to be amplified. Conditions for the various sets of primers used were determined as
follows. Each set of conditions always had an initial cycle with a longer denaturation step at a
higher temperature (generally, 94°C for 3 minutes- Perkin Elmer Cetus DNA Thermal Cycler,
93°C for 2 minutes- Hybaid machines). This was then followed by a series of cycles, the number
of which was dependent on the efficiency of amplification (generally 30 cycles were performed
initially). This series of cycles consisted of a denaturation step (generally, 92°C for 45 seconds-
Perkin Elmer Cetus DNA Thermal Cycler, 91°C for 30 seconds- Hybaid machines) followed by
an annealing step. The annealing temperature (Ta) was 5°C lower than the melting temperature
(Tm) of the primers. This was determined by the equation Tm (at 1M concentration) = 4(G+C) +
2(A+T). Annealing was generally carried out for 1 minute- (Perkin Elmer Cetus DNA Thermal
Cycler) or for 30 seconds- (Hybaid machines). The annealing step was followed by extension at
72°C for approximately 1 minute per kb to be amplified. The final cycle had an increased
extension step of 5 or 10 minutes depending on expected size of the product. In a number of
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cases these conditions required modification, in order to promote maximum amplification.
Generally changes were made to the annealing temperature and the number of cycles of
amplification. 'Touchdown' PCR (Don et al., 1991) has also been reported to enhance the
specificity of PCR reactions. Here the annealing temperature of the first cycle is approximately
10°C higher than the theoretical annealing temperature. Over subsequent cycles the temperature
is lowered by 1 or 2°C every one or two cycles until the theoretical temperature is reached. The
cycles which are carried out under the stringent conditions provided by higher temperatures
should promote amplification of the correct template molecules, in preference to aberrant
amplifications from mismatched template. Thus by the time the temperature has been lowered to
that which prevents misprinting, the correctly amplified product has an advantage over any
misprinted products.
2.4.2 Template
2.4.2.1 PCR from plasmid isolates
Only a very small amount of template is needed for a plasmid in pure form since its small size
means that there are many copies present in a small mass of DNA. Thus generally only l-100pg
were used as template. For amplification of the OMP cosmid, however , I found it necessary to
amplify lOOpg-lng, due to the increase in complexity.
2.4.2.2 PCR from bacterial colonies
Template can be prepared by either of two simple methods I have found the two stage method
gives more product
• Touch the colony lightly with a toothpick then place directly in a tube containing the rest of PCR
components
• Swirl, then remove toothpick
• Simply add oil then amplify as normal
Or
• Touch the colony lightly with a toothpick, then place in an eppendorf containing IOOjj.1 of dH20
• Swirl, then remove toothpick
• Incubate at 94°C 5 min (to denature the DNA)
• Incubate on ice 2 min
• Centrifuge 2 min
• Amplify 5(0.1 of the supernatant
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2.4.2.3 PCRfrom human genomic DNA
Generally lOOng of genomic DNA was amplified in a standard 50|a.l PCR. The only difference
between setting up genomic and standard plasmid PCRs is that you must ensure that the DNA is
properly in solution before removing an aliquot to PCR, and that the aliquot is evenly dispersed
in the PCR mix. This is done by thoroughly vortexing the PCR mix before the addition of oil.
2,4.3 Oligonucleotides
Primers were designed using either the 01igo4 programme (Hybaid) or the Primer programme-
(Whitehead Institute for Biomedical Research, available through HGMP)
Oligonucleotides were synthesised, in the form of ammonium stocks, on an Applied Biosystem
381A oligonucleotide synthesiser. HPLC purification was not performed.
2.4.3.1 Purification
Oligonucleotide stocks consist of about 1ml 30% NH4OH and a sediment of beads on which the
oligonucleotides are synthesised. The DNA must therefore be precipitated from the NH4OH
supernatant. Two methods were used from this although only the second method is now in use.
Conventional method
To 350|il NH4OH stock
• Add 3M NaOAc pH5.5
• Add 770(il cold absolute EtOH
• Vortex briefly
• Incubate -20°C at least 30 min
• Centrifuge at 1400rpm for 30 min at 4°C
• Wash pellet 2x70% ETOH
• Air dry
• Resuspend in 200*ll TE
• Store -20°C
Rapid/butanol method (Sawadogo & van Dyke 1991)
• 100*11 NH4OH stock
• Add 1ml n-butanol (ACS reagent grade)
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Vortex vigorously 15 sees
Centrifuge 1 min 12,000rpm
Remove single H20-containing n-butanol phase and discard
In some cases to complete removal of contaminants- resuspend pellet in 100(0.1 dH20 and repeat the
butanol extraction
Dry pellet under vacuum
Resuspend pellet in 50|il d H20, or TE
store at -20°C
2.4.3.2 Annealing Oligonucleotides
This was used to create insert for the ligation independent cloning vectors. Combine an equal
volume of the two complementary oligonucleotides in lOmM Tris HC1, 5mM MgC12.
Heat to 70°C for 10 min, then cool slowly to room temperature. The newly annealed
oligonucleotides can then be stored at -20°C until ready to use
2.4.4 Details of primers and amplification conditions
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Table 2.1 OMP PCR primers
PRIMER NAME DESCRIPTION SEQUENCE PCR CONDITIONS
5un OMP PCR primer 5' AGG CTT TGG TGA Ta=57°C
pair for amplification TTG GGT GTG 3' 10% DMSO
of 5' coding and 5' CGA GGT GCC TGT
Cod5 untranslated region GAT GGT GAC 3'
Codd3 OMP PCR primer 5' CTA CGC GTG GAG Ta=53°C
pair for amplification AGC CTG AAG 3'
of 3' coding and 5' AAC CCT GCC CCA
3uun untranslated region TAT CCT GAG 3'
5uun2 OMP external 5' 5' TTG GTG ATT GGG Ta=45°C
primer used with 3uun TGT GGA 3' 13% DMSO
to amplify gene and 3'
& 5' untranslated
regions
C OMP rat derived 5' GCA GAG GAC Ta=56°C
primer pair used to GGG CCA CAG AAG
amplify the 5' section C 3'
of the coding region. 5' CAG TTC TGC GAG
C' GTG CCC GTG 3'
s OMP mouse 5' GCA GAG GAT Ta=56°C
equivalent of primer C GGG CCG CAG AAG
C 3'
A OMP rat derived 5' GCT GGT TAA ACA Ta=56°C
primer, nested within CCA CAG AGG C 3'
primer R.
R OMP rat derived 5' GCC ATC AGA GCT Ta=56°C
primer which overlaps GGT TAA ACA C 3'
the stop codon.
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Table 2.2 OMP sequencing primers
PRIMER NAME DESCRIPTION SEQUENCE PURPOSE
IntAf OMP internal
forward primer A












5' AAA GGG AGG











5' GAC CCC ACT











5' GGG TGA AGT
TGA GGC GGT A
3'
Used as probe to





5' CCC CAT CTC












Table 2.3 Universal PCR primers
The Ml3 sequencing primers are single-stranded DNA primers suitable for
sequencing and amplification of inserts cloned into all M13 lac cloning phages
and plasmids (e.g. pUC) beginning at opposite sides of the polylinker (Sanger et
al., 1980). Recently the design of the M13 reverse primer has been altered to
increase its performance in cycle sequencing (Kretz et al., 1994).
PRIMER PURPOSE SEQUENCE CONDITIONS
M13 forward sequencing + PCR 5' GTA AAA CGA
CGG CCA GT 3'
Ta =55°C
Ml3 reverse sequencing 5'GGA AAC AGC
TAT GACCAT G3'
Ta =55°C
Ml3 reverse PCR 5' CAG GAA ACA
GCT ATG AC 3'
Ta =52°C




614 5' G TGA GCC GAG ATC GCG CCA CTG CAC T 3' Ta =65°C
C324 5' CCC CCG CGG CCC GAG CCG AGA TCG CGC
CAC 3'
Ta =55°C
C325 5' GGG GGC GCC CCC GAG CCG AGA TCG CGC
CAC 3'
Ta =55°C
> c 00 5' Cc/TA/G TCT CAA AAA AAA AAA 3' Ta =46°C
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Table 2.5 CA repeat primers
The sequence derived from the clone containing each repeat was used to design primers flanking
the CA dinucleotides. Where possible primers were designed to give a product of 150 -250 bp.
In each case the shortest primer was fluorescently labelled.
PRIMER NAME PURPOSE SEQUENCE CONDITIONS






5' TCA GGA AGT









5' CTA TGG GGA
TGG TAA GTA
GCC3'
5' GCC ACC TCT
CTT TCT GCT
CT3'









5' GCA GCC TCC
ACC TTC CAG 3'
5' GAG AGG CCG
AGG CAG ACA 3'
Touchdown to Ta =
52°C






5' TGA ACT GGT
ATG ATC TCA 3'
Ta = 55°C










Table 2.6.1 and 2.6.2 PCR primers for chromosome 11 markers
These are the primers and PCR conditions for markers (Evans et al., 1995) and
ESTs (Slorach et al., 1995) previously mapped to 11 q 12-13 by other members of
the group.
LOCUS SEQUENCE CONDITIONS REFERENCES
PGA 5'GCA TCT CTG ACA CCA ATC AG 3'
5TGG AGA AGA GAC AGA TGG AG3'
Ta = 54°C W Cookson pers.
comm.
Evers et al., 1989
ROMI 5'AGG CCT GGA GCT TGG GGT GA3'
5' CCA TCC AAA AAC TTT ATT GAG
TCT 3'
Ta = 55°C Primers designed
from Bascom et
al., 1992 by Evans
etal (1995)
MDUI 5'TCT TCA AAG CCT CTG TCT AAC C
3'
5' CTC ATC TCC AAC CTG TCT AAC
C 3'
Ta = 57°C Primers designed
from Gottesdiener
et al., 1988 by
Evans et al (1995)
GSTPI 5' GGG AGG GAT GAG AGT AGG
ATG 3'





from Cowell et al.,
1988 by Evans et
al (1995)
FGF4 5' GAT GAG TGC ACG TTC AAG GAG
3'
5'CAG AGA TGC TCC ACG CCA TAC
3'
Ta = 62°C Primers designed
from Yoshida et
al., 1987 by Evans
etal (1995)
D11S527 5' ATG CGC CTC CAA GAC AAG TTC
3'
5'GCC CCT CTA CTT GTC TGG AG 3'
Ta = 55°C Brown et al 1991
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LOCUS SEQUENCE CONDITIONS REFERENCES
EST01878 5' TTT TCC AAT AAT GTG ACT
TC 3'




Slorach et al (1995)
EST02002 5' TGA AGG TGA CTT AAA CAG
CT 3'




Slorach et al (1995)
EST00220 5' TTT CCG AAG AAG GCA GTT
TG 3'




Slorach et al (1995)
EST00294 5' GTT TGA AGG AAG TGA TTT
CC 3'




Slorach et al (1995)
EST00218 5' TAC CCC GTC AGA TCA GTT
ATG 3'
5' CCA ACA ACG TTT GCCT CAC
AT 3'
Ta = 55°C Slorach et al (1995)
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2.5 Enzymatic manipulation ofDNA
2.5.1 Restriction endonuclease digestion of DNA
Digestions with restriction endonucleases (Boehringer Mannheim) were carried out in the
appropriate buffer (supplied by the manufacturer) at the recommended temperature. l|Xg DNA
was digested in 10|il, containing 5mM spermidine (Sigma), with 1-2 units of restriction enzyme
for between 1 hour (Plasmids and low complexity DNA) and overnight (YACs, somatic cell
hybrids, and genomic DNA). When two different enzymes, both of which required the same
buffer, were used the reactions were carried out simultaneously. Otherwise, digestion with the
enzyme requiring the lower salt buffer was carried out first. The salt concentration was then
increased by addition of the appropriate amount of sodium chloride solution and the second
reaction carried out. Alternatively KGB was used. Reactions were terminated by heating to 68°C
or 80°C for 10 minutes, according to the heat sensitivity of the enzyme, or if the enzyme was heat
stable, by phenol/chloroform extraction of the reaction. Restriction digests which were run on
agarose gels were terminated by the addition of l/10m of their volume of 'stop mix' (lOOmM
EDTA pH8, 20% Ficoll and orange G)
2.5.2 Dephosphorylation of linear plasmid DNA
This is used to remove the 5' phosphate and prevent the self-ligation of DNA fragments. Usually
a stock of dephophorylated vector was prepared.
To ljig of linearised plasmid DNA
Add 2(j.l of lOx calf intestinal phosphatase buffer (BM)
Add dH20 to 19(0.1
Add lpl (1.5 units) calf intestinal phosphatase (BM)
Incubate for 30min at 37°C (cohesive ended molecules) or 50°C (blunt ended molecules)
Add an additional lp.1 calf intestinal phosphatase (BM)
Incubate for 30min at 37°C (cohesive ended molecules) or 50°C (blunt ended molecules)
Stop the reaction by adding 0.4|il 0.5M EDTA (final concentration lOmM)
Phenol/chloroform extract the DNA
2.5.3 Ligation of blunt ended molecules
According to Cobianchi and Wilson (Cobianchi and Wilson 1987) the optimal ratio of ends for
such a ligation event is 3:1 vector to insert. Typically, between 10 and lOOng of vector was used.
To vector and insert DNA add
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lfxl lOx T4 DNA ligase buffer (50mm Tris-HCl pH7.5, 7mM MgCl2, ImM DTT, ImM rATP:BM)
Potassium chloride to 30mM final concentration
ATP to ImM final concentration
dH20 to 10pl
0.1 unit of T4 DNA ligase (BM)
Incubate overnight at 4°C
Incubate 68°C 20 min to inactivate the enzyme
2.5.4 Ligation of cohesive ended molecules
According to Cobianchi and Wilson (Cobianchi and Wilson 1987) the optimal ratio of ends for
such a ligation event is 1:2 vector to insert. Typically, between 10 and lOOng of vector was used.
To vector and insert DNA add
l|il lOx T4 DNA ligase buffer (BM)
dH20 to 10(il
0.1 unit of T4 DNA ligase (BM)
Incubate overnight at 16°C
Incubate 68°C for 20 min to inactivate the enzyme
2.5.5 Ligation Independent cloning
Alu-PCR products need to be purified to remove excess nucleotides (which would prevent T4
from producing single stranded tails) and primers (which could interfere with the cloning
process). This was either done by gel purification and DNA isolation using a Spin-X column, or
directly using a Wizard PCR column. The optimal conditions are given below:-
Production of single stranded tails




1 unit of T4 DNA polymerase (BM)
Incubate 15 min 37°C
Incubate 68°C
Non-covalent linkage of ends
Combine vector and insert DNA in a 3:1 insert to vector ratio and
Incubate 10 min at 60°C
Immediately transfer to 4°C
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2.5.6 Turbo cloning
This is a rapid, efficient method for the cloning of blunt-ended DNA into plasmids. It relies on
coupling efficient intermolecular ligation under conditions of macromolecular crowding (15%
PEG 6000), with subsequent Cre-mediated recircularization at vector-borne lox sites. Again
inserts were prepared by a two stage PCR protocol, initial amplification with 614 primer was
followed by reamplification of an aliquot with the Alu18 end primer. A stock of Smal cut
dephosphorylated pBSlox vector was kindly provided by Dr Chris Boyd.
Primer phosphorylation
A lOpg aliquot of Alujg was kinased by combining it with-
lx Polynucleotide kinase buffer (BM)
10 units of Polynucleotide kinase (BM)
ATP at 0.5mM final concentration
Incubate 40 min 37°C
Incubate 10 min 68°C to heat inactivate the kinase
Precipitate in 0.3M Sodium Acetate and 2 volumes of cold ethanol
Resuspend in 10(il dH20
This was then used to amplify an aliquot of 614 PCR products. T4 DNA polymerase was then
used to ensure that the ends of the PCR products were blunt
Combine an aliquot of the Alul8 PCR reaction with
dNTPs at 200|om final concentration
1 unit of T4 DNA polymerase (BM)
Incubate 30 min 37°C
Incubate 10 min 68°C
Use aWizard PCR column to purify the DNA and reassess the concentration
Turbo cloning
This method was adapted from Boyd (1993). Typically a 16(0.1 reaction was set up, in the order
given-
8|0l vector (dephosphorylated) and insert (at a 10:1 vector to insert molar ratio)
1.6(11 lOx buffer (0.5M Tris-HCl, 50mM MgCl2, 5mM ATP, 5mM DTE pH8.0)
6|ol 40% (w/v) PEG 6000 (BDH)
0.4(ol T4 DNA ligase (Boehringer: lU/(il)
Incubate room temperature 15 min
Incubate 75°C 5 min, to heat kill ligase
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Add 64(j.l (4 volumes) of M buffer (medium salt restriction enzyme buffer- Boehringer Mannheim)
containing 0.1-0.3|J.g Cre protein (Dupont)
Incubate 30°C 30 min
Incubate 75°C 10 min, to heat kill Cre
Desalt the reaction prior to transformation by drop dialysis (section 2.7.4)
2.5.7 Restriction endonuclease digestion of DNA embedded in agarose plugs
This method was also adopted from Maule (1994)
soak plugs for 10 min in a large excess of sterile TE, inverting tube frequently
immerse plugs in 5ml TE containing phenylmethylsulfonylfluoride (PMSF - a protease inhibitor) at
40(ig/ml
incubate at 50°C for 30 min
repeat previous two steps
soak plugs for 2 hours in 10 volumes of IX restriction enzyme buffer at room temperature, inverting
frequently
transfer single plugs to eppendorfs containing IX restriction enzyme buffer, 0.1% Triton X-100, and
200|ig/ml BSA. Add 20U of restriction enzyme. The final volume should be 100(0.1., and plug
should be fully immersed in the absence of air bubbles.
incubate overnight in waterbath at recommended temperature for digestion
cool tube on ice 15 min then remove supernatant with a fine tipped pastette
fill tubes with ice-cold TE
2.6 Electrophoresis ofDNA
2.6.1 Electrophoresis solutions
20xTBE: 1M Tris, 20mM EDTA and 1M Boric acid pH8.3. Agarose gels were run in 0.5XTBE
buffer.
20xTAE: 0.8M Tris, 20mM EDTA,pH8 and 0.4M acetic acid. Agarose gels were run in 1XTAE
buffer.
lOx DNA loading buffer/ 'stop mix': 20% ficoll, lOOmM EDTA, orange G
6% Denaturing polyacrylamide (Severn Biotech LTD 6% polyacrylamide ratio 19:1 7M Urea,
1XTBE)
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2.6.2 Agarose gel electrophoresis
DNA molecules were separated, according to size, in horizontal agarose gels by electrophoresis.
The percentage of agarose (Sigma Type II medium EEO) in the gel was varied according to the
range of size separation required. Restricted genomic DNA was run in a 0.8-1% agarose gel.
Smaller DNA fragments, such as plasmids or PCR products were run on 1-2% gels, with
fragments smaller than 200bp being run on either 2% low melting point agarose (Gibco BRL,
ultrapure LMP agarose) or 4% Nusieve agarose (FMC Bioproducts). Ethidium bromide was
added to all agarose gels and buffer at a concentration of lpg/ml buffer. 1/10 volume of 10X stop
mix was added to the sample prior to loading on the gel. The size marker used was lkb ladder
(Gibco BRL) or <|)X 174 Haein marker (Promega), for large and small fragments respectively.
Gels were run in Electro-4 gel boxes (Hybaid) generally at 75-120 volts or at 10-30 volts
overnight.
2.6.2.1 Preparative gel electrophoresis
DNA fragments were run in low melting point agarose gels (Ultrapure LMP agarose-Gibco BRL).
Gels were viewed on a transilluminator at 305nm , and the required fragment was cut out of the
gel using a sterile scalpel blade. Care was taken to ensure that the minimum size of gel slice was
excised and that exposure to UV was minimised.
DNA was isolated from the gel slice using one of the methods in section 3.7.
DNA fragments which were to be used only as hybridisation probes were not isolated, but
prepared as follows:- the gel slice was weighed and l-3x the weight of water was added, such that
13(Ji of diluted gel slice contained 25-50 ng of DNA.
2.6.3 Polyacrylamide gel electrophoresis
Denaturing polyacrylamide gels were used to visualise DNA sequencing reactions
Preparation of gel plates
The gel plates are initially scrubbed using a powder detergent such as Flash, to remove any
residual gel. After rinsing thoroughly with water they are laid flat on a sheet of 3MM in a fume
hood. The plates are then rubbed down thoroughly with absolute alcohol, and once dry each plate
is coated appropriately. The backplate is coated in a solution of 10ml 100% ethanol; 30|il acetic
acid; and 30(il methacryoxypropyltrimethylsilane. The frontplate is coated with about 10ml of
dimethyldichlorosilane solution. In each case the coating is spread across the plate lightly with a
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tissue and left to dry for about 30 minutes, after which time the plates are rubbed dry very lightly
with a tissue.
Pouring the gel
The plates are placed together, coated side inwards separated by two spacers at either side. They
were then either taped together and the gel poured at an angle or laid flat and the gel dispersed
between the two plates by capillary action in the absence of tape. The gel itself consisted of 40ml
of 6% acrylamide mix which was polymerised by the addition of 240(il 10% ammonium
persulphate and 40|il Temed. The gel takes about 40 minutes to polymerise.
Running the gel
The gel is run vertically (Scodab vertical slab gel apparatus) in lxTBE buffer at 3000V, 300mA
with a constant 30W power. A metal plate is placed across the front of the glass plates to ensure
even heat distribution and the gel is often preheated before loading by running for about half an
hour. The urea is washed out of the wells just prior to loading samples. The wells are formed by
inserting a sharks tooth comb.
Processing the gel
It is very important for the method used here to ensure that the gel sticks completely to the
backplate. It was discovered that this could be facilitated by first cooling the plates in the cold
room before attempting to separate them. After separation the backplate is soaked in 10%
methanol and 10% acetic acid for 20 min. This fixes the gel and removes the urea. The gel is
then washed under flowing water for another 20 min, before drying in a 68°C oven. Although it
is not necessary for the development of [a-S35] ATP to expose the gel to film at -70°C, it does
ensure that the gel doesn't stick to the film and thus alleviates the need to wrap the gel in Saran
wrap which reduces the signal. The gel was incubate at -70°C overnight, or longer if required.
2.6.4 Pulsed field gel electrophoresis
Large undigested YACs were resolved using the CHEF. The sizes of inserts in the ICI YAC
library range between 200 and 500 Kb so appropriate conditions to allow separation across this
size range were selected, i.e. 200 volts for 24 hours at a pulse time of 50 seconds. Markers were
chromosomes of the yeast strains AB970 (Link and Olson 1991), and strain YP148 (Jones et al.,
1989).
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Size of chromosomes in YP148 (Kb): 90; 220; 280; 360; 445; 555; 610; 690; 760; 800; 830; 920;
960; 1010; 1100; 1600; and 2500.
Size of chromosomes in AB970 (Kb) : 240; 280; 350; 440; 590; 680; 755; 810; 840; 950; 980;
1095; 1120; 1130; and 1640.
2.7 Isolation of DNA from agarose blocks
2.7.1 Gene clean
Here the Geneclean® II kit (BIO 101 Inc.) was used. This method gave the lowest yield of DNA,
typically only 10-15%, but the DNA was very clean.
• For DNA in solution add 3 volumes Nal
• For DNA in agarose add 4.5 volumes Nal, if TBE buffer was used also add 0.5 volumes TBE
modifier. Mix well and melt agarose at 45-55°C for 5-10 min
• Add 5|il glass milk suspension to 5pg DNA (an additional 2(il should be added for each additional
Ipg)
• Vortex, and incubate on ice for 5 min, vortexing after every 2 min
• Centrifuge 5 sees, and discard supernatant
• Resuspend pellet in 250pl New Wash
• Centrifuge 5 sees, and discard supernatant
• Repeat the last two steps 3 times
• Resuspend pellet in 10(il TE
• Incubate 2-3 min at 45-55°C
• Centrifuge 30 sees and remove supernatant which contains the DNA
• Repeat the last two steps
2.7.2 Wizard DNA preparation
These kits are produced by Promega and were found to be easy to use and gave consistently high
recovery of DNA (60-100%).
Wizard™ DNA clean up system
• Melt agar block at 70°C
• Add 1ml of resin and gently invert several times
• Pipette mixture into a 2ml syringe, and use plunger to gently push solution through the mini column
• Detach syringe, remove plunger, reattach syringe
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• Wash column by pipetting 2ml 80% isopropanol into syringe, and push through
• Centrifuge 20 sees, and leave at room temperature for 5-15 min to remove isopropanol
• Transfer column to a fresh eppendorf and add 50pl prewarmed TE (70°C)
• Incubate 1-30 min
• Centrifuge 20 sees to elute the DNA
Wizard™ PCR clean up sytem
• Transfer reaction to a fresh tube, avoiding carry over of mineral oil
• Add lOOpl direct purification buffer
• Vortex briefly
• Add 1ml of resin and vortex 3 times over a 1 min period
• Pipette mixture into a 2ml syringe, and use plunger to gently push solution through the mini column
• Detach syringe, remove plunger, reattach syringe
• Wash column by pipetting 2ml 80% isopropanol into syringe, and push through
• Centrifuge 20 sees, and leave at room temperature for 5-15 min to remove isopropanol
• Add 30(il of TE to the column, and incubate 1-30 min
• Centrifuge 20 sees to elute the DNA
2.7.3 Spin X
These were simple columns produced by Costar. This is the quickest method of purification of
DNA from agarose, but the yield (40%) is not as high as with Wizard™ kits nor is it is clean as
with Gene Clean. Good for fast crude recovery of DNA. DNA must be in regular agarose
(Seakem GTG), LMP agarose does not work
• Chop up agarose block into small pieces
• Place agarose on spin column
• Spin 15 min at room temperature
• Rotate column through 180°
• Spin 15 min at room temperature
• Discard column and precipitate DNA- 0.3M sodium acetate and 2 volumes cold ethanol
• Purification of DNA
2.7.4 Drop dialysis
This is a very simple and quick method which can be used to purify DNA away from salts,
buffers, and enzymes. It can also be used to change the buffer which the DNA is in simply by
dialysing the DNA against the buffer instead of distilled water.
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Half fill a petri dish with dH20 or buffer
Drop a filter (0.025|iM Millipore VS), glossy side up, on the surface
Leave to equilibrate for 15 min
Drop >5(xl of the DNA solution on top
Dialyse for >15 min
Take off the dialysed DNA
2.8 Transfer ofDNA to membranes
The transfer of DNA fragments from an electrophoresed agarose gel to a membrane support
results in immobilisation of the DNA fragments, so that the membrane carries a semi permanent
replica of the banding pattern of the gel. After immobilisation, the DNA can be subjected to
hybridisation analysis, enabling bands with sequence similarity to a labeled probe to be identified
(Ausubel et al., 1995).
2.8.1 Southern transfer
• Soak gel in denature for 30 min
• Rinse with dH20
• Soak gel in neutraliser (pH to 5.5 with HC1) for 40 min
• Rinse with dH20
• Place gel in 2xSSC
• Place gel, wells down, on 3MM wick
• Cover gel with a sheet of Hybond membrane
• Place two sheets of 3MM (Whatman) on top of membrane
• Place one sheet of 15MM on top of 3MM
• Cover evenly with paper towels
• Place a plastic board on top of towels to disperse evenly the 0.5 - lKg weight which is then
placed on top
• Leave transfer 4 hours - overnight
• Remove towels, weights & paper
• Mark wells on membrane before lifting off gel
• Wash gel briefly in 2xSSC
• Dry on bench 30 min
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• Bake 80°C Vacuum oven 30 min
When transferring molecules over 20kb eg YACs the gel was initially depurinated by incubation
in 250mM HC1 for 20 min, prior to denaturation, and the gel was blotted for 48 hours.
2.8.2 Colony lifts
Bacterial colonies containing a particular insert can be identified directly by hybridisation. The
first step in the nucleic acid hybridisation screening procedure is to grow large numbers of
colonies on agar plates. Replica copies of these colonies are transferred to nitrocellulose filters
where they can be screened.
• Lay filter down gendy on plate, being careful not to trap any air bubbles
• To allow identification of colonies mark the plate and membrane at corresponding positions
• The filter is then placed ,DNA side up, on a series of sheets of 3MM paper soaked in various
different solutions as indicated below
• lmin 10% SDS (sharpens signal)
• 2-5min 1.5M NaOH (denatures DNA), 1.5M NaCl(sharpens signal)
• 2-5min 1.5M NaCl, 0.15M Tris pH7.4 (neutralises)
• Rub down the filters using a tissue under 2xSSC (removes bacterial cells and salt)
• Dry filters on 3MM paper then bake under vacuum in an 80°C oven for about half an hour
2.9 Hybridisation protocols
2.9.1 Hybridisation solutions
Hybridisation buffer (1 litre) commonly used for Random Prime labelled DNA:
• 5xSSC
• 5xDenhardts (BSA, Ficoll, Polyvinylpyrolidone all at lg/1)
• Add =100ml dH20
• Dissolve stirring on low heat
• Add detergent, the amount and type depends on what the buffer will be used for
• Hybond membranes -0.5% SDS
• Nitrocellulose membranes -0.1% SDS
• YAC DNA -2.5% Lauroyl Sarcosine
• Add 0.1% Pyrophosphate
• Add 10% Dextran Sulphate
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• Make up to llitre with dH20
• Filter through a 8(J.M filter under suction
Quick oligonucleotide hybridisation mix (1 litre):
• 5x SSC
• 2.5xDenhardts (BSA, Ficoll, Polyvinylpyrolidone all at 0.5g/l)
• 0.5% SDS
• Add dH20 to 1 litre
2.9.2 The ICIYAC library
The ICI YAC library (Anand et al., 1990) was screened by Southern hybridisation (Southern
1975). The library consists of approximately 35,000 YAC recombinants gridded at a high
density on 23 filters of 8cm x 12cm. The average insert size is approximately 350Kb and the
theoretical complexity of the library is therefore >3.5 genome equivalents. The presence of
chimaerism in the library is estimated at approximately 15%. The ICI YAC library was obtained
through the Human Genome Mapping Project (HGMP) Resource Centre,London. The YACs
were received in the form of an agar plug which was then restreaked on an AHC agar plate and
grown overnight. A single colony was then picked and grown overnight in AHC complete
medium and the DNA extracted the following day. The method used to extract the DNA was
very crude hence it was more accurate to estimate the DNA concentration on a 0.8% gel against a
marker of known concentration than spectrophotometrically.
2.9.3 Pre-hybridisation protocols
Pre-hybridisation of filters was carried out in oligo hybridisation mix at 5°C below the Tm of the
oligonucleotide and in hybridisation mix at 68°C. Filters were placed between two gauze sheets
in a hybridisation botde (Hybaid). 10ml of hybridisation mix was used for smaller bottles and
20ml for larger bottles. Denatured sonicated salmon sperm was added to the hybridisation mix at
a concentration of 100|ig/ml. Bottles were placed in a Hybaid hybridisation oven for 1-4 hours (a
longer prehybridisation is required on the first use of a filter). The ICI YAC library was
incubated in a perspex box (50ml of hybridisation buffer) with a sealed lid, shaking vigorously in
a 68°C oven for at least 4 hours.
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2.9.4 Hybridisation and washing protocols
End labeled oligonucleotide hybridisations were carried out for 4-16 hours at 5°C below the Tm of
the oligonucleotide. Filters were then removed from the botdes and washed three times for 5
minutes each at room temperature in 4x SSC, 0.1% SDS, heated to the same temperature as the
hybridisation reaction.
Random primed hybridisations were incubated for 16 hours at 68°C. Filters were then washed at
increasing stringency with 2xSSC, 0.1% SDS; lxSSC, 0.1% SDS; or O.lxSSC, 0.1% SDS at
68°C.
2.9.5 Removal of hybridisation signal
Two different methods were used to remove the radioactive probe from a membrane enabling it to
be rehybridised.
Gentle stripping
• Place membranes DNA side down in 0.4 M NaOH at 50°C
• Incubate, shaking, at 68°C, for 30 min
• Transfer membranes to O.lxSSC; 0.1% SDS; 0.2M Tris HC1 pH7.4 at 45°C
• Incubate, shaking, at 68°C for 30 min
Faster, more effective stripping
• Add filter DNA side down to a metal tray of boiling 0.1% SDS
• Incubate 30 sees, then remove tray from hotplate
• Allow to cool to room temperature
• In both cases check that all the radioactive signal has been effectively removed by exposing the
filters to film overnight.
2.9.6 Hybridisation signal detection
2.9.6.1 Autoradiography
Filters were exposed to Kodak X-OMAT film in cassettes with intensifying screens. Films were
exposed for a period of 30 minutes to two weeks (depending on the signal strength) before being
developed, using an automatic X-ray film processor RGII (Fuji).
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2.9.6.2 Phosphorimaging
A Molecular Dynamics Phosphorimager was also used for detecting and quantifying
hybridisation. Filters were exposed on a phosphor screen for 30 minutes to 48 hours. They were
then scanned on the Phosphorimager, where the radioactive signal is converted into a digital
image, with variations in the pixel values proportional to the amount of radioactivity present.
The image was displayed on a grey scale. The upper and lower limits of the grey scale were
adjusted to give good image visualisation. The image was then printed out on a grey scale laser
printer.
2.10 Radiolabelling of DNA
2.10.1 Random primed DNA labelling
The DNA fragment to be labelled was usually in the form of a block of LMP agarose, although
occasionally purified DNA was labelled. The labelling technique was performed using a kit
produced by Boehringer Mannheim and is described below. The kit is based on the hybridisation
of a mixture of all possible hexanucleotides to the DNA to be labelled. Complementary strands
are then synthesised from the 3'OH termini of the annealled random hexanucleotide primers,
using Klenow enzyme. Modified deoxynucleotide triphosphates (in this case32P) are incorporated
into the newly synthesised complementary DNA strand.
• Add 1-2 volumes dH20 to the agarose block
• Heat to 68°C until melted, mix
• Remove 15|il (50-100ng) to a fresh tube, boil 5 min
• Add 5pJ Random prime reaction mix + GAT ( 2jll1 hexanucleotide reaction mix in lOx reaction
buffer, and lpJ of each of dG/T/ATP all at 0.5mM)
• Add lfxl Klenow enzyme
• Add 3pi [a-P35] CTP (lOpCi/pl)
• Centrifuge briefly, and incubate 37°C 45-60 min
• To test the incorporation of radioactivity: touch the labelled probe lightly with a Gilson P200 tip,
then touch the tip onto a piece of filter paper. Place a monitor at a position relative to the filter
such that it reads 100 counts. The filter is then washed twice under suction with 5% TCA, and
the number of counts re-measured at the same distance from the monitor. This second reading
therefore gives a rough measure of incorporation. If the incorporation is more than 50% the
probe is boiled for 5 minutes, then added to the prehybridisation mix. If however the
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incorporation is poor the probe is boiled for another 5 minutes, then another lpl of Klenow
enzyme is added and the mixture reincubated for another hour. The incorporation is again
measured and a decision made whether or not to go ahead with the probe. If the incorporation is
less than 20% the probe is abandoned. If however the incorporation is 20-50% a Nick™ column
is used to remove the unincorporated radioactivity as described below
• Pour the top layer off the column
• Equilibrate with 2ml of TE
• Dilute the probe so in 50- lOOptl and apply to the column
• Apply 350-300|ll of TE to the column
• Discard flow through
• Apply 400pl TE to the column
• Collect hot probe
• Boil 5 min then add to the prehybridisation mix
On hybridisation of a probe to the ICI YAC library it was necessary to measure the level of
incorporation after removal of unincorporated label using a scintillation counter. 1 x 105 -1 x 106
counts per ml of hybridisation buffer were required which meant setting up 4-6 random prime
reactions.
2.10.2 Non-random primed DNA labelling of small probes
Probes which are less than 200bp long do not label well using the standard Random prime kit, an
adaptation of the kit where primers specific to the fragment to be labelled are used , is however
very efficient and is described below.
• Denature lOOng of each primer for 3 min at 95°C
• Add 3pl GAT (lpl of each of dG/T/ATP all at 0.5mM)
• Add lpl Klenow enzyme
• Add 3pl [a-P35] CTP (lOpCi/pl)
• Centrifuge briefly, and incubate 37°C 30 min
• Add lpl Klenow enzyme
• Centrifuge briefly, and incubate 37°C 30 min
• Repeat the last two steps
• Boil 5 min then add to the prehybridisation mix
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2.10.3 End labelling of DNA oligonucleotides
Polynucleotide kinase catalyses the transfer of the terminal phosphate group of ATP to the 5'
hydroxylated terminus of DNA or RNA.
• Prehybridise filters in oligonucleotide hybridisation buffer containing denatured salmon sperm at
lOmg/ml for 5-30min at 68°C
• To 30 ng of oligonucleotide DNA
• Add 2(il PNK buffer (BM)
• Add dH20 to 16(il
• Add lpl Polynucleotide Kinase (BM)
• Add 3pi [y-32P] ATP (lOpCi/pl)
• Incubate 40min 37°C
• Add Kinase reaction to prehybridisation solution
• Incubate overnight at 48°C
• Wash filters in 4xSSC 0.1%SDS l%PPi for 4 sets of 5min
2.10.4 Preannealing of repetitive sequences
Two methods were tried to block non-specific hybridisation. On direct comparison, using
sonicated human DNA proved to be more effective, and hence was the method used. In both
cases the probe was labelled using a standard random prime reaction, but once a sufficient degree
of incorporation had been achieved (70-90%) the probe was not put down a nick column, but
repetitive sequences were suppressed using one of the methods described below.
2.10.4.1 Cot-1 suppressedprobes
• Precipitate the probe by adding 50pl Cot-I DNA (lmg/ml), 10.5pl 2M NaOAc, and 140pl cold
absolute EtOH
• Incubate 15min -70°C
• Centrifuge 15min in the cold room
• Resuspend the vacuum dried pellet in lOOpl TE + Cot-I DNA at lOmg/ml
• Add 50pl 20xSSC, 25pl dH20, 20pl 0.1M Tris pH7.4; 0.1M EDTA, 1% SDS
• Vortex
• Incubate 100°C 5 min
• Incubate 65 °C at least 20 min
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• Add probe to prehybridisation mix
2.10.4.2 Sonicated human DNA suppressedprobes
• Add 500|J.g of sonicated human DNA for every 25ng of probe
• Add 500|ig of sonicated salmon sperm DNA for every 25ng of probe
• Incubate at 100°C for 5 minutes to denature the DNA
• Incubate at 68°C for 30-45 minutes to allow the DNA to reanneal
• Add to prehybridisation
2.11 Mutational analysis of the OMP gene
2.11.1 Usher type IB patients
Patient DNAs were provided by groups from Newcastle, Manchester and USA. Most of the work
was done on the latter two since these came with parental and affected/unaffected sib DNAs,
making it possible to assess whether or not a mutation/ polymorphism was inherited. Each group
sent DNA stocks of a known concentration, which were then used to make dilutions to lOOng/jil
for PCR. Laboratory numbers were given to these samples for simplicity during mutation
analysis.
Families A, B, & C were supplied by William Kimberling (Kimberling et al„ 1992), hence these
had been linked to D11S527. The remaining families were British and these were typed as
USHIB on the basis of clinical features and ethnic origin. The latter were therefore given to us in
order to test this supposition at the candidate gene level.
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Table 2.7 Usher IB families
Family Laboratory No. Sample No. Relationship
A 1 D3677 unaffected father
2 D3680 unaffected mother
3 D3678 affected sib
4 D3681 affected sib
5 D3679 unaffected sib
B 6 D2734 unaffected father
7 D2735 unaffected mother
8 D2377 unaffected sib
9 D2378 affected sib
10 D2376 affected sib
C 11 D2127 unaffected father
12 D2139 unaffected mother
13 D2137 unaffected sib
14 D2134 unaffected sib
15 D2138 unaffected sib
16 D2129 affected sib
D 17 920922 unaffected father
18 920921 affected sib
19 920923 affected sib
E 20 920920 unaffected mother
21 920919 affected child
F 23 92/959 unaffected mother
24 92/957 unaffected father
25 92/958 affected child
G 31 No.5 affected sib
32 No.6 unaffected sib
H 34 No. 17 unaffected sib
35 No. 18 affected sib
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2.11.2 Chemical mismatch detection
The mutation detection method chosen was the HOT technique (so-named for the hydroxylamine
and osmium tetroxide used in the method). This method was originally developed by Cotton and
colleagues (1988), and is based on chemical modification of mismatched bases (mismatched Cs
with hydroxylamine, Ts with osmium tetroxide) in heteroduplex molecules, followed by
piperidine cleavage of the DNA molecule at the site of modification. The theory of the technique
relies on the principles of Maxam and Gilbert sequencing (1980).
This technique is very reliable, and in cases where both wild type and mutant DNA fragments are
labelled has been shown to identify 100% of mutations. Mutations still need to be confirmed by
sequencing, although the nature of the mismatch (depending on the particular chemical it was
identified by) and its location (a specific distance from either of the primers) are inherently
indicated in the process of the technique. Another advantage of this technique is that it can be
used to assess whether a mutation is homozygous or heterozygous, simply by labelling mutant
DNA and heteroduplexing (see below) it back to cold self DNA. If the sample is heterozygous
then a shortened fragment characteristic of the mutation is seen. The HOT technique can be
routinely used to identify mutations in fragments of 1Kb or more (Cotton et al., 1988). The only
drawback of this technique is that it uses hazardous chemicals and is relatively labour intensive,
but these are far out weighed by its accuracy and the fact that it can be used to screen fragments
4-5 times the size of those used in the other major techniques.
The protocol described below is based on that used by Montandon et al (1990), but modified for
the osmium tetroxide reaction along the lines of Cotton et al and is published in Condie et al.
Both target and wild type DNAs are amplified by PCR and the products excised from a low
melting agarose gel. The bands are then purified using the Wizard DNA prep kit and the
recovery assessed by running an aliquot on a mini gel. The actual heteroduplex reactions are set
up in two ways: labelling wild type and heteroduplexing to cold mutant DNA; and the converse,
labelling mutant and hteroduplexing to cold wild type DNA. About 10 to lOOng of the purified
DNA is kinase labelled
Kinase end labelling
• 10-100ng DNA
• 2(il lOxPolynucleotide Kinase Buffer
• 2(tl [y-32P] ATP, specific activity -5000 Ci/mmole
• l|il (2.5 units) Polynucleotide Kinase
• distilled water to 20|il
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• Incubate at 37°C for 30 minutes then transfer to ice
• Precipitate by adding: -
• 22.5(xl dH20
• 7.5(d 2M Sodium Acetate
• 1.5(il mussel glycogen (lmg/ml)
• 750|il cold absolute ETOH
• Incubate 15-30 min -70°C
• Centrifuge 15 min
• Wash 2x70% ETOH
• Resuspend in 10(il dH20
Formation of heteroduplex
• lOOng cold DNA
• lOng labelled DNA
• IjjJ lOx salts (3M NaCl, 1M Tris pH8)
• dH20 to 10|il
• Overlay with paraffin oil
• Incubate 100°C 5 min
• Incubate 65°C overnight
To clean and precipitate the heteroduplex
Pipette off the majority of the oil, then to remove the remainder of the oil add
• 50|il 0.3M Sodium Acetate, 0.1M EDTA
• 50|il chloroform
• Vortex, centrifuge and remove the top layer to a fresh eppendorf. The chloroform can be
re-extracted with 150|il of 0.3M Sodium Acetate, 0.1M EDTA, if the majority of radioactive
counts have not been removed at the first attempt.
Precipitate by adding
• 1.5pl mussel glycogen (lOmg/ml)
• 750pl absolute ETOH
• Incubate 15 min in dry ice/methanol bath
• Centrifuge 15 min
• Wash 2x70% ETOH
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Dry 1 min under vacuum
Resuspend in 13|il TE
Divide into two tubes, 7(il for hydroxylamine modification, leaving 6(il for osmium tetroxide
modification in the original tube.
Hydroxylamine modification





Vortex and add 20pl to each 7pl sample
Mix, incubate at 37°C for 1 hour, then transfer to ice
Osmium Tetroxide modification
To the 6(il aliquot of heteroduplex add
2.5pl of lOx Osmium Tetroxide buffer (lOOmM Tris pH7.7, lOmM EDTA, 15% pyridine). This
buffer should be stored frozen, and each aliquot used only once.
15(jJ freshly diluted (4% to 0.8% in dH20) Osmium Tetroxide
Mix, do not centrifuge
Incubate 5 min at 37°C, then transfer to ice
After each chemical modification precipitate add
200(jl 0.3M Sodium Acetate, 0.1M EDTA
5pl Dextran (lOmg/ml)
750pl absolute ETOH
Incubate 15 min in dry ice/methanol bath
Centrifuge 15 min
Wash 2x70% ETOH
Dry 1 min under vacuum
Piperidine cleavage
To dried pellet add
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• 50(xL freshly diluted piperidine (1/10 dilution to make 1M stock)
• Vortex 1 min
• Centrifuge briefly
• Incubate 90°C 30 min, then transfer to ice
• Precipitate by adding
• 200pl 0.3M Sodium Acetate, 0.1M EDTA
• 750ptl absolute ETOH
• Incubate 15 min in dry ice/methanol bath
• Centrifuge 15 min
• Wash 2x70% ETOH
• Dry 1 min under vacuum
• Resuspend the dried pellet in 5pl TE
• Add 2|al denaturing dye
• Store at -20°C
• Before loading on denaturing polyacrylamide gel, heat samples to 100°C for 2 min
2.12 Sequencing ofDNA
2.12.1 Conventional sequencing with a radioactive isotope
The method used here was that used by Stillman's lab at Cold Spring Harbour (pers. comm.) and
is outlined below. Many of the constituents came from the Sequenase® Version 2.0 DNA
sequencing Kit (United States Biochemical Corporation).
• 7jnJ of DNA, either 7pi from an alkaline lysis preparation which has been resuspended in lOpl, or
3-5pg of alternatively prepared DNA
• Add lpl of RNase A (lOmg/ml)
• Incubate 15 min room temperature
Annealing reaction
• Add lpl of the appropriate primer (lOng/pl)
• Add lpl of 1M NaOH
• Incubate 10 min 68°C
Sequencing reaction
• Add 4|il TDMN (0.28M TES (Sigma T-1375), 0.5ml chloroform, 50mM DTT (USB), 80mM
MgCl2,0.2M NaCl, dH20 to 50ml pH to =1.6)
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• Incubate 10 min room temperature
• Place on ice until ready to use
• Add 4pl labelling mix
• lplO.lMDTT
• 0.4(-tl 5xSequenase labelling mix (USB - 7.5pM dCTP, 7.5(iM dGTP, 7.5p.M dTTP)
• 2.1(il LoTE (3mM Tris pH7.5, 0.2mM EDTA)
• 0.5(il [a-35S]-dATP
• Add 2(B T7 DNA polymerase (USB) diluted 1:10 in enzyme dilution buffer (USB lOmM
Tris.HCl pH7.5, 55mM DTT, 0.5Mg/ml BSA)
• Incubate 45 sees room temperature
Termination reaction
• Add the labelling reaction in 4pl aliquots to 2.5pl of each termination reaction (USB)
• Incubate 10 min 37°C
• Add 5pl stop buffer (USB)
• Store at -20°C immediately or denature at 100°C for 2 min and run on a polyacrylamide gel
In this method the first 50 bases of sequence is obscured because prior to this the salt forms a
front which decreases the resolution severely. It is possible to get rid of the salt by precipitating
and washing the DNA prior to the addition of stop buffer as described below
• To the sequencing reaction
• Add 0.4|il 0.5M EDTA
• Add 1.5(il 2M Sodium Acetate pH5.5
• Add 1(0.1 tRNA (lpg/pl)
• Add 0.6fil dH20
• Add 2 volumes of cold absolute ETOH
• Incubate -70 C 15 min
• Centrifuge cold room 15 min
• Wash 70% ETOH
• Dry 1 min under vacuum
• Resuspend 6|il dH20
• Add 4pl stop buffer
118
2.12.2 Double stranded PCR sequencing with DMSO
This method also uses many constituents from the USB Sequenase® Version 2.0 DNA
sequencing Kit, but has been specially adapted to allow sequencing of PCR products
Normally a lOOfil PCR reaction was gel purified, and the DNA isolated by Gene Clean, then
combine:-
Annealing reaction
• 6(il DNA solution (~100ng)
• lpl DMSO
• l|il sequencing primer (~l|i.g)
• 2(il sequencing buffer (USB - 200mM Tris.HCl pH7.5, lOOmM MgC12, 250mM NaCl)
• Incubate at 100°C for 2 min then place immediately in a dry ice/methanol bath
Sequencing reaction
Add to annealing reaction:-
• lplO.lMDTT
• 0.5pl of deoxyadenosine-5'-triphosphate (a35S)
• 1.5(jJ Sequenase enzyme (USB) diluted 1:6 in enzyme dilution buffer (USB)
• 2(il labelling mix (USB) diluted 1:15 in dH20
• Incubate 45 seconds at room temperature
Termination reaction
Add 3.2(il of sequencing reaction to:-
• 2pi of each termination reaction (USB) diluted 9:1 with DMSO
• Incubate 37°C 10 min
• Add 4|il stop solution
2.12.3 ALF sequencing
Two methods were used for fluorescent sequencing of templates on the Pharmacia ALF machine.
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2.12.3.1 ALF cycle sequencing
In an attempt to improve the quality of sequence obtained PCR products for cycle sequencing
were also purified using Mung Bean Nuclease or Isopropanol, since excess PCR primers interfere
with subsequent PCR-like sequencing reactions..
Mung Bean Nuclease (Dowton and Austin 1993)
Mung bean nuclease is a single-strand-specific nuclease purified from germinated mung bean
sprouts. It degrades DNA and RNA to 5'-phosphoryl mononucleotides.
To 6(xl of the PCR reaction add
• 4.4jj.l of 25mM MgCl2
• 1.2|ilof ImMEDTA
• 0.4jil of distilled water
• 2U Mung Bean Nuclease (NEB)
• Overlay with oil and incubate 25°C for 30 min
• Incubate 100°C for 5 min
Isopropanol
Isopropanol precipitation allows the purification of PCR-amplified DNAs away from excess
nucleotides and amplification primers.
To 6(il of the PCR reaction add
• 20|jJ of4M Ammonium Acetate, vortex
• 40|il of Isopropanol
• Incubate room temperature 10 min
• Centrifuge 20 min
• Wash pellet with 70% ETOH
• Resuspend pellet in 12(il dH20
Cycle sequencing
This was carried out using the BRL dsDNA Cycle sequencing system
Prereaction mix
• 5|il fluorescently labelled primer
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• 4.5(jJ Taq sequencing buffer
• 26(il template DNA (~50fmol)
• 0.5(tl Taq DNA polymerase (5U/jj.1)
Reaction mix
• Add 8|il from prereaction mix to each of four tubes containing 2|_l1 termination mixes -A, -C, -G,
and -T
• Overlay with oil, then amplify as described below
20 cycles: 30s 95°C ->30s 55°C ->60s 70°C then 10 cycles: 30s 95°C ->60s 70°C
2.12.3.2 ALF single stranded sequencing
Primarily single stranded DNA must be prepared. This was done using Dynabeads as described
below
Washing the Dynabeads and extracting the DNA
• Take 20(tl well suspended Dynabeads per reaction
• Wash twice with 100(il 2M Binding and Washing Solution (2M BWS - lOmM Tris HC1 pH7.5,
ImM EDTA, 2M NaCl) removing the liquid with a long tipped pastette
• Resuspend the beads in 20(tl BWS
• Add up to 40(tl PCR product (template amplified using one biotinylated and one nonbiotinylated
template)
• Incubate at least 30 min at room temperature on an IKA Vibrax VRX at 1400rpm
• Wash twice with 100(jJ TE to remove unbound material
Preparation of the biotinylated strand
• Add 10(il 0.1M NaOH (Analar BDH 1M stock stored in aliquots at -20°C)
• Incubate 5 min room temperature
• Remove the NaOH, which contains the non-biotinylated strand
• Wash twice with lOOfil TE, which neutralises the solution and removes the high salt
• Resuspend the Dynabeads in 13(1.1 dH20 to elute the biotinylated strand
• Store the biotinylated strand, ready to sequence, at 4°C
Preparation of the non-biotinylated strand
• Add l(il of 1M HC1 (Analar BDH 1M stock stored in aliquots at -20°C) to the NaOH supernatant,
this allows the non-biotinylated strand to return to its native conformation.
• Mix well
121
• Add 2pl dH20
• Store the non-biotinylated strand, ready to sequence, at 4°C
Pharmacia Autoread sequencing protocol
• Add 2(il annealing buffer (a buffer solution containing MgCl2) to each tube
• Add 2(il fluorescent primer (1 pmol)
• Mix by tapping
• Incubate in a 65 °C water bath 10 min
• Allow to cool slowly for at least 10 min
• prewarm tubes containing the 2.5(il of dNTP mix in 42°C water bath
• Add lpl extension buffer to each sample
• Add 2pi of T7 DNA Polymerase (diluted 1:2 in enzyme dilution buffer)to each sample
• Mix, and add 4.8|il to each dNTP tube
• Incubate 5 min at 48°C
• Add 5(il stop solution
• Store at -20°C immediately or denature at 100°C for 2 min and run on a polyacrylamide gel
2.12.4 ABI cycle sequencing
This involves a linear amplification of the sequencing reaction using 25 cycles of denaturation,
annealing, and extension in the presence of Taq polymerase and labelled di-deoxy nucleotides
(the primer is unlabelled). There are several advantages of this method over conventional
sequencing. The dideoxy terminators are each labelled with a different fluorescent dye, which
means that the entire reaction can be carried out in a single tube and run out in a single gel lane.
In addition false stops go undetected since no fluorescent dye will have been incorporated. The
reaction is very simple and easy to set up as it is just like setting up a PCR reaction. The only
time consuming step is cleaning up the reactions after the PCR to remove any excess dye
terminators, since these will obscure the signal at the start of the gel. A few recommendations
were also made by the kit manufacturers as to the design of the primer and the preparation of the
template.
Double stranded template was prepared in bulk by caesium chloride centrifugation, then any
residual caesium removed by drop dialysis. Smaller amounts of plasmid template were prepared
by PEG precipitation. PCR template was purified using the Promega Wizard PCR Kit.
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Primers were recommended to be longer then 18 base pairs for good hybridisation and to avoid
false priming. Long runs of single bases were avoided as far as possible, as were primers able to
form secondary structure or able to dimerise. The GC content was recommended to be over 50%.
If however this was not possible primer lengths were extended to longer than 18 bases ensuring
that the Tm of the primer was greater then 45°C. These conditions were on the whole not that
difficult to meet and every single primer used worked. The primers were designed using the
Primer programme and purified by rapid butanol purification.
Reaction set-up
The reaction was set up using the Taq DyeDeoxy™ Terminator Cycle Sequencing Kit as
described in the booklet provided with the kit, a basic description of which is shown below.
For both double stranded sequencing and sequencing of PCR fragments (also double stranded) the
primer was used at 3.2pmol per reaction. Less template is required for PCR sequencing than
double-stranded plasmid sequencing i.e. 100-500ng compared to l-1.5pg.
Firstly a reaction premix is prepared. This can be stored for at least a month at 4°C hence
enough for several reactions was usually prepared. Amounts for the lx mix are shown.
Reaction premix
• 4pl 5xTACS buffer (400mM Tris.HCl, 10mMMgCl2, lOOmM (NH4)2S04 pH9)
• lpl dNTP mix (750pM dITP,150pM dATP, 150pM dTTP, 150pM dCTP)
• lpl DyeDeoxy™ A Terminator
• lpl DyeDeoxy™ T Terminator
• l(il DyeDeoxy™ G Terminator
• lpl DyeDeoxy™ C Terminator
• 0.5|il (4 units) AmpliTaq® DNA Polymerase
Sequencing reaction
• 9.5pl reaction premix
• 9.5pl template (1 pig ds DNA, lOOng purified PCR products)
• lp.1 primer (3.2pmol)
• Overlay the reaction with a drop of mineral oil
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Cycling the reaction
The tubes are then placed on a thermal cycler preheated to 96°C. Ramping time for cycle
sequencing is optimal at 1°C /sec hence Perkin Elmer Cetus Model 480 was used and the
programme is shown below.
• 96°C for 30 sees
• 50°C for 15 sees
• 60°C for 4 minutes
• 25 cycles total
• Rapid thermal ramp to 4°C and hold
Removal of excess Taq dye terminator dyes using phenol/chloroform extraction
• Transfer the reaction products to a fresh tube, taking as little oil as possible
• Add 90|il dH20
• Add 100(il of ABI phenol/chloroform/water (68:14:18) reagent, mix first to ensure homogeneous
• Vortex 5 sees, and centrifuge 2 min
• Remove 105(il of the top aqueous phase to a fresh tube
• Add lOOpl of phenol/chloroform/water reagent
• Vortex 5 sees, and centrifuge 2 min
• Remove 93(il of top aqueous phase to a fresh tube
• Add 15(Jl of 3M NaOAc pH4.5 followed by 300(il cold EtOH and mix thoroughly by vortexing
• Incubate on ice 15 min
• Centrifuge 15-20 min
• Remove as much EtOH as possible with a pastette
• Centrifuge briefly, and remove remainder of EtOH using a Gilson P2 micropipettor
• Dry pellet 85°C 1min
• Pellets can now be stored at -20°C or resuspended 4(tl of formamide/EDTA
• Incubate 90°C 2min, store on ice for up to 1 hour before loading on gel
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3. Cloning a repeat free resource
3.1 Optimizing the product complexity of Alu PCR
Inter Alu-PCR was used to amplify human specific fragments of DNA from human
chromosome 11 reduced somatic cell hybrids (E67.4, WJX11.2, WJX3.4 see
section 2.1.3.1). The primer chosen was designed to match a consensus sequence
near the 3' end of the Alu repeat. Amplification only occurs if two sufficiendy
close Alu repeats are inversely orientated toward each other. Alu PCR produces a
complex mixture of inter-Alu sequences which may be cloned in order to isolate
specific products. Factors influencing the efficiency with which inter-Alu
sequences are amplified include i) degree of match to the consensus sequence to
which the primer sequence is directed, from one or both adjacent inversely
orientated Alus; ii) the distance separating inversely orientated Alus; iii) the nature
of the intervening sequence. It was desirable to minimize the effects of these
factors and identify the conditions which gave the most uniform distribution of
products and maximize their number, thus ensuring a comprehensive representation
of products from all regions of the human component of the hybrid.
3.1.1 Comparison of different buffer and enzyme combinations
These experiments predate the licensing restrictions of the PCR technique,
allowing the optimal enzyme and buffer combination for this particular experiment
to be established. Initial experiments were carried out using Taq (isolated from
Thermus aquaticus - Promega) and Tth (Thermus thermophilics - Hybaid)
thermostable DNA polymerases. Each enzyme was tested with another two
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buffers in addition to those supplied by the manufacturers. Tricine buffer (Ponce
and Micol 1992) unlike the others does not contain KC1 and has been shown to
allow the preferential amplification of larger (3-6 kb) fragments. A fourth buffer
was designed for Alu-PCR "in house" to give optimised reproducibility with a
variety ofDNA templates, and is referred to as Edinburgh buffer.
Initial experiments were carried out to find the most efficient annealing
temperature. The templates used for these experiments were the somatic cell
hybrids WJX11.2 and E67.4, both of which contain subfragments of chromosome
11 as their sole human component (-50 Mbp complexity in each case). Annealing
at 65°C was found to give more distinguishable products than 60°C in a 35 cycle
PCR reaction. Taq polymerase failed to give any products with Tricine or
Edinburgh buffer, few products with Tth buffer and only gave a satisfactory result
with Taq buffer. In contrast, Tth polymerase gave many distinguishable products,
and more than Taq polymerase itself with Taq buffer, under all conditions tested.
Fig. 3.1 shows Taq and Tth enzyme amplification with each buffer: Fig. 3.2 shows
the range of products achieved with Tth enzyme.
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Hybrid E67.4 WJx11.2
Enzyme Taq Tth Taq Tth
Buffer M '1 2 3 4I[1 2 3 4'r1 2 3 4"1 2 3 4'
Figure 3.1 Comparison of different buffer and enzyme combinations
The range of products obtained by Alu-PCR amplification of the somatic cell
hybrids E67.4 and WJX11.2, using the Alu repeat primer 614. Each hybrid was
amplified using different enzyme and buffer combinations as indicated. For both
hybrids, Tth enzyme gave a greater range of products, and was able to function
with all of the buffers tested.
Key: M = lkb ladder marker (Gibco BRL); 1 = Tth buffer; 2 = Taq buffer; 3 = Tricine
buffer; 4 = Edinburgh buffer
127
Hybrid E67.4 WJx11.2
Ml 2 3 4 1 2 3 4
Figure 3.2 The range of products achieved with Tth enzyme
The range of products obtained by Alu-PCR amplification of the somatic cell
hybrids E67.4 and WJX11.2, using the Alu repeat primer 614. Each hybrid was
amplified using Tth enzyme and different buffer combinations as indicated.
Human, hamster, and mouse controls were all blank but have been left off this
gel for clarity.
Key: M = lkb ladder marker (Gibco); 1 = Tth buffer; 2 = Taq buffer; 3 = Tricine
buffer; 4 = Edinburgh buffer
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3.1.2 Obtaining the point prior to saturation
The maximum product complexity is most likely to be obtained during the
exponential phase of Alu-PCR. Therefore, using Tth enzyme with all four buffers,
I attempted to establish the point at which each amplification reaction became non-
exponential. Generally after 25 cycles of amplification (using lOOng of human
genomic in a 50|il reaction) the amount of product is still doubling with each cycle,
hence this was chosen as the start point. Samples were removed at cycles 25 to 35
with a final single long extension cycle at 72°C. In order to keep the total
concentration of DNA constant, the amount of sample loaded on a gel was
decreased by half for each additional cycle beyond 25. This was because the
number of products should approximately double with every amplification cycle
when the reaction is in exponential phase. If, however, the reaction has become
saturated then some products will be amplified in preference to others, resulting in
a stronger signal for specific products. Some of the reactions gave very faint
products, so the complexity was assessed by Southern transfer of the DNA to a
nylon membrane and hybridisation with the Alu primer probe 614. The greatest
product complexity was gained after 27 cycles using Tth polymerase in
combination with Taq buffer (Fig. 3.3). After 27 cycles the amount of product
falls off indicating that the reaction is no longer exponential. A further comparison
of the rodent background amplification by Tth showed that the enzyme produced a
high background in combination with mouse and hamster with Tth buffer (Fig. 3.4)
but none with Taq buffer (Fig. 3.4).
129
Buffer Tth Taq
.. o en CO r*- CD Ln
M CO CM CM CM CM CM 8 o) co h- co inCM CM CM CM CM M
Figure 3.3 Assessment of product complexity
Alu PCR reactions using Tth enzyme in combination with Tth or Taq buffer were
carried out for increasing numbers of cycles, using the somatic cell hybrid E67.4
as a template. With each extra cycle half as much sample was loaded on a gel,
which was run until the 500bp products reached the bottom, then Southern
blotted. The membrane was then hybridised with 32P labelled Alu primer 614. The
greatest product complexity, within the exponential phase of the reaction, was
achieved after 27 cycles with Taq buffer. M = lkb ladder. The Taq polymerase
26 cycle sample was underloaded.
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Buffer Tth Taq
M 1 2 3 4 5 M 1 2 3 4 5
Figure 3.4 Assessment of buffer specificity
Here 35 cycle PCR was carried out using the Alu repeat primer 614, in
combination with Tth enzyme and Tth or Taq buffer. The somatic cell hybrids
E67.4 and WJX11.2 and their rodent cell backgrounds were used as template.
Tth buffer appeared to be contaminated at source, and gave bands with
rodent DNA and even in the total absence of template (3).
Key: M = lkb ladder marker; 1 = E67.4; 2 = mouse genomic DNA; 3 = blank;4 =
hamster genomic DNA; and 5 = WJX11.2.
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3.2 Cloning Alu PCR products
Initially my aims were to devise a quick and simple ligation independent cloning
(LIC) method for selectively cloning Alu PCR products. However, ultimately a
new strategy for cloning Alu-PCR products was devised and proved to be more
conveniently carried out. Thus, the aim of cloning Alu PCR products from a
specific chromosomal region was achieved via a method called 'Turbo cloning"
which gave many more cloned products than LIC, which were also easier to map.
3.2.1 The principle of Ligation independent cloning
The pBluescribe vector was specially adapted to contain a 30 base pair GC rich
linker with a central Smal site (by Catherine Scahill, a summer student in or lab).
Linearisation with Smal results in a vector with GC rich ends which can be made
single stranded using T4 DNA polymerase which in the absence of dGTP and
dCTP and the presence of excess dATP and dTTP acts as a 3' - 5' exonuclease
removing the G and C nucleotides. This activity terminates after 12bp where the
enzyme reaches an A or T nucleotide. Alu-PCR fragments with a complementary
12bp tail are produced using a primer (C324 or C325) which has a 5' tail
complementary to the vector. These primers comprise a slightly shortened version
of the Alu primer 614, in addition to the GC rich tail, and were always used to
reamplify fragments produced using 614 primer since a two stage PCR gave a
greater complexity of products than using just C324/5 alone, probably due the fact
that 614 is better matched to the consensus sequence. These products too could
132
be made single stranded with T4 DNA polymerase. Since the single stranded tails
of vector and PCR product are complementary to each other, annealing in the
absence of DNA ligase should result in cyclisation. Although the cyclised product
contains four nicks (non-covalently linked ends), it may be used directly to
transform competent E.coli. Once inside the bacterial cell the two nicks are

















Figure 3.5 Ligation Independent Cloning
The overall scheme of ligation independent cloning is shown. Inter-Alu PCR
products and LIC vectors are treated with T4 DNA polymerase to produce single
stranded ends, which are then annealed in the absence of DNA ligase. The
mixture can then be transformed as normal. Once inside the bacterial cell E.coli
DNA ligase will repair the nicks indicated by arrows 4).
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3.2.2 Production of tailed products for Ligation Independent Cloning
3.2.2.1 Maximising the complexity
The hybrids E67.4 and WJX11.2 were chosen because mapping of markers to
these showed that they retained shared as well as distinct regions of chromosome
11 (Fletcher et al„ 1993), and as such were good substrates for testing the
coincident sequence cloning of Alu-PCR products. PCR amplification reactions
primed by 614 were each reamplified with a different tailed primer: E67.4 with
C325 ; and WJX11.2 with C324 (these primers contain a shorter Alu consensus
than 614 which makes them less specific, but here they are being used as nested
primers on a resource of reduced complexity so it was thought unnecessary to alter
the annealing temperature). In order to ensure the majority of products were tailed
in this reaction it was necessary to remove any excess 614 primer from the first
round of amplification. This was done by passing the whole 50|il 614 PCR
reaction down a Nick™ column. The sample was now in 400|il. An eight fold
range of volumes was reamplified (0.5, 1, 2,4jiL) for 35 cycles at 65°C. All four
volumes gave roughly the same amount of product so it was decided to proceed
using lpl template. In each case, however, the reaction was obviously non-
exponential, so decreasing cycle PCR was carried out as before. Amplification was
shown to be exponential between 29 and 34 cycles. Thus conditions had now been
identified which produced the greatest complexity of Alu-PCR products.
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3.2.3 Vector production
The vectors required for LIC had already been constructed in this laboratory by
Catherine Scahill, and their ability to clone Alu PCR fragments tested. These early
tests indicated that the technique had promise, but the cloning efficiency was not as
high as had been expected.
The three vectors were constructed by insertion of 30bp linkers into the unique
Smal site of the pBluescribe vector (see Fig. 3.6). In each case the Smal site was
destroyed and a new Smal site created in the middle of the linker flanked by a 12bp
G/C sequence and terminated with a T/A only triplet. Each 30bp linker was
produced by annealing together two complementary 30 base oligonucleotides,
which were then blunt end cloned by ligating to Smal linearised pBluescribe.
Primers are readily available for the amplification and sequencing of inserts cloned
into the Bluescribe polylinker (Ml 3-20 and Ml 3 reverse primers).
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BssHII BssHII
pBLIC 5' TTA GGG GGC GCG CCC GGG CGC GCC CCC TAA




5'TTA CCC CCG CGG CCC GGG CCG CGG GGG TAA
AAT GGG GGC GCC GGG CCC GGC GCC CCC ATT 5'
Smal
Figure 3.6 The oligonucleotides used to convert pBS into LIC vectors
The oligonucleotides used to convert pBS to LIC vectors are illustrated above,
and Fig. 3.5 illustrates the way in which complementary single stranded tails were
produced at the ends of the PCR products and the vector. The PCR primers are
described in the previous table (2.4).
Both strands are shown in each case. The names of the vectors (pBLIC and
pSLIC), and the positions of restriction sites are also indicated, are Ligation
Independent Cloning vectors.
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The obvious way of verifying the identity of such a short sequence would be to
sequence it. However the sequence of the linkers meant that this was not as simple
a process as it at first seemed. The polylinkers in pSLIC and pBLIC are entirely
self complementary, in addition to which all of the linkers were by design GC rich.
Sequencing was normally done using the Sequenase 2.0™ kit (USB). Sequences
of dyad symmetry containing G and C residues can form hairpin loops and are
often not fully denatured during electrophoresis, and this causes the regular pattern
of migration of DNA fragments on the gel to be compressed to such an extent that
the bands become difficult to read, and sequence information for such regions is
lost. The ability of regions which are rich in G and C nucleotides to form
secondary structure can be avoided by using dITPs (analogues which form weaker
secondary structure) instead of dGTPs in the sequencing reaction. In cases of
exceptional secondary structure, however, the enzyme is more likely to pause with
dlTPs than dGTPs, resulting in stops in the sequence. Presumably as a result of
these factors the sequence of these vectors was only readable up to the Smal site
where the linker was inserted, after which point the sequence was compressed and
there were many stops. It was thought that the problems with dyad symmetry
might be avoided by first separating them by linearising the vector at the linker
Smal site and then sequencing out towards either end of the vector.
After several attempts, the linker at both ends of linearised pSLIC was sequenced
and the deletion of a single base from one of the Sstll sites was observed. pBLIC
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proved less amenable to sequencing and only one end of the linearised vector was
sequenced, but the sequence of this was correct.
The integrity of the vectors was further investigated by PCR amplification of the
polylinker followed by restriction enzyme digestion to look for the presence of
expected sites.
In each case lOpg of vector was amplified in a 50pl PCR reaction which was then
divided into six 8(il aliquots. These were digested individually with each of the
three enzymes and double digested with each of the three possible pairs. The
expected and observed results are shown below.
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Table 3.1 Expected and observed results on digest of vector polylinker.
The results of restriction enzyme digestion of the three vectors in comparison to
the results expected from each if the required sites are present. The fragment
sizes are shown in base pairs. The smaller fragments (<80bp) would not be
observed on a 2% agarose gel.
Enzyme


























111/82 114/85 199 111/82 111/82 114/85 Observe
These results showed that pBLIC did contain all the expected sites. pSLIC also
gave the result predicted by sequencing : one of the Sstll sites had been lost
without a noticeable decrease in size, consistent with a single base deletion. The
absence of digestion with Sstll need not necessarily indicate the absence of a site
since Sstll is known to show preferential cleavage of some sites in the same
substrate, but the fact that this conclusion agreed with the sequence made it highly
likely that the site was missing. Thus pSLIC had to be remade to its original
specification.
pSLIC was made by linker insertion. The efficiency of the blunt end ligation was
very low, so these were repeated in the presence of PEG6000. This creates a
phenomena called macromolecular crowding and causes DNA molecules to be
ligated together into concatemers (Upcroft and Healey 1989). This technique was
a forerunner variant of 'Turbo cloning" (Boyd 1993) and can be done using any
vector. The vector was phosphatased and the oligonucleotides kinased to ensure
that concatamers consisted predominantly of trimeric vector-insert-vector units. It
was then possible to cut the vector at a unique site using an enzyme which
produces cohesive ends (EcoRI), to give single vector-insert units which could
then be ligated efficiently via the cohesive ends.
Initially an efficiency of lxlO4 colonies/qg of vector was achieved, but sequencing
of clones which were of the appropriate size, judged by PCR, showed that they
contained two Sstll sites although only one would be functional as the other had a
single base deleted from the site just like the earlier version of pSLIC. After
several failed attempts the ligation was repeated again, but this time with a new
batch of oligonucleotides. Ten fold more colonies were produced. Colonies were
screened for positives using 32P labelled oligonucleotides on colony lifts of these
plates, and 6 of the positive colonies analysed by restriction enzyme digestion of
the PCR product. 3 gave the appropriate pattern, whereas 3 gave the pattern
previously observed indicating that either the oligonucleotide stock was
contaminated or some peculiarity of the oligonucleotide sequence caused it to
rearrange.
The inserts were also characterised by sequencing. pSLIC was as expected. Both
ends of pBLIC were sequenced this time. While still compressed, the end of the
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linker previously non-amenable to sequencing was readable. One of the Ts from
the AT triplet had been lost, but as this should have no affect on the usefulness of
the vector it was ignored.
3.2.4 Testing the system
The vector structures were now correct so it was time to test their cloning ability.
Conditions were developed which gave the highest cloning efficiency. The Alu-
PCR products used are described in section 3.2.3.2. The conditions were
developed using just the pSLIC vector and the appropriate C324 amplified insert.
These optimal conditions were then compared to conventional cohesive end
cloning and turbo cloning of the same Alu PCR products.
3.2.5 Optimisation of ligation independent cloning conditions
Initial attempts to clone purified insert into vector using the suggested conditions
gave very few colonies on electroporation into XL-1 blue cells indicating that at
least one of the stages was not optimal. Each stage, therefore, was altered in turn
in an attempt to increase the yield of recombinants. In brief, Alu-PCR fragments
reamplified with the appropriate primer were separated by gel electrophoresis and
the DNA purified on a Spin-X column, to remove excess dGTP and dCTP which
would prevent the proper formation of overhangs, then precipitated and
resuspended in KGB buffer. These fragments and Smal linearised plasmid were
each incubated for 20 minutes at 37 °C with 1 unit of T4 DNA polymerase,
allowing the 3'-5' exonuclease activity of the enzyme to produce the single stranded
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tails, in a buffer comprised of 1.5xKGB and 0.5mM dATP and dTTP. The enzyme
was then heat inactivated by incubation at 68°C for 10 minutes. 40ng of T4 DNA
polymerase treated Alu-PCR product was then combined with lOng of vector and
incubated at room temperature for at least 30 minutes to allow annealing prior to
transformation.
Aslanidis and deJong (1990) used chemical transformation, not electroporation, to
transform their cells. Something in the electroporation process could have been
causing the insert to be lost, even if it had annealed properly to the vector in the
first place. Hence the normal lab method of preparing competent DH5a cells was
compared to the Hanahan method and the Calcium/Manganese-based method
(CCMB) (Hanahan 1983), but here DH10B cells were used. E.coli strain DH10B
has a similar genotype to DH5a but is capable of being made more transformation
competent. The efficiencies of these three types of chemical transformations were
compared to electroporation of XL1 blue cells. Both chemical transformation
methods and electroporation gave the same low numbers of colonies when
transformed with LIC reactions (CCMB gave none at all). Transformation of the
cells with a uncut pSLIC plasmid, however, indicated that the cells prepared for
electroporation were at least 10 fold more competent (100 fold for CCMB) than
those made chemically competent. This indicated that something was occurring
during electroporation of LIC products to cause the loss of insert annealed to
plasmid, leading to a reduction in cloning efficiency. Perhaps the unligated tails
were somehow separating under the high current applied. Whatever the reason,
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the net effect was that the method of transformation used made no difference to
the LIC efficiency.
It was thought that KGB may not have been optimal for the T4 DNA polymerase
stage, so tests were carried out using the buffer recommended by Aslanidis and
deJong (1990), but this failed to increase the efficiency. It was also possible that
the enzyme was either degrading the DNA or was not sufficiently inactivated by
incubation at 68°C. The occurrence of any degradation was tested by comparing,
by transformation and on a gel, the nature of an insert after incubation for 5,10,15
and 20 minutes in the presence and absence of T4 DNA polymerase. On a gel the
DNA appeared unchanged. On transformation the same number of colonies were
produced by incubation at 5 as 15 minutes, but fewer at 20 minutes. In contrast,
the number of background blue colonies decreased with increasing in time. Thus
15 minutes was chosen as the optimal length of time for incubation. The use of
phenol/chloroform and ethanol precipitation to ensure the removal of T4 DNA
polymerase did not increase the efficiency of the cloning process indicating that
heat inactivation was sufficient
The single stranded vector and insert ends all have a degree of self
complementarity, are GC rich, and are at a relatively low concentration in the
cloning reaction. All of these factors favour self annealing. In order to decrease
the rate of self annealing, vector and insert were incubated at 60°C for 2 minutes
then allowed to cool slowly to room temperature. This produced a further increase
in cloning efficiency, and later work showed that incubation at 60°C for 2 minutes
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could be carried out on a thermal cycler and cooled rapidly to 4°C without any
decrease in efficiency.
Increasing the amount of insert to 120ng (12:1 weight ratio instead of 4:1) also
produced a slight increase in efficiency. Thus the optimal conditions were:
incubation for 15 minutes with T4 DNA polymerase, heat inactivation of enzyme
for 10 minutes, combining vector and insert and annealing by brief incubation at
60°C and cooling rapidly to 4°C. All positive results were obtained with the
pSLIC vector; pBLIC was never observed to contain any insert. This was thought
to be due to the greater self complementarity of the vector ends, so pBLIC was
abandoned at this stage.
The best way to get an idea of the efficiency of a novel cloning methodology is to
compare it to existing methodologies. The methods chosen for comparison here
were standard cohesive end cloning using the pSLIC vector, and Turbo cloning
(Boyd 1993). It was decided to use Alu PCR to produce a library from the
somatic cell hybrid WJX3.4. This hybrid was chosen because it covers the
relatively poorly mapped region llql2-13. Hence any products could be used to
increase the density of markers in the region.
3.3 Comparison of three different cloning methods
3.3.1 Preparation of material for cloning
The inter-Alu PCR products were prepared by amplification of the hybrid WJX3.4
using the 614 primer using the conditions which gave the optimal number of
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products (section 3.2.2.1). The products were electrophoresed on a 1.5% Seakem
GTG agarose gel. A control track containing a small amount of sample was run
between the preparative track and a track containing the 1Kb size marker (Gibco
BRL). The control and size marker tracks could then be excised, stained with
EtBr and realigned allowing size estimation in the preparative track. When the
products had run the full length of the gel the bottom part was cut off to exclude
everything under 350bp including any excess primers and small products. The gel
was then electrophoresed in the opposite direction to concentrate the products.
The concentrated products were cut out in three separate fractions (see Fig. 3.7).
The DNA was purified from the agarose using a Spin-X column and resuspended






Figure 3.7 Concentration of WJX3.4 Alu-PCR products
Products from Alu-PCR amplification of WJX3.4 were run on a gel alongside the
1 kb ladder marker in the absence of ethidium (see text). The three different size
fractions are indicated
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3.3.2 Ligation independent cloning
Either lpl or lpl of a 1/10 dilution of each fraction was reamplified using the
primer C324. The products were electrophoresed on a 1.5% agarose gel to assess
the range of fragments amplified (Fig. 3.8). The 1:10 dilutions of fractions 1 and 3
were chosen for cloning because unlike the others they did not contain over-
amplified products. The products were purified using Wizard PCR columns
(Promega). Smal digested pSLIC vector was prepared by cutting out the
linearised band from a 1.5% Seakem GTG gel. This vector DNA was then purified
using a Spin-X column and resuspended in 10pl
l|il aliquots of purified vector and C234 PCR products were electrophoresed
adjacent to each other on a 1.5% agarose gel in order to assess their relative
concentrations. It was estimated that there was four times as much PCR product
as vector. Both the PCR product and linearised vector were treated with T4 DNA
polymerase and combined in several different ratios (Table 3.2), and the ends
annealed by incubating at 60°C for 10 minutes then immediately transferring to
4°C. The annealed mix was then electroporated into DH10B cells. The same
proportion of the annealed mix was transformed in each case by altering the
volume and precipitating where necessary. The amount of insert transformed
ranged from 10-200ng.
148
3.3.3 Cohesive end cloning of PCR products
In cohesive end cloning a sequence containing an appropriate restriction site is
added to the 5' end of the PCR primers. Vector and insert restriction digestion
with the enzyme, then produces identical overhanging ends which can be ligated in
the conventional manner. A C324 (a primer which contains an added Sstll site)
PCR ofWJX3.4 was carried out on fractions as described above and again the
product from the 1:10 dilutions of fractions 1 and 3 were chosen for cloning.
Some products were present at higher concentrations, so prevent preferential
cloning of these the volume was estimated which contained 400ng of the lowest
concentration products and correspondingly 400ng of the highest concentration
products, and these were cloned separately. The products were digested with Sstll
as was lOOng of vector. Products and vector digests were then combined,
extracted with phenohchloroform, ethanol precipitated and resuspended in ligation
mix (l|il Ligase, l(il 10 x Ligase buffer: Boehringer Mannheim) and incubated
overnight at 16°C. lp.1 of this ligation mix was then electroporated into DH10B
cells. This corresponds to 40ng of insert.
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Gel Fraction 12 3
Dilution M 1 1/10 1 1/10 1 1/10
Figure 3.8 Tailed amplification products from gel fractions
Either lp.l or VI of a 1:10 dilution of each gel fraction from the concentrated
WJX3.4 Alu-PCR products (Fig. 3.7) was reamplified using the tailed primer C324.
Comparison here on a 1.5% agarose gel indicates that the 1:10 dilutions of
fractions 1 and 3 together contain the full range of equally amplified products
hence these were chosen for cloning. Marker (M) = 1 Kb ladder.
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3.3.4 Turbo cloning
Turbo cloning is a fast, efficient method for cloning PCR products and other blunt-
ended DNA fragments into plasmids (Boyd 1993). Fragments are cloned into a
vector containing the 34bp site-specific recombination sequence lox in the presence
of the cognate Cre recombinase system of bacteriophage PI. The same three
fractions of the WJX3.4/614 PCR were used as in the previous two methods, but
here only the 1:10 solutions were amplified. The primer used was A1ui8, which
first had to be kinased. This primer is homologous to the polyA end of the Alu
consensus sequence, hence products contain negligible Alu sequence within them,
and are therefore more useful as probes. Fraction one was selected to clone as this
produced even intensity products across the size range (Fig. 3.9). The ends of the
products were made blunt ended using T4 polymerase, and purified using a Wizard
PCR column, before combining with dephosphorylated vector.
The vector needed to be dephosphorylated to reduce the background of
regenerated vector, and prevent production of long concatemers with multiple lox
sites. Several micrograms of vector (pBSlox : bluescribe containing a 34bp lox
site) were prepared as a stock. Typically the vector was cleaved by Smal and
dephosphorylated with Calf intestinal phosphatase (Promega). To reduce
background of uncut vector the linearised DNA was purified by excision from an
agarose gel, and extracted on a Spin-X column. In this case two aliquots of
purified Smal - linearised dephosphorylated vector were kindly provided by Chris
Boyd. These were called batch 1 and 2 in Table 3.2.
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The concentrations of purified vector and PCR products were assessed on an
agarose gel before combining in a 10:1 molar ratio (lOOng vector:30ng insert) in a
ligation mix containing 0.4 units of T4 DNA ligase (Boehringer), and a final
concentration of 15% PEG 6000 (BDH). This was incubated for 15 minutes at
room temperature, then the ligase was inactivated by incubation at 75°C for 5
minutes. The reaction was then diluted to below the level of PEG concentration
where macromolecular crowding takes place by adding four volumes ofM buffer
(Boehringer medium salt restriction enzyme buffer) containing 0.1-0.3fig of Cre
protein (NEN) which causes circularisation of vector insert trimers (vector-insert-
vector). After incubation at 30°C for 30 minutes, Cre activity was destroyed by
incubation at 75°C for 10 minutes. 5|il of the cloning reaction was desalted by
drop dialysis (section 2.7.4), and 2|al of this corresponding to an estimated 750pg
of insert was electroporated into DH10B cells.
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Gel Fraction 12 3
M
-§Z-
Figure 3.9 Reamplification of gel fractions with primer Alu„
Shown here are the products from the reamplification of the 1:10 dilutions of each
gel fraction from the concentrated WJX3.4 Alu-PCR products (Fig. 3.7). The Alu
repeat end primer Aluig was used in the reamplification. Fraction one gave the
greatest range of products and hence was chosen for cloning. Marker (M) = lkb
ladder.
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3.3.5 Tabulation and discussion of results
Table 3.2 shows the number of recombinants achieved by each method. Cohesive
end cloning, although it produced the largest number of overall recombinants, gave
the highest background of non-recombinant colonies (12-26%). Turbo cloning on
the other hand also gave a large number of recombinants but a low background of
non-recombinant colonies (2-5%). LIC gave a fairly low background of non-
recombinant colonies (5-18%), but the actual number of recombinants was also
fairly low due to the low efficiency of the cloning methodology (see Table 3.2).
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Table 3.2.1 and 3.2.2 The number of colonies achieved per ml of cells plated
The numbers of recombinants and background blue colonies achieved with

















0 1.8xl03 1.3xl04 5.8xl03 880 640
No. of
blues0
0 200 1.4xl03 318 120 60
%
whites
- 90 90 95 88 91
Cloning Turbo cloning Turbo cloning Cohesive Cohesive
method
batch I batch II
minb maxb
No. of whites0 2xl06 3xl06 2.8xl05 4.6xl05
No. of blues0 3.5xl04 1.6xl05 or-HXr-H 6xl04
% whites 98 95 74 88
a ratio of insert to vector; b here approximately 400ng of the lowest/highest
concentration products were cloned; c the number of
white(recombinant)/blue(non-recombinant) colonies per jig of insert DNA.
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The next stage was to analyse these colonies in order to determine how many were
real recombinants (i.e. contained an insert), and the range of fragments cloned. 96
colonies were picked from each ligation experiment and stored as glycerol stocks
in microtitre plates, which could then be recovered by streaking out on an agar
plate as required. The size of insert was assessed by carrying out PCR
amplification using universal primers. Fig. 3.10 shows the results from the
universal PCRs, and these results have been tabulated (Table 3.3) as has the overall
efficiency of each cloning method.
In this case, turbo cloning is more efficient than cohesive cloning. Previous studies
have shown the efficiency of the two to be equivalent (Boyd 1993). However, the
ten fold decrease in the efficiency of cohesive end cloning observed here is likely to
be due to the nature of the vector and insert ends.
Colonies obtained by LIC amplified poorly and very few of the clones appeared to
contain any insert. PCRs from amplification of colonies obtained by cohesive end
cloning contained a lot of primer dimers. Many of the latter clones appeared to be
the same size indicating selection for a specific product may have occurred.
However no size selection was observed in C324 PCR products cloned in pSLIC.
The ability to reamplify inserts with Aluig is important if they are to be used as
markers since this removes the need for competition and stringent washing
conditions in hybridisation. Neither cohesive clones nor LIC clones amplified well
with this primer, even though Aluig is exactly matched to the consensus. In general
C324 PCR products cloned into pSLIC were difficult to amplify. The problem
most likely results from the flanking GC rich sequences preventing the primer from
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annealing, possibly by forming some sort of hairpin structure.
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U
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Figure 3.10 Universal PCRs of Inter-Alu PCR products
Clones were amplified using the M13 universal primers and run on a 1.5%
agarose gel alongside the lkb ladder marker (M). The flanking GC rich
sequences appear to be hindering amplification by Taq polymerase of inserts
cloned into the pSLIC vector (cohesive cloning and LIC), since theoreticclly the
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Table 3.3 Efficiency and range of insert size













many of the clones obtained by cohesive end cloning appeared to be of similar size
The next step was to assess the repeated sequence content of the clones. Alu
repeats are not the only repeat present in the human genome and others can be
equally problematical to mapping. Human repeat content was assessed by
hybridising 32P labeled Cotl DNA to blots of the Aluig PCRs from all three cloning
methods. The results of this are shown in table 3.4.
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Table 3.4 Human repeated sequence content
The results of PCR amplification and Cotl hybridisation are shown. A total of 46
clones were analysed in each case. The proportion of clones which contain













None Low Medm High
LIC 13 2 2 6 23 4
Cohesive 3 8 12 5 18 16"
Turbo
cloning
0 24 4 5 12 16
a PCR products which were greater than 300bp and had either no or low repeat
content
b
only 6 of these were reamplifiable with Alu„ primer, so could be used as probes;
3.3.6 CA repeats
Microsatellite markers, particularly CA repeat elements, have allowed the
construction of genetic maps for a number of genomes as well as human (Gyapay
et al„ 1994). Such repeats appear to be homogeneously distributed along the
genome (Weber et al., 1990), exhibit length polymorphisms, and can be typed by
PCR (Weber et al., 1989). It was decided to screen the chromosome 1 lql2-13
libraries for CA repeats containing clones which would then be useful in refining
linkage data for disorders associated with the region.
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CA repeat containing clones were identified by hybridisation of an oligonucleotide
probe consisting of 12 CA dinucleotides. The probe was labelled by kinase end
labelling and hybridised to Southern blots of universal PCRs of 96 clones from
each cloning method. In this way 7 CA repeats were identified: 3 produced by
cohesive end cloning and 4 by turbo cloning. Plasmid template from each clone
was prepared by PEG precipitation and sequenced by ABI cycle sequencing. The
sequence obtained was then used to design primers for PCR amplification across
the repeat region. Two clones contained a repeat of less than 12 nucleotides,
which has been shown to be the threshold for repeats to be polymorphic (Weber et
al„ 1990) hence primers were not designed for these. In three cases the repeat lay
very close to the end of the Alu repeat sequence, here primers were designed to be
used in conjunction with the Aluig primer. The optimised PCR conditions and
primer sequences are shown in section 2.4.4.5.
3.3.7 Conclusions
Three different methods were used to clone Alu-PCR products which had been
produced from the somatic cell hybrid WJX3.4. All three involved a two stage
PCR and various vector and insert modifications prior to the cloning step. The
simplest and most rapidly completed procedure was ligation independent cloning.
Here the steps between the secondary PCR and transformation took under 2 hours
to complete. The next fastest was turbo cloning which, when kinasing of the
primer was taken into account, took approximately 5 hours to complete (although
the actual ligation process takes under 2 hours). Cohesive end cloning took the
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longest, requiring an overnight ligation step. Overall the most efficient method
was turbo cloning, which gave the largest range of readily reamplifiable products.
The small numbers of colonies produced by cloning in pSLIC indicated that in a
coincident sequence cloning experiment where the amount of clonable DNA would
be reduced this method of LIC would not be efficient enough. Attempts could be
made to further optimise the conditions for LIC, but as these conditions become
more complicated the method loses its advantage in being simple and rapid. It was
therefore decided not to pursue LIC further and instead to assess the use of
turbocloned Inter-Alu PCR DNA as probes.
Five CA repeat containing clones were isolated from the 1 lql2-13 libraries,
primers and conditions allowing their PCR amplification were designed, but their
heterozygosity for the CEPH families remains to be determined (Weissenbach et
al„ 1992).
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4. Mapping a repeat free resource
4.1 Mapping repeat free clones to a somatic cell hybrid panel
In order to map the inter-Alu PCR products relative to each other, a resource was
required which allowed the region of origin to be subdivided. The resource used
to produce the library of inter-Alu DNA clones was the somatic cell hybrid
WJX3.4, which previous studies (Fletcher et al., 1993) had shown to contain a
single contiguous region from human chromosome llpl 1.2-1 lql3.5. A set of
hybrid cell lines, which retained different subfragments of chromosome llq was
also available. These hybrid cell lines had previously been used to successfully map
a number of ESTs (Slorach et al., 1995) and to refine the localisation of established
markers (Evans et al., 1995). This somatic cell hybrid mapping panel, then could
be used to orient these new inter-Alu PCR markers relative to previously mapped
markers, and possibly identify new mapping intervals..
Basically the somatic cell mapping panel consisted of six fragmentation hybrids.
Four were X-irradiation hybrids, WJX3.4 (source), WJX5.4, WJX7.4 and
WJX11.2 which contain fragments of chromosome 11 in the background of a
Chinese hamster ovary cell line, WG3H (Fletcher et al., 1993). The other two
were independent HRAS-1 selected chromosome mediated gene transformants
(CMGT), E67.1 and E67.4 which carry fragments of chromosome 11, in the
background of a murine cell line C127(Porteous et al., 1986). In addition, two
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translocation cell lines were included : MAR1 which carries the derived 11
translocation chromosome (Fletcher et al., 1993); and CF52 which has the well
characterised t(ll;16)(ql3;pll) translocation chromosome as its sole human
component in the background of a murine cell line, A9 (Koeffler et al., 1981)).
Cell lines WG3FI (hamster background) and RAG (murine background) were used
as negative controls. J1C14, a hybrid cell line which contains an intact
chromosome 11 as its sole human component (Jones et al., 1984) and was the
chromosome donor for the WJX series, and F4 (human female placental DNA)
were used as positive controls.
Turboclones which were either repeat free or had shown a very low level of repeat
when screened with CotI human DNA and gave a product of larger than 300bp
when amplified with Alu 18 primer (section 3.3.5), were selected for mapping on
the somatic cell hybrid panel. A probe was obtained by amplifying each clone with
Alu 18 and labelling the gel purified product in a Random Prime reaction. Those
clones which had shown a low level of repeat in the CotI human DNA pre-screen
were suppressed with sonicated salmon sperm and sonicated human DNA prior to
hybridisation. Control and hybrid cell line DNAs were digested with EcoRI, and
5p.g of each electrophoresed on a 0.8% agarose gel, which was then Southern
blotted and hybridised with these labelled markers. The blots were washed to
various levels of stringency depending on the probe, ranging from 0.1-lxSSC.
Initially, 18 turboclones were isolated which were suitable for mapping on the
somatic cell hybrid panel. At a later date another 46 turboclones were amplified
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with Alul8 and screened with Cotl human DNA. Thus a further 26 clones which
were suitable for mapping were obtained. In total an attempt was made to map 30
of a possible 44 clones. Of the first set of clones 5 of 12 tried were successfully
mapped. Mapping the next set of 18 clones gave a similar success rate: 11 were
successfully mapped. The mapping results are summarised in Table 4.1.
Table 4.1 Mapping turbo clones on the somatic cell hybrid panel
Summary of the results from mapping Alul8 PCR products from the WJX3.4 library
on a panel of chromosome 11 q somatic cell hybrids. Suitable markers were
those which gave a low or negative result when probed with Cotl DNA, and








No.of suitable markers 18 26 44 NA*
No. used as probes 12 18 30 NA*
No. mapped 5 11 16 53
No. giving ambiguous
mapping result
1 1 2 7
No. hybridising to repeats 5 6 11 37
No. which were plasmid
contaminants
1 0 1 3
*
NA = not applicable
Even after prescreening with Cotl, 40% of clones still gave a hybridisation smear
on the somatic cell hybrid panel. It was realised in retrospect that a proportion of
these may have been due to poor transfer of DNA during the Southern blotting
step, as many of those which were mapped gave positive results on the same blot,
indicating that lack of signal may have been due to poor quality of the actual blot.
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In some cases, however, a blot which had already given a good result with a
previous probe produced a smear on re-hybridisation. This had to be due to the
individual clone and indicated that some sort of repeat sequence was present in the
probe which is not effectively stripped by Cotl DNA. This may have been due to
MERs or some other type of repeat (Kaplan et al., 1991). MERs belong to a
family of medium reiteration repeats, and a number of members have been shown
to lie within 500bp of Alu repeats.
Markers which gave an unambiguous result were ordered on the panel relative to
markers previously positioned. This was done in such a way as to minimise the
number of independent blocks of human DNA in each hybrid. The results are
shown in Table 4.2. In all, 21 distinct patterns of hybridisation identifying 21
different mapping intervals were discerned, giving an average resolution less than
1.5Mbp.
Table4. 2 Location of turbo clones on the somatic cell hybrid panel
Turboclones (shaded) have been positioned relative to known genes, Expressed
Sequence Tags (ESTs), and polymorphic markers CD 11S-). The location of ET58 is
also shown. This is an exon trap product of the myosin type VII related protein,
mutations in which have recently been shown to cause Usher Syndrome Type IB
(see Discussion). Some clones gave more than one band and these have been
given the suffix A-D. Brackets denote the individual mapping intervals. The
marker order in these intervals is non contiguous.
+ = band observed in this hybrid
- = no band observed in this hybrid
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A number of clones mapped to previously defined intervals: TC10, TA8, TE5,
TB11, TE7, and TH8 mapped to the same interval as ROM1 and MDU1; TB10
mapped to the same interval as the ESTs 218, 1878, 2002; TF7 mapped to the
same interval as GSTP1 (figure 4.1); and TG1B mapped to the same interval as
OMP. This provides a substantial increase in the density of markers in these
intervals.
Four clones gave more than one band when hybridised to the panel. In two cases
this appeared to be due to the insert containing an EcoRI site, as the bands were
always present in the same hybrid. TA8 (figure 4.2) showed this type of pattern as
did TA12. TA12, however, gave only one band in E67.1, indicating that it may in
fact bridge the breakpoint in this hybrid. The presence of an EcoRI site in each of
these clones was confirmed by restriction enzyme digestion. The two bands from
TGI and four from TF9 (figure 4.3) all mapped to different intervals, several of
which were not present in WJX3.4 suggesting that the hybridisation was to a
related sequence. TG1 gave a strong background smear on human genomic DNA
indicating that it contained a repetitive sequence. TF9, on the other hand, gave
about twelve distinct bands on human genomic DNA. A subset of four of these
was present in J1C14, indicating that the clone contained a low copy number
repeat.
TH1 defined a new E67.1 sub-fragment between EST294 and D11S533. Three
clones (TF11, TA6, and TC9) gave the same result on the hybrid panel and
suggested the identification of a new E67.4 sub-fragment above EST200.
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Two clones (TD7 and TE6) gave ambiguous results. In order to position them on
the hybrid panel more than one novel sub-fragment would have to be introduced.
The status of these results awaits confirmation by other markers.
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Figure 4.1 Mapping TF7 on the somatic ceil hybrid panel
Clone TF7 was amplified with the Alu„ primer and the gel purified product
labelled by random priming. This was then hybridised to a Southern blot of the
chromosome 11 somatic cell hybrid mapping panel. This allowed the clone to
be mapped to the same interval as GSTPI (Table 3.2). The hybrids are described
in more detail in the text: F4 = total human genomic DNA; J1 = chromosome 11
only hybrid; WG3H and RAG = hamster and mouse background respectively;
E67.1 and E67.4 = CMGT hybrids; WJX- = X irradiation hybrids.
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Figure 4.2 Mapping TA8 on the somatic cell hybrid panel
Clone TA8 was mapped in the same way as TF7 (Fig. 4.1). This clone gave two
different bands, both of which were positive for the same hybrids (Table 4.2). This
was later shown to be because the clone encompassed an EcoRI site. The
hybrids are described in more detail in the text: F4 = total human genomic DNA;
J1 = chromosome 11 only hybrid; WG3H and RAG = hamster and mouse







+ + + +






Figure 4.3 Mapping TF9 on the somatic cell hybrid panel
Clone TF9 was mapped in the same way as TF7 (Fig. 4.1). This clone gave four
different bands each of which showed a different hybridisation pattern (Table
4.2). Three were negative for WJX3.4 indicating that the signal was actually due
to hybridisation to a related sequence. The result showed that TF9 represented a
low copy number repeat, four copies of which were located on chromosome 11
(J1 result). The hybrids are described in more detail in the text: F4 = total human
genomic DNA; J1 = chromosome 11 only hybrid; WG3H and RAG = hamster and




In parallel with mapping individual products of the WJX3.4 Alu-PCR library on the
somatic cell hybrid panel, the cytogenetic location of pooled clones was confirmed
by FISH. The results of this experiment, which was done by Dr Yoshiro Shibasaki,
are shown in Fig.4.4c. Comparison to previous mapping results (previously
published by others in our group - Fletcher et al„ 1993) with complete Alu-PCR
products from the hybrid, shows that the turboclones clearly map to the same
chromosomal location. The FISH methods used here were as previously described
(Fletcher et al., 1993).
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Figure 4.4 Mapping WJX3.4 on normal mitotic spreads
a) The human content of WJX3.4 was assessed by in situ hybridisation of the Cotl
fraction of human DNA onto the hybrid. A representative mitotic spread is
shown on the right, with an enlarged view of the human fragment-bearing
chromosome on the left.
b) This shows human DNA from WJX3.4, isolated by Alu-PCR, painted back onto
a normal human mitotic spread. A representative mitotic spread is shown on the
right, with an enlarged view of the human fragment-bearing chromosome on
the left.
Figures a and b show the apparent single contiguous region of chromosome 11 q
in WJX3.4.
c) This shows hybridisation of human DNA from a selection of turboclones,
isolated by Alul8 PCR and combined in equimolar quantities, to normal mitotic
spreads. Chromosome 11 was identified using a cosmid clone for IGF2 (green
signal) which identifies 11 p 15-ter (de Patger-Hothuizen et al., 1987).
4.3 An integratedmap of chromosome 11q12-13
Having shown that the turboclones mapped to the expected region by FISH and
sublocalised them within the region on the somatic cell hybrid panel, it was now
appropriate to investigate the region in order to determine the usefulness of the
markers. Several of the genes which have been mapped to chromosome 1 lql2-13
have been shown to be directly involved in disorders (Royle et al., 1987; Rochelle
et al., 1992; Smith et al., 1993), for example PC (pyruvate carboxylase) and F2
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(human prothrombin). A number of other disorders have been linked to
polymorphic markers, and in some cases candidate genes have been identified.
Disorders mapped to the region include several types of cancer, eye retinopathies,
diabetes and of course Usher syndrome type IB. These disorders have been
described in the Introduction (section 1.1.3).
The recent Chromosome 11 Mapping Workshop (van Heyningen and Little 1995)
was able to successfully consolidate much of the chromosome 11 mapping data.
Using this, the latest genetic linkage map (Gyapay et al., 1994), other information
in disorder mapping papers (described in section 1.1.3), and cloned DNA maps
derived from disease associated regions (Smith et al., 1993; Carrier et al., 1993;
Stafford et al., 1994;Bystrom et al., 1990; and Bascom et al., 1992a,b), an
integrated map of llql2-13 was compiled (Fig. 4.5).
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Figure 4.5 An integrated map of chromosome 1 lq!2-13
The construction of this map has been previously described in more detail
(fig. 1.2 ). Here the relative positions of the turbo clones is also given. The
orientation of turboclones TD1, TB10, TGIA and TF9 could not be determined





VMD2 vitelliform macular dystrophy/Best's disease
MENI Multiple endocrine neoplasia
CMH4 Familial hypertrophic cardiomyopathy
PYGM McArdle disease
BBS Bardet-Biedl syndrome
EVRI Familial exudative vitreoretinopathy
SCA5 Spinocerebellar ataxia type 5
PC Pyruvate carboxylase deficiency
CCND1 Parathyroid adenomatosis I
BCL1 Chronic lymphatic B-cell leukemia
IDDM4 Insulin independent diabetes mellitus type 4
IGER Atopy
VRN1 Neovascular inflammatory vitreoretinopathy
USHIB Usher syndrome type IB
DFNB2 Neurosensory, non-syndromic deafness type 2
GIF Congenital pernicious anemia
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Using distance estimates based on the number of breakages observed between two
markers when exposed to a specific dose of radiation (Cox et al., 1990; van
Heyningen and Little 1995) it was also possible to estimate the size of llql2-13.
The region spans 570.5 cR (606-35.5) and if lcR is roughly equal to 50.2Kb
(James et al., 1994) then the region covers 28.6Mb. This estimate is in rough
agreement with the estimated size of llq at 81.5Mb (James et al., 1994).
Figure 4.5 shows that a number of turboclones mapped to regions which had been
linked to disorders. A significant number of the turboclones appeared to be
concentrated in the region which had been linked to Best Disease (VMD2), Bardet
Biedl Syndrome (BBS), and Spinal Cerebellar Ataxia (SCA5). It was decided to
use a selection of these to build up a more universally useful cloned DNA map of
the region, in the form of a YAC contig.
4.4 Isolation of YACs using repeat free clones
Clones which gave extremely low or no background on the somatic cell hybrid
panel were selected and used to screen the ICI YAC library (Anand et al., 1990).
Thus TD1, TB10, and TF7 were used individually and TA8, TA12, and TH8 as a
pool. A number of ICI YAC spot filter sets were available which had previously
been screened in the course of another mapping project. Initial experiments
indicated that some of the filter sets were of poor quality, i.e. probes which had
previously given good results on these now gave faint hybridisation. The use of
these sets was discontinued. Some typical results obtained when screening the
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YAC panel are shown in Figs. 4.6 and 4.7. These results are summarised in Table
4.3. 18 YACs were positive in the primary screen although 20 YACs were
actually acquired from the HGMP resource centre, because one of the signals from
TF7 and TD1 was difficult to position precisely on the filter due to low
background, which meant that the layout of the gridded colonies could not be seen.
Clearly at the stage of screening the YAC filter there were no obvious differences
between correctly identified clones and those which later turned out to be negative.
Thus it was necessary to acquire all of the primary positive YACs and carry out a
secondary screen.
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Table 4.3 Results of primary screen
ICI YAC spot fitters were screened using pooled probes TA12, TA8, and TH8 and
individual probes, TB10, TD1, and TF7, and the results are shown below.
+ = the YAC was positive for this probe
- = the YAC was negative for this probe
Shaded results represent those which were difficult to orientate, only one of the
two YACs was actually positive.
2 4 4 6 7 11 13 14 17 22 22 2' 27 35 35 36 36 38 39 40
YACs C F G I A B F I I E G H I G H B B G B I
F F B f F B E A E F E D A F B A D E E H
2 6 11 3 3 8 2 7 4 5 5 6 8 5 5 5 5 6 6 3
Probes
TA12 + + - - - - + - - + + + + +
TA8 + + - - - - + - - + + + + +
TH8 + + - - - - + - - + + + + +
TD1 m + . +■ ii|
TB10 + - + + - - - - - + - + - - +




Figure 4.6 Screening YAC filters with pooled turboclones
Alu18 PCR products from turboclones TA8, TA12, and TH8 were labelled by
random priming, pooled and used to screen the ICI YAC filters. Large arrows
identify true positives, and small arrows show those later shown to be false. Four
of the primary positives are shown here; a - 4FF6; b - 2CF2; and c - 27HD6 and
27IA8. Rescreening of isolated YACs, later showed 4FF6 to be a true positive for




Figure 4.7 Screening the YAC filters with the turboclone TF7
TF7 identified three YACs in the primary screen, one of which, 2CF2, was also
identified by the TA8, TA12 and TH8 pool, in neither case however was the
primary result confirmed by the secondary screen suggesting that nonspecific
hybridisation was occurring. Shown here are the primary positives a- 4GB11 and




Approximately 0.5|ig YAC DNA was then digested with EcoRI and after re-
estimating the relative concentration of each YAC on a gel, equal concentrations
were electrophoresed on a preparative gel which was Southern blotted.
Initial positives were then confirmed by hybridising turboclones TF7, TB10, TD1,
TH8, TA8, and TA12 to these blots. Blots were also screened with the remainder
of the turboclones. In addition ESTs, known gene probes, and polymorphic
markers which had been mapped to the somatic cell hybrids were hybridised to the
blots. Primers were available for all of the latter set of markers so a probe was
prepared by amplification of J1C14 DNA, and the gel purified product labelled by
Random Priming. In some cases the product was less than 200bp, in which case
the conditions were altered so that fragment specific primers were used in the
random prime reaction.
Both the YAC and somatic cell hybrid Southern blots, which were screened with
the turboclones, were produced from EcoRI digested DNA. In addition, the YAC
library had also been prepared from EcoRI digested DNA. Thus each individual
probe would be expected to produce a band of the same size on each positive YAC
and hybrid. Moreover the same amount of each YAC had been loaded in each lane
hence the intensity of signal would be expected to be the same for each true
positive YAC. These provisos were used to confirm or disregard positive bands
during the secondary YAC screen leading to the results illustrated in Table 4.4.
Examples of some of the results and the justification behind their inclusion or
exclusion are shown in Fig. 4.8. The size and intensity of any bands obtained on
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the YACs was compared to genomic DNA which was run on the same blot. In the
end only 5 of the 18 YACs from the primary screen were confirmed to be positives
which in each case was only for the clone used in the initial selection process.
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Table 4.4 Results of rescreening primary positives
Southern blots of EcoRI digested YACs which were positive in the primary screen
were rescreened using turboclones, probes for known genes, and polymorphic
markers from the region. Those probes used in the primary screen are shown in
bold. Many of the probes failed to give a positive signal on any of the YACs :
EST220; PGA; TE7; ROMI; MDUI; TGI; TF9; EST218; EST1878; EST2002; GSTPI; D11S527;
EST294; and THI.
YACs 2 4 4 6 7 11 13 14 17 22 22. 27 27 3f 35 36 36 38 39 40
C F G I A B F I I E G H I G H B B G B I
F F B f F B E A E F E D A F B A D E E H






TH8 - - - - - - - - - - - - + - - - - - - -
TD1 - - - - + - - - - - - - - - - X - - - -
TB10 - +
TF7 - +
+ confirmed positive in the secondary screen
X established as false positive by the secondary screen
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Figure 4.8 Confirmation of positive YACs
a) TA12 was one of the three markers used in a pooled probe. Secondary
screening confirmed it to be responsible for selection of the 4FF6 YAC. The
presence of two bands was also observed in screening of the somatic cell hybrid
panel and was due to the fact that the turboclone insert contained an EcoRI
site.
b) TE5 was not used in the primary screen, since it contained a small amount of
repeated DNA sequence. In the secondary screen it appeared to be positive
for the 11BB8 and 36BA5 YACs. The position of this clone on the somatic cell
hybrid panel, separated by several markers from the other turboclones (TF7 and
TB10) which were definitely positive for these YACs, and the fact that the band
obtained on YACs was 12Kb compared to the 7Kb band obtained on the
somatic cell hybrids indicated that these were false positives due to the repetitive
DNA in TE5.
c) TF7 was used to select three YACs in the primary screen - 2CF2, 4GB11, and
36BA5. Secondary screening confirmed 36BA5 to be positive, as a band of 7Kb
was obtained on somatic cell hybrids and YACs. 11BB8 was clearly negative in
the primary screen, but appeared to be weakly positive in the secondary
screen, although hybridising to a band of lOkb. This result was put down to weak
hybridisation and therefore not scored as a positive result.
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The 5 confirmed positive YACs were sized by preparing agarose plugs which were
then run on a pulsed field gel. Not all of the YACs were clearly distinguishable
from the yeast chromosomal background, so the gel was Southern blotted and
probed with 32 P labelled CotI DNA to detect human specific DNA (see Figure
4.9).
• 4FF6 was identified using TA12 and on secondary screening two bands were seen,
as had been observed when this clone was used to screen the somatic cell hybrid
panel. Restriction enzyme digestion confirmed that this clone contained an EcoRI
site, and the presence of only one band in the hybrid E67.1 indicated that it
overlapped the end of this particular subfragment of E67.1.
• 27IA8 (280kb) and 7AF3 (350kb) both lay within the ROMI-MDUI subregion, but
were identified with separate clones. In addition none of the other markers from
this subregion came up positive on these YACs indicating that the region must be
relatively large. The distance between ROMI and MDUI is estimated at 10.9cR
(van Heyningen and Little 1995) which is equivalent to 500kb. The combined size
of the YACs and that fact that they do no contain any other markers for the region
makes it likely that the YACs themselves bridge the endpoints of the region.
• 36BA5 maps to the same region as GSTPI, and yet is negative for this marker
indicating that this region is more than 150kb.
It was possible that the YACs, in particular 27IA8 and 7AF3, might overlap in
regions not covered by markers. This was tested by comparing the Alu-PCR
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profiles of the YACs. After amplification using the A1u6m primer. The annealing
temperature found to give the highest complexity of products was 50°C. The Alu-
PCR fingerprint, obtained at this annealing temperature, was then compared by
electrophoresing the products in parallel on a 1.5% agarose gel (Fig.4.10). No
bands of the same size were observed in the YACs indicating that there were no
regions of overlap. FISH was then carried out by Dr Yoshiro Shibasaki, essentially
as described by Breen et al„ (1993) using the pooled Alu-PCR products to ensure
that the YACs did in fact map to the right region (figure 4.11).
192
Figure 4.9 Sizing positive YACs
Agarose plugs were prepared and run on a CHEF pulsed field gel as described in
Material and Methods. Some of the YACs were of the same size as the yeast
chromosomes, so the gel was Southern blotted and hybridised with Cotl DNA to
identify the YACs. Each could be roughly sized relative to the markers: 4FF6 =
205kb; 7AF3 = 265kb, 350kb; 11BB8 = 150kb; 27IA8 = 280kb; and 36BA5 = 150kb.




cd co CO 2 <
co u_ u- m < en
in IL < T- N (D
mcD ul n r- cm co
Figure 4.10 Alu-PCR profile of positive YACs
YAC s were amplified using Alu614 at Ta = 50°C. Profiles can be directly
compared here on a full length 1.5% agarose gel. None of the bands are
common between the YACs. M = lkb ladder, F5 = human genomic DNA.
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Figure 4.11 FISH with positive YACs
The Alu-PCR products shown in Fig. 4.10 were combined and used as a probe in
in situ hybridisation to normal mitotic chromosome spreads. This was done by Dr
Yoshiro Shibasaki as described in Breen et al (1992).
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4.5 Discussion
A library of repeat free clones have been mapped to chromosome llql2-13
defining a total of 21 mapping intervals in this region. One interval in particular
(ROMI-MDUI) contained several clones. Clones mapping to interesting regions
were used to screen the ICI YAC library, and 5 YACs were isolated. Screening
these YACs with additional markers, and comparing Alu PCR fingerprints failed to
identify any overlap between them. The results obtained were however consistent
in that all the turboclones and YACs mapped to the expected region. The mapping
process was simple and did not require complicated preannealing of the probe to
remove Alu ends. Turbo cloning also allowed the cloning of a broad range of
product sizes.
The results presented here are encouraging and demonstrate the feasibility of this
method as a means of isolating new markers at a high density from a specific
region. In order to build up a contig of 1 lql2-13 it would be necessary to either
map additional markers; isolate larger insert containing YACs; or use end clones of
the primary YACs to isolate more YACs.
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5. Human Olfactory Marker Protein gene
In mice the shaker-1 mutation was shown to lie on chromosome 7 within 200kb of
the Omp gene. The fact that the human OMP gene lay within a homologous
region, 11 q 13.5, to which Usher syndrome type I had been linked, and the
observed ciliary defects, suggested the OMP gene as a candidate for this syndrome.
Hence the gene was subcloned and mutation analysis was carried out as described
in the following sections.
5.1 Subcloning
The human olfactory marker protein gene had already been isolated from a cosmid
library using an exonic fragment as a probe, which in turn had been obtained by
cross species PCR using primers directed against the published sequence of the rat
OMP gene (Evans et al., 1993). To obtain the sequence of the human gene it was
necessary to subclone the gene from the cosmid. This was done by digesting the
cosmid, identifying OMP containing fragments by hybridisation analysis and
cloning these into appropriately prepared plasmid vectors.
At the stage when I took over the project part of the OMP gene had already been
subcloned as a PstI fragment into the Bluescribe plasmid cloning vector pBS
(Stratagene™)(see Fig.5.1). The appropriate cosmid fragment had been identified
by hybridisation of a rat PCR product to a cosmid PstI digest, and the identification
of the cloned product confirmed by restriction enzyme digestion and sequencing.
From the sequence it was clear that only part of the coding region and the 3'
untranslated region had been cloned. Comparison with the rat sequence suggested
that about 80bp were missing from the human coding region. In order to clone the
rest of the coding region and some of the 5' untranslated region the available
human OMP sequence was examined for restriction sites compatible with the
pBSK polylinker. TaqI recognises the tetranucleotide target sequence TCGA,
which lies 173bp downstream of the PstI site, and produces ends compatible with
the hexanucleotide target sequence ATCGAT recognised by Clal in the pBSK
polylinker. The 5' end of the gene was identified in a TaqI digest of the cosmid
using a rat primer that covered the start codon (primer C) as a hybridisation probe
(Fig.5.1).
5' UTR — coding region
ATG
— 3'UTR
Figure 5.1 Subcloning the human OMP gene
The human gene was subcloned in two overlapping fragments into the
Stratagene vectors pBS and pBSK. The overlapping fragments and their positions
relative to the rat gene are shown. Primer C was derived from the rat coding
sequence and used to identify the Taq fragment in the cosmid digest.
CM digested phosphatased pBSK vector was prepared. l(ig of cosmid was
digested with TaqI, run out for the full length of a 1% gel and Southern blotted.
Primer C was kinase end labelled and used as a probe on the blot and a hybridising
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band of approximately 800bp was identified. The digest was then repeated, and
the 800bp band cut out after the gel had been run its full length. DNA was purified
from the agarose using a SpinX column. To increase the efficiency of DNA
recovery 20|ig of glycogen were added to the precipitation. A ligation was then
set up containing 35ng insert:25ng vector, and 2|il of the ligation mix transformed
into electrocompetent XL1 Blue cells. Colonies could have been analysed by
colony lifts and hybridisation with primer C. Due to the low number of white
colonies obtained, however, it was decided to use small scale plasmid preparations
and colony PCR. Minipreps of six of the ten resulting white colonies were
prepared. TaqI digestion of these showed that none of them contained any insert
A further 4 colonies were analysed by colony PCR, and only a fragment the size of
amplified polylinker resulted. The insert preparation and cloning reactions were
repeated several times, using different methods to purify the digested insert. This
was an attempt to achieve higher returns and thus increase the number of different
vector: insert ratios used in the cloning reaction. In addition, the ligation mix was
precipitated and resuspended in 2pl allowing the whole reaction to be transformed.
Again no positives containing an insert of the appropriate size were obtained. To
increase the concentration of insert yet further, three l(ig aliquots of the cosmid
were combined, precipitated (to decrease the volume) and run out in a single well.
Success came when equimolar quantities (18ng insert:77ng vector; vector size
~3000bp, insert size ~700bp, recovered just 18ng of insert so 3000/700x18=77ng)
of vector and insert were combined in the ligation mix, which was again
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precipitated, resuspended in 4(il, and 2pl electroporated. PCR showed 8 of the 13
white colonies contained a fragment of the appropriate size and were positive for
primer C by hybridisation. Sequence analysis of two clones confirmed the presence
of the appropriate fragment, although in a different orientation in each case.
5.2 Sequence analysis of OMP
The foremost requirement of mutation analysis is an absolute certainty in the wild
type sequence of the gene of interest. To confidently produce a consensus
sequence for the entire human OMP gene I had to sequence both strands in both
directions, which meant the insert had to be cloned in both orientations. The
simplest way to clone the PstI fragment in the opposite orientation was to release
the insert by a PstI digest, religate and use another restriction digest to determine
the orientation of the insert. (Alternatively more colonies could have been
screened from the original ligation mix, but unfortunately this was unavailable).
2|ig of the PstI clone were digested with PstI, and run out on a gel to check the
reaction had gone to completion. The reaction was then cleaned up using
phenol/chloroform, ethanol precipitated, and the end concentration estimated on a
gel. Ligations of 15ng/|il and 1.5ng/(il were set up. l(il of the reaction was
electroporated, and 200|il of the reaction plated, resulting in 20 and 5 white
colonies respectively. 12 colonies were grown up and small scale plasmid
preparations carried out. The orientation of the insert was determined using a
Hindin/StuI double digest (Fig.5.2). Early sequencing of the PstI clone had
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indicated that the Hindlll site at the M13 reverse primer end of the pBS polylinker
was unique. There were at least two sites for StuI: one in the 3' untranslated
region (307bp from Hindlll) and one in the coding region (280bp from the other
StuI site). Initial single digests with each enzyme were used to prove that the
enzymes cut at the expected sites; Hindm cut at one site and linearised the clone,
whereas StuI released a 280bp fragment. The exact size of the PstI clone was not
known, but it was estimated to be around 950bp by PCR. Thus if the orientation
of the insert was reversed, then the size of the Hindlll to StuI fragment would
increase to approximately 360bp (Fig. 5.2).
The digests of the 12 small scale plasmid preparations of colonies were run out on
a 2% gel to separate the two smaller products, and 3 had the insert in the correct
orientation. In these the Hindlll to StuI fragment had increased in size to around
360bp. Large scale plasmid preparations were prepared of two of these and the
orientation confirmed by sequencing.
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Figure 5.2 Cloning the Pstl insert in the opposite orientation
The left-hand figure shows the insert as it was originally cloned. The right-hand
figure shows the insert after it had been recloned in the opposite orientation.
Fragment sizes are shown in base pairs. Restriction enzyme sites are indicated:
H=Hindlll; P=Pstl; S=Stul.
The two parts of the OMP gene had been cloned into Stratagene™ vectors which
contain sequences complementary to the Ml3 forward and reverse primers
flanking the polylinker. These primers were initially used in PCR amplification and
sequence analysis of inserted DNA. The sequence obtained from these reactions
could then be used to design primers internal to the insert, allowing further
sequence to be obtained. Conventional sequencing with a radioactive isotope was
carried out first.
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At first, only the PstI clone in one orientation was available for sequencing. Using
the M13 primers almost 200bp of sequence was obtained from either end of the
insert. Primer Y was designed to lie internal to the Ml3 reverse primer and thus
another 260bp of sequence was obtained. 2qg of the PstI clone was double
digested using StuI and Hindlll and the 307 and 280 base pair fragments (see Fig.
5.2) were removed from the clone by gel purification of the large fragment. This
removed part of the polylinker and previously sequenced OMP gene between the
M13 reverse primer and the unknown region. The fragment was then made blunt
ended using T4 DNA polymerase, precipitated, resuspended in 10(il and l(il run
out on a gel to assess the concentration. 50ng of the fragment was ligated
overnight in lOql, and lpl electroporated. Plating 200|il produced 23 white
colonies. Amplification of 14 of these showed 8 of them to contain insert of the
appropriate size. This new clone was called the StuI clone and the M13 reverse
primer was then used with it to sequence into the unknown region of a large scale
preparation of a positive colony. Thus the sequence of the PstI clone was
obtained, by walking out from the M13 reverse primer, although sequencing of
both strands at each point was needed to produce a consensus sequence. This
sequence information would however allow further primers to be designed.
Sequencing of the two TaqI clones proved less successful. It was possible to
complete the sequencing of the OMP coding region, but due to the high proportion
of G and C nucleotides the 5' untranslated region proved very difficult to sequence.
Even using dITPs and deaza-dGTP, very little interpretable sequence information
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was obtained. The use of dITPs in sequencing has been described in a previous
section. The substitution of 7-deaza-dGTP for dGTP in the nucleotide mix can
reduce compressions. When incorporated in the sequencing product, 7-deaza-
dGTP reduces potential hydrogen bonding, and hence decreases band
compressions during gel electrophoresis. Using the universal primers and primer X
the clones were sequenced to 50bp beyond the start codon, but only a further
200bp were obtained of the 5' untranslated region from the other end of the clones.
This left almost 300bp of sequence internal to the clones unsequenced.
At this point the reverse orientation PstI clone became available as did an
automatic sequencer for fluorescent sequencing. Efficient completion of large
DNA sequencing projects has been greatly facilitated by the development of
fluorescence based dideoxynucleotide sequencing chemistries and instruments for
real-time detection of fluorescence labelled DNA fragments during gel
electrophoresis. In addition to eliminating the use of radioactive isotopes, these
systems automate the task of reading sequences and provide computer readable
data that may be directly analysed or entered into a sequence assembly project.
The sequencer was the Automated Laser Fluorescent A.L.F.™ DNA Sequencer
from Pharmacia LKB. Reactions are carried out using fluorescently labelled primer
and run on a gel which is part of the sequencing apparatus. The sequence is
obtained by a fixed point laser beam which reads and analyses the bases as they
pass by. Cycle sequencing was used instead of conventional single primer
annealing and extension sequencing. This involves the linear amplification of the
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sequencing reaction using repetitive cycles of denaturation, annealing, and
extension in the presence of Taq polymerase. In cycle sequencing, less DNA is
required than in a normal non-cycling reaction, and the resulting sequencing data
have less background, few (if any) stops, and can extend to over 500 bases from
the primer. An initial attempt to sequence the original PstI clone, using the BRL
cycle sequencing kit and fluorescently labelled M13 forward primer, achieved 380
bases of readable sequence. Comparison to rat and previously sequenced human
showed the sequence to contain only a few ambiguities towards the end of the
sequence. It was decided that this would be the quickest and most accurate way to
complete the sequencing of the human gene and resolve any previous ambiguities.
All of the clones were then sequenced using fluorescently labelled universal
primers. Some of the caesium chloride plasmid preparations proved difficult to
sequence and it was necessary to ensure the removal of any residual impurities by
phenol/chloroform and ethanol precipitation. By comparison to the estimated size
of the TaqI clone, the amount of sequence obtained from both ends of the TaqI
clones should have revealed an overlap. Using the GCG fragment assembly
program, all of the sequences obtained so far were put into contigs. Using Gel
Merge, even under very non-stringent conditions, it was still not possible to
produce one contig and the 5' untranslated region remained in a separate contig
from the rest of the gene. It was hoped that the fact that the kit contained 7-deaza-
dGTP and the reactions were extended at 70°C would be sufficient to reduce false
stops induced by template secondary structure, but this was obviously not the case.
The sequence information obtained so far, however, did make it possible to design
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primers for sequencing the gene in genomic DNA (Fig. 5.3). Two sets of primers
were required: an outer set to amplify the gene by PCR; and an inner set (nested)
to specifically sequence these PCR products.
It was recommended by Pharmacia that the most accurate sequence information
would be achieved using a single stranded template. For this, one of the primers
used in the genomic amplification reaction had to be biotinylated. The biotinylated
and non biotinylated strands could then be separated using Dynabeads™
(streptavidin coated magnetic beads), and individually sequenced using nested
fluorescently labelled primers. The primers were designed using the 0LIG04
program (Hybaid) to overlap in a similar way to the clones, and it was hoped that
four reactions would be sufficient to sequence the gene (see Fig.5.3).
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Figure 5.3 Primers designed for genomic amplification and sequencing
The location of the primers designed for genomic amplification and sequencing
of OMP relative to the plasmid subclones and the gene itself. Start (ATG) and
stop (TGA) codons are also shown, as are the untranslated regions (UTRs). The
outer primersC^ 5uun,codd3,codd5 & 3uun) were ordered in biotinylated and
non biotinylated forms so that either single strand could be pulled out using
Dynabeads™ The inner primers were dll fluorescently labelled, as indicated by
the T suffix.
The complete sequence of TaqI clones was finally achieved using the ABI
sequencer in conjunction with the ABI cycle sequencing kit as described below.
The ABI sequencer is very similar to A.L.F., the only major difference being that
the laser scans by actually moving across the glass plate. Special primers had to be
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designed for use with this kit which contains fluorescently labelled dideoxy
terminators, enabling all four termination reactions to be carried out in one tube.
Basically the primers had to be longer than 18 bases, have a TM of at least 45 °C,
and avoid long stretches of any single base. These were designed using the GCG
primer design program Primer, and their locations on the clones are indicated
below (Fig. 5.4). The optimum amount of accurate sequencing data expected was
300 bases, hence the primers were designed to produce even coverage of the gene.
Sequencing of both the TaqI and PstI clones once using these primers was
sufficient to close the gap in the 5' untranslated region and resolve all ambiguities
(Fig. 5.4). The advantage of this kit over previously attempted sequencing
methods was the combination of dITPs and extension at 60°C. dITPs are
traditionally used to reduce secondary structure, but are incorporated less well than
dGTPs at 72°C. Consequently lowering the temperature at which Taq polymerase
extends allows efficient incorporation of dITPs and, as shown here, allows the





















ACACGCCAGC TGCTGGACCC CACTGCCATC TTCTGGCGCA AGGAGGACTC 900




GGCCAAGATC CGCAAGGTCA TGTACTTCCT CGTCACCTTT 1000
TGGAGCCCGC CAACCTCAAG GCCTCCGTGG TTTTTAACCA 1050
GCTC^HCAG CAGCTGCCAG CTGCTGCTCT CCTCTAGCCC ACCTGTGCTC 1100
TCCCCTGCCC CTGCCACTTT CCCCCCTGTA TTTTTGGGGC CATTATTCTC 1150
GCTGCTCAGC CTGTCCTCTG CTTGCCCAGA GGCCCCCTGA GTCCCACACC 1200
TTTCCTCCTC TGCTTCTCCC TGGGGCCAGC ACTCCAGCTC ACAGGAAGAA 1250
GATTCTGAGG CTCCATAGCC TAGAAGCTGG ACTGGCTGCT GCATTGCTAT 1300





TTCTCTCTGC TTCATTGTGG GAGAGAGAGA CTGAGAAAGA 1400
CACAGAGACA GAGATTGAAA AACCCAGCAT CCACTTCCTC 1450
CAGAGTCAGG GAGACAGAGA TGATGGGGCG TCTCCACGGG GAGTCCAGCA 1500
AGCCGGCATT CACTGCTCCC TGGCCTTGGT GCCCTTTGCC GGAGCCTGTG 1550
TCTGGGCTGC TGGTCCCATA ACACGTCGAC AACCCTCAGG ATATGGGGCA 1600
_____ 3uun
GGGTTGC
Figure 5.4 The consensus sequence of the human OMP gene
The sequence of the human OMP gene is shown. The Olf-1 binding site and the start
and stop codons are shown boxed. The orientation of primers is indicated by the
arrowhead. Those pointing right to left match the antisense strand sequence.






















5.3 Comparison to rat andmouse
Comparing the coding region of the rodent and human OMP genes could
potentially allow conclusions to be drawn on the importance and putative function
of specific regions of the gene. The mouse (Brown et al., 1994) and rat gene
(Rogers et al., 1987) sequence have been reported earlier. Comparison at the
nucleotide level revealed identity between humamrat, human:mouse, and mouse:rat
of 90%, 88.6% and 98.2% respectively. Several of these differences did not result
in changes at the amino acid level, consequently the identities here were 90.8%,
89.6% and 96.5%. These differences and the overall consensus sequence at the
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Figure 5.5 Comparison of the deduced amino acid sequence of human, rat and
mouse olfactory marker protein gene
This figure was compiled using the GCG pretty command on a 'file of file names'
of the three sequences (i.e. pretty -con -dif -threshold= 1.5 @fofn5.seq).The overall
consensus sequence is shown below each line.
Since then the sequence of the human OMP gene has been confirmed by another
group (Buiakova et al„ 1994). They have, however, made several errors in their
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alignment of the deduced amino acid sequence of OMP. Amino acids 31 and 49
appear as arginine (R) and glutamic acid (E) respectively, when in fact the
sequence submitted by the same group to the data base indicates these amino acids
were conserved between the species and are actually therefore serine (S) and
alanine (A). There are also three typing errors: amino acids 58 and 103 are shown
as isoleucine when they are in fact both threonine; and amino acid 62 is shown as
glutamine when it is actually arginine. My sequencing of the gene confirmed that
the sequence lodged in the database was correct and that the published
discrepancies were errors. This paper was useful in confirming the location of an
upstream Olf-I binding site, 260 bases upstream of the start codon (see Fig. 5.4).
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6. OMP as a candidate for Usher Syndrome
type IB
OMP is a relatively small single exon gene and it was necessary to decide exactly
how much of the Hanking regions to analyse. I had sequenced some although not
all of the untranslated regions, but it was decided that given the fact that only
300bp of the untranslated region was required to give appropriate expression of
OMP in transgenic mice (see the end of section 1.2.6.4), it would be sufficient to
carry out mutational analysis on this extent of the 5' untranslated region. Very
little is known in general about 3' untranslated regions, so it was decided to look
for any major changes in the region encompassed by sequencing. A number of
different methods were used to look for mutations in OMP, and the success of
these is described in litis section. All of the methods used were PCR based, hence
conditions for amplification of the gene from genomic DNA had to first be
optimised. This was a relatively simple task for the 3' end of the gene. Standard
genomic PCR conditions, annealing at 53°C, were sufficient to produce a single
960bp PCR product, using the primers codd3 and 3uun (Fig. 5.4).
Sequencing had shown that the 5' end of the gene was GC rich, and this region had
proved difficult to sequence. Similarly the region also proved troublesome to
amplify. Primers had been designed such that the whole gene should be amplifiable
with 5uun and 3uun, and the 5' end of the gene should be amplifiable with 5uun
and codd5. Several attempts using annealing temperatures been 40 and 60°C
produced either no product or, as was the case with 5uun-3uun at Ta=40°C, too
small a product (~500bp instead of 1600bp). Increasing the concentration of Mg2+
(from 1.5-4mM) in the reaction buffer also proved unsuccessful. Several sets of
external primers were designed to replace 5uun and 3uun in the hope of increasing
the specificity, none of which were successful, and any product was too small. 4
sets of external primers now existed and it was decided to try using them in
combination in nested PCRs in the hope of increasing the specificity and sensitivity
of the reaction.
Primary PCR A:Extf+Extr B:5uun+3uun C:Extfl+Extf2
Secondary PCR AiiExtfl+Extrl B^ExtfZ+Extrl Ci:5uun+Extrl
A2: Extf2+Extr2 B2:Extf2+Extrl C2: Extf2+Extrl
The template used was cosmid DNA, and two genomic DNA samples from normal
individuals. The annealing temperature for both PCR reaction stages was 45°C.
After an initial 25 cycles of PCR, l|il was transferred to the secondary PCR which
was also amplified for 25 cycles. PCRs Ai, Ci, and C2 gave a 500bp product; A2
and B2 gave a smear with faint bands of the wrong size; and Bi gave a strong
1.6Kb band in the cosmid track and very faint bands of the same size in the
genomic tracks (Fig. 6.1). In an attempt to increase the amount of product the
number of cycles in either the primary or the secondary PCR were increased.
Increasing the number of cycles in the primary PCR led to no bands even with
cosmid template. Increasing the number of cycles in the secondary PCR failed to
produce any more of the specific 1.6Kb product in the genomic samples, and
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indeed appeared to increase the level of non specific product. Reducing the
annealing temperature in the primary PCR to 40°C and increasing the annealing
temperature to 60°C in the secondary PCR also failed to produce any more
product from the genomic samples.
Dimethyl sulphoxide has been shown to prevent template reannealing and hence aid
in the sequencing of double stranded templates (Winship 1989). A literature
search showed that it had also been used to prevent the formation of complex
secondary structures in some PCR templates (Shen and Hohn 1992). DMSO was
shown by Shen et al to be the decisive factor for Taq mediated PCR amplification
of DNA fragments containing complex secondary structures. In the test case,
inclusion of DMSO at a final concentration of 5-10% proved sufficient to increase
the product size from 200bp to the expected size of 1.5Kbp. Similarly it was
hoped that inclusion of DMSO in amplification of the OMP gene would be capable
of allowing specific amplification of the whole gene.
35 cycle 5uun-3uun PCRs were set up at Ta=45°C with DMSO at a final
concentration of 2, 5 or 10%. At 10% a reasonably strong 1.6Kb product was
visible in the genomic track. The genomic product was very weak at lower
concentrations of DMSO although the cosmid amplified extremely well at all
DMSO concentrations. The experiment was repeated with DMSO at a final
concentration of 11, 12, and 13% and the level of genomic product increased with
each increase in DMSO. Tests with 15 and 20% DMSO showed that it began to
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inhibit the reaction above 13%. All further amplification of the whole gene
included 13% DMSO in the reaction.
In the same way inclusion of DMSO in the amplification of the 5' end of the gene
at 10% was sufficient to produce the expected 816bp genomic product, where
combinations of all of the available 5' primers and nested PCRs on the whole gene





M ,1 2 3 4„1 2 3 4, ,1 2 3 4,
C1 C2 5unF-cod5F
Figure 6.1 Attempt to amplify the 5' untranslated region of the OMP gene
The results of attempts to amplify the whole OMP gene are shown, A1-C2; see
text for conditions used. Also shown is an attempt to amplify only the 5' end of
the gene with primers 5unF and cod5F using 35 amplification cycles at 57°C
annealing. Only B1 gave product of the correct size, although the amount of
product obtained from genomic DNA was very poor.
Key: M = lkb ladder marker (Gibco); 1 = blank; 2 = OMP cosmid DNA; 3-7 =
human genomic DNA samples.
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- 1.6kb
M ,1 2 3 4M1 2 3 4,1 2 3 4,
DMSO 2% 5% 10%
- 1.6kb
M,1 2 4 5 6 7, ,1 2 3 4,,1 2 3 4,
DMSO 13% 15% 20%
Figure 6.2 Successful amplification upon inclusion of DMSO
Reactions shown here were carried out in the presence of increasing amounts of
DMSO, as indicated. Increasing the concentration of DMSO increased the
amount of product. The reaction was found to be optimal in the presence of
13% DMSO, increasing the concentration beyond this point appeared to be
inhibitory to the reaction.
Key: M = lkb ladder marker (Gibco); 1 = blank; 2 = OMP cosmid DNA; 3-7 =
human genomic DNA samples.
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their locations are shown below (Fig. 6.3). Rodent primers were also tested in
combination with human primers which lay within the coding region, and the
relative positions of these are also shown.










Figure 6.3 The location of primers used in interspecies comparison
Primers A and R match rat and mouse, primer C is designed to rat and primer S
to mouse. Primers C and S begin at the first base after the start codon; primer C'
is complementary to bases 239-259 in the coding region; primer R begins 4 bases
downstream from the stop codon, and includes it in its sequence; primer A is
nested within primer R and is complementary to bases 465-487. The relative
location of the human primers is also shown.
All primer combinations were tested on genomic DNA from human (F4-human
DNA obtained from a female placenta), mouse (RAG1- a mouse cell line), and rat
(FA2A- a rat liver cell line from Dr Robert Hill). In the end, the primers C and C'
were selected for amplification, since they gave a strong specific product. These
primers can be used to amplify a section at the 5' end of the coding region (bases 3-
259). C' was biotinylated and as such could be used to isolate single strands for
sequencing. The non biotinylated strand could then be sequenced with the
fluorescently labelled human primer cod5f, which was perfectly matched to the
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rodent sequence. None of the primer combinations tested gave a specific human
product hence it was decided to go ahead and use orphan peak analysis to compare
rat and mouse C-C PCR product, sequencing the non biotinylated strand with the
human primer cod5f.
6.1.1.2 Orphan peak analysis
Here only two samples were being analysed so two different base reactions could
be loaded adjacent to each other, as indicated below.
Table 6.1 Colours applied to base specific sequencing reactions
The A.L.F. automated DNA sequencer normally draws the four base profiles of a
sample in different colours. Here rat and mouse base specific sequencing
reactions were loaded in alternating lanes, such that those from A and C
dideoxynucleotides (and similarly G and "0 would be treated as one sample.
Lane Associated Base Species
Colour loaded
A Green A Rat
C Blue A Mouse
G Yellow C Rat
T Red C Mouse.
A Green G Rat
C Blue G Mouse
G Yellow T Rat
T Red T Mnn.se.
The region sequenced using the primer cod5f includes several differences between
mouse and rat. It was possible to predict the nature of the expected orphan peak,
and the time point at which it should occur. Similarly the time point and nature of
any unknown mutations will be easily detected. Identifying the time point required
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a standard sequencing reaction, using the cod5f primer, to be run on the same gel
as the samples being analysed. The differences between rat and mouse and the
expected result are tabulated below. All of the differences are on the antisense
strand since this is the strand sequenced by cod5f. Normally, when loading as
indicated above, each blue peak would be expected to be overlaid with a green
peak and each yellow peak with a red peak, any unmatched peaks or overlaying of
the wrong coloured peaks would indicate that the sequences differ at this point.
Table 6.2 Sequence differences and expected orphan peaks
The base differences, on the antisense strand, and their position in the coding
region between rat and mouse are shown. The unmatched (orphan peaks) or
overlaid peaks that these differences should produce are also indicated.
Base in coding region Nature of difference Expected peak
36 A rat - C mouse Green (A) - Red (C)
66 A rat - G mouse Green (A) orphan/
Blue (G) orphan
105 G rat - A mouse Green (G) orphan/
Blue(A) orphan
138 A rat - G mouse Green (A) orphan/
Blue (G) orphan
155 A rat - G mouse Green (A) orphan/
Blue (G) orphan
167 G rat - T mouse Green (G)-Red (T)
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It became clear that it was imperative to have a good quality sequencing reaction in
order to clearly identify orphan peaks. Poor quality sequencing was difficult to
align and in such cases even matched peaks were difficult to clearly observe. Only
the A/G mismatch at base 66 was clearly identified as an orphan peak (see Fig.6.4).
The result was however so unequivocal that it was obviously worthwhile pursuing
this method for mutational analyses of Usher IB patients.
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Page: i/l
Time: ©1:33 .. 02:31 [h: ml Date: 04-08-93
; - ; ™1
Clone: 3. rat/mouse (Pi
Figure 6.4 Orphan peak
Here the relative position of the A and C nucleotides in rat and mouse are
shown. The arrow indicates the mismatched A nucleotide in the rat. The
equivalent base in mouse is a G which had not been run here hence an orphan
peak results.
Key: green = rat A; blue = mouse A; yellow = rat C; and red = mouse C.
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6.1.2 Testing the technique by interhuman comparison
To test the efficacy of the method further and optimise the conditions, it was
decided to compare four different normal genomic samples that were available in
the laboratory. From each a single 960bp PCR product was amplified, using the
primers codd3 and 3uun (see Fig. 5.3). Using the biotinylated version of either
primer a single strand could then be isolated and sequenced using the appropriate
internal fluorescently labelled primer. Multiple attempts were made at sequencing
the biotinylated and non-biotinylated strands of several different genomic samples.
Only the non-biotinylated strand was ever successfully sequenced and of these
reactions all were fairly poor apart from one where 625bp of sequence was read.
No reasonable explanation could be offered by Pharmacia or Dynabeads for the
inconsistency of the method, as at all stages the conditions used appeared to be
optimal. An experiment was undertaken to look at the efficiency of primer
biotinylation. 300ng of primer 3uunB was run out on a gel adjacent to the
supernatant from binding 300ng of primer to 20|il of Dynabeads. The primer lane
showed a band of the expected size and intensity. The supernatant lane however
contained no visible band indicating that all of the primer had been efficiently
bound. In addition a sample of 300ng of 3uunB combined with l(ig of streptavidin
immunoperoxidase, showed complete gel retardation of the primer on gel
electrophoresis. Thus the problem lay not with the primer, but at some later stage.
Since only the non-biotinylated strand was ever sequenced it was possible that the
beads were somehow inhibiting the sequencing reaction.
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An attempt was also made to directly sequence the double stranded PCR products.
A PCR reaction was split into two aliquots. For one aliquot, single biotinylated
and non biotinylated strands were isolated and sequenced as before. Samples of
the remaining aliquot were purified using either mung bean nuclease (digests PCR
primers and misprimed, single stranded amplification products) or isopropanol
precipitation and cycle sequenced with each of the fluorescently labelled primers.
These attempts were also unsuccessful. At this point the usage of the ALF
sequencer became entirely devoted to the analysis of CA repeat polymorphisms
and an ABI automated sequencer became available instead for sequencing. The
success with this machine in completing the consensus sequence of the OMP gene
(Fig. 5.4) indicated that more consistent results could be obtained and therefore it
could also be used to look for differences in the OMP gene of patients.
6.2 ABI cycle sequencing
Orphan peak analysis, however, could not be carried out with the ABI sequencer
since each dideoxy nucleotide is labelled with a different fluorescent dye allowing
the entire sequencing reaction to be carried out in a single tube and run out in a
single gel lane. Primers labelled with different fluorochromes could be used, but
obtaining enough primers to cover the whole gene would prove prohibitively
expensive. The ABI cycle sequencing kit is also very expensive, and all of the gene
would have to be sequenced in each individual in order to identify potential
mutations, hence the decision was made to use the HOT technique to identify
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putative mutations and confirm these results by ABI cycle sequencing of the
relevant part of the gene.
6.3 Chemical mismatch analysis /HOT
Equipment and expertise were available in the Unit for all three major mutational
analysis techniques (SSCP, DGGE, & HOT) generally used in the detection of
single base changes. It was decided to screen a small number of patients using
HOT since this should detect 100% of all mismatches. The nature of the technique
is such that the point at which a base change occurs is indicated by the size of the
fragment on a gel, and that position can then be sequenced providing appropriate
primers are available (see introduction for detailed description). Using labelled
sense and antisense DNA meant that any cleavage fragments could be due to a
base difference on either strand, thus for every fragment there were two possible
points at which the mismatch could have occurred. Not only does the HOT
technique give an accurate indication as to where the mismatch has occurred, it
also indicates the nature of the mismatch. This gives less chance of ambiguities
and compressions being mistaken for polymorphisms/mutations. HOT is a highly
user dependent technique. The clarity of the results very much depend upon the
level of expertise. The saving grace of the technique is that it is accurate, detects
all types of mismatches and you often have two chances to identify a mutation. If
both labelled wild type and patient DNA are used the mismatch is often expected
to produce a fragment from each, so with a 50% percent success rate with respect
to the chemical reaction you would still expect to detect 100% of the mismatches.
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In these experiments the cosmid was used as the control DNA because this had
been used to determine the consensus sequence.
It was decided to carry out HOT analysis on the two separate PCRs of the 5' and 3'
end of the gene since these overlapped in the coding region, and were of a more
manageable size for electrophoresis in a polyacrylamide gel. These were known as
C5 and C3 PCRs and covered bases 2-817 and 644-1605 respectively (Fig. 6.5).
Figure 6.5 The PCR fragments used for HOT analysis
The two PCR fragments used in HOT analysis, and how these relate to the gene
structure are shown. C5 PCR amplifies bases 2-817 and produces a fragment of
816bp, and C3 PCR amplifies bases 644-1605 and produces a fragment of 962
base pairs.
Nine patients were chosen for analysis. These were selected on the basis that
either an affected sib or additional family member DNA was available, hence any
potential mutations could quickly be followed through in the family and confirmed.
Mismatches would be classified as mutations if they were seen in affected and not
in normals, and altered to the coding sequence. Mismatches would be classified as
polymorphisms if they were seen in both affected and normals. The presence of a
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mismatch in only one of a sib pair could be an indication that it was due to a
polymorphism or a new mutation.
The results are shown in two separate tables corresponding to the two different
fragments analysed. These are then followed by the sequence of the gene
annotated to show where the mismatches might lie and the primers designed to
cover the region.
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Table 6.3 Results of HOT analysis on the C5 PCR product
The size of products obtained by HOT analysis of the C5 815bp PCR fragment.
PNo. indicates the laboratory number given to the samples which are described
in more detail in table 2.7. Sizes are in base pairs. NC = no cleavage products
observed.





P3 550 172/550 NC NC
P4 550 550 NC NC




P16 NC NC NC NC
P17 73/550 73/172 NC NC
P18 NC NC NC NC
P21 NC NC NC NC
P25 550 550 NC NC
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Table 6.4 Results of HOT analysis on the C3 PCR product
The size of products obtained by HOT analysis of the C3 962bp PCR fragment.
Sizes are in base pairs. NC = no cleavage products observed.









P9 800 112/144 454 NC
P10 800 NC 65/454 NC
P16 409/800 NC NC NC
P17 112/144/800 112/144 NC NC




P25 800 NC NC NC
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5un ^
CAGGCTTTGG TGATTGGGTG TGGAGGAGTG AGAGGGAGGC GGGCGTCAGG 50
Af
GGTAGCTCCA AGGTTTAACT TA^TGACTT CAGATCTCCA ATCACCAAGC 100
CCTCTCTGGT CCTGCCTTCT CCACCTGCTC CTGCGGGTCT TGCATCTTCT 150
CCTGTGTACC TCCAGTGAGG AGTG0TCCCC ACCACCCTCC CC^TCAGTGC 200
ACTTACGAAG TGCTCTCATC TTCACAAACA AGCCAGCACC CAGCCCAGCC 250
CTGGTAGTCA GGGCGGTT0C C0CAGCAATT GACATCAGCG ACCTGGTCCC 300
OLF-1
CAAGGAACCT GCCACCTTCC GCCTGCCTGC AGGGCCTGCA TTATCGCTTC 350
TGCGGGGACT GGAGTGGAGG CAGATGGGGA CTCCCACCCC TGACACACAC 400
Bf2
CCCATTTTGA GAACTGAGTG GGGCTGGGAA GAGCCAGTGG CAAAGGGAGG 450
<
) Ar
GGAAGAGGGA AGGGCAGAAA GTAGGTGGGS CCCCCCTTTG GTGGCCTCTT 500
CTCTCCACGG CCCCAGGCTC CAGCCCACTT GGGTCCTTGG CGTTGG@3(^ 550
AGCAGCACTT GGGCCj^GC GGAGGACAGG CCGCAGCAGC CGCAGCTGGA 600
CATGCCGCTG GTCCIGGAljc AGGGCCTGAC CAGGOAGATG CGGCTACGCG 650
CQOflJ.- ..... fe cd3i
TGGAGAGCCTGAAGCAGCGC GGGGAGAAGC GCCAGGATGG GGAGAAGCTG 700
A * PrX
CTGCAGCpVG CGGAGTCTGT GTACCGCCTC AACTTCACCC AGMGCAGCG 750
Gcffi^AGTTC GAGCGCTGGA ATGTCGTGC^ GGACAAcQcA GGCAAGGTCA 8 00
CCATBACAGG CACCTCGCAG AACTGGACGC CTGACCTCAC CAACCTCATG 850
Cf >■
ACACGCCAGC TGCTGGACCC CACTGCCATC TTCTGGCGCA AGGAGGACTC 900
GGATGCCATA GATTGGAATG AGGCCGACGC CCTGGAGTTT GGGGAGCGCC 950
Br -«£ =
TGTCGGACCT GGCCAAGATC CGCAAGGTCA TGTACTTCCT CGTCACCTTT 1000
==*" Fs
GGCGAGGGTG TGGAGCCCGC CAACCTCAAG GCCTCCGTGG TTTTTAACCA 1050
GcQtlGACAG CAGCTGCCAG CTGCTGCTCT CCTCTAGCCC ACCTGa||cTC 1100
TCCCCTGCCC CTGCCACTTT CCCCCCTGTA TTTTTGGGGC CATTATTCTC 1150
02TGCTCAGC CTGTCCTCTG CTTGCCCAGA GGCCCCCTGA GTCCCAACC 1200
^
TTTCCTCCTC TGCTTCTCCC TGGGGCCAGC ACTCCAGCTC ACAGGAAGAA 1250
GATTCTGAGG CTCCATAGCC TAGAAGCTGG ACTGGCTGCT GCATTGCTAT 1300
AGACGATAGA GGCCTACTAG GGGCCAGTGT GCATGGACAG TGAGGCCAGG 1350
31 3- -6
GCCATCTGCC TTCTCTCTGC TTCATTGTGG GAGAGAGAGA CTGAGAAAGA 14 00
CCAAGAGAGA CACAGAGACA GAGATTGAAA AACCCAGCAT CCAC|TCCTC 1450
CAGAGTCAGG C^ACAGAGA TGATGGGGCG TCTCCACGGG (^^TCCAGCA 1500
AGCCGGCATT CACTGCTCCC TGGCCTTGGT GCCCTTTGCC ^GAGCCTGTG 1550
TCTGGGCTGC TGGTCCCATA ACACGTCGAC AACC^TCAGG ATATGGGGCA 1600
GGGTTG^""
Figure 6.6 Compilation of potential mismatches in the OMP gene of Usher IB
affected individuals
Boxed sequence indicates the binding side for the Olf-1 transcription factor,
start (ATG)and stop (TGA) codons Primers used in PCR amplification are
represented as red (C3) and dark blue (C5) arrows. All other arrows represent
primers used in sequencing, Ovals and squares indicate potential position of
mismatches, each pair corresponding to the two possible sites.
Initially attempts were made to resolve the mismatches by ABI cycle sequencing.
Each of the patients which appeared to have a particular mismatch by HOT were
sequenced through the two possible regions where the mismatch may have
occurred. The sequences were then overlaid using the GCG pile up command, to
compare and highlight the differences between each of these and the consensus
sequence. Problems were encountered at this stage which are inherent to
sequencing with this particular kit. The conditions used are such that Taq
polymerase does not incorporate all dideoxynucleotides with the same efficiency.
The efficiency of incorporation is influenced by local base composition and the
structure of the different dyes attached to the ddNTPs. This results in a number of
characteristic base patterns: C's following G's are often weak; T's following G's
are often weak; in a string of four or more G's the third G often shows a reduced
signal, and the following G's are elevated; and A's after T's can show reduced
signal. Point mutations leading to a nonfunctional gene may be identical in both
alleles, but sometimes each allele will be mutated at a different point resulting in a
compound heterozygote. In such a situation a mismatch would be visualised as a
reduction in peak size, and it quickly became clear that a difference in just one
allele would be almost impossible to resolve from inefficient incorporation of a
particular base. Sequencing on the opposite strand reverses the orientation of the
bases and therefore resolves the ambiguity, although at the same time creates more
ambiguities particular to the base composition of this strand. This meant that for
each patient at least four sequencing reactions were required to resolve each
mismatch, and any mismatch had to be detected by visually scanning the
chromatograms obtained by sequencing through the region in both orientations and
comparing these to control sample. It was decided therefore that it would be more
accurate to carry out 35S sequencing on the PCR products, in the presence of
DMSO.
In each case the size of the HOT product was estimated from a sequencing
reaction of the PstI clone which was run alongside (see Tables 6.3 & 6.4). Both
potential sites of the mismatch were then sequenced and the presence of a
mismatch confirmed if the base change would have resulted in the observed HOT
result. Thus a number of mismatches were confirmed in the human OMP gene as
described below.
C5 PCR fragment sequencing results
P17 patient DNA produced a very strong 73bp fragment when heteroduplexed to
cosmid and treated with osmium tetroxide (Table 6.3). Sequencing with primer 5r
showed the mismatch was not in the 5' untranslated region. Subsequent
sequencing with primer cod5 revealed a C/A mismatch at base 743 (Fig. 6.10).
This would result in the T nucleotide on the antisense strand being mismatched and
would produce the observed 73bp fragment when treated with osmium tetroxide.
The complementary 743bp product resulting from hydroxylamine treated labelled
cosmid was also faintly visible. In addition, a band of 73bp was also faintly visible
in the patient hydroxylamine track, which was probably due to a slight effect of the
mismatched T on the adjacent C nucleotide. This mismatch should also be covered
by the C3 PCR fragment (see Fig. 6.6), and would be expected to produce a band
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of 862bp (when labelled patient heteroduplex is treated with osmium tetroxide).
The failure to detect this band is most likely due to its proximity to the excess of
full length end labelled fragments. The 99bp fragment expected from
hydroxylamine treatment of the cosmid was also not observed. The observed
nucleotide change from C to A would change amino acid 59 from a glutamine
(CAG) to lysine (AAG).
A band of approximately 634bp was observed with hydroxylamine treated
heteroduplex between labelled cosmid and P25 patient DNA (Table 6.3).
Sequencing with primer X revealed no mismatches around base 634, which meant
the change had to have occurred in the 5' untranslated region probably at base 175,
since this is the closest G base 182 (816-634=182). Unfortunately primer Af gave
very poor sequencing data, and the mismatch lay within primers Aif and 5r (see
Fig. 6.6), therefore the status of this putative mismatch was unresolved.
Several fragments, in particular those at 172bp and 550bp (Table 6.3) were
observed in reactions analysed from the C5 PCRs which could not be confirmed by
sequencing. They appeared to be gel or reaction dependent, such that analysis
carried out on the same PCR product on a different occasion did not show the
same fragments. These may have resulted from secondary structure formation in
the highly GC rich 5' untranslated region, particularly the 172bp fragment since
sequencing with primer 5r revealed a compression in this region.
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C3 PCR fragment sequencing results
The 65bp fragment produced by hydroxylamine treatment of labelled cosmid
heteroduplexed to P10 patient DNA (Table 6.4) could have been either due to
mismatched C at 708 or G at 1540 in the gene (Fig. 6.6). Sequencing with primer
cod5 showed it was not at base 708 and hence not in the coding region.
Subsequent sequencing with primer 3f revealed a G/A mismatch at 1540 (Fig.
6.10). The wild type sequence was G at this point hence on labelled wild type
antisense strand a C/A mismatch would occur resulting in the 65bp cosmid-
hydroxylamine product Similarly a T/G mismatch would be expected to be picked
up by osmium tetroxide treatment of labelled patient heteroduplex. This was not
observed.
The 409bp band in patients 3,4,16, and 21 produced by hydroxylamine treatment
of labelled patient heteroduplex DNA (Fig. 6.5 and Table 6.4) could have been due
to a mismatch at base 1196 or 1053 (Fig. 6.6). Sequencing with primer Fs gave
perfect sequence at 1053, whereas primer Cr revealed a G/A polymorphism at base
1196 in patient 3,4 and 21 and a change from A to G in both alleles from P16
patient DNA (Fig. 6.8). The wild type sequence at this point was an A, hence on
labelled patient antisense strand a C/A mismatch would occur resulting in the
409bp patient hydroxylamine product. The complementary cosmid labelled
osmium tetroxide 552bp band was not seen.
The 454bp hydroxylamine treated cosmid labelled band in patients 3,9, and 10 (Fig.
6.7 and Table 6.4) could have been due to a mismatch at base 1098 or 1151 (Fig.
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6.6). Sequencing with primers Fs (Fig. 6.8) and Rs revealed the cause to be a G/A
polymorphism at base 1151. The wild type sequence was G at this point hence on
labelled wild type antisense strand a C/A mismatch would occur resulting in the
454bp cosmid-hydroxylamine product. The complementary patient labelled
osmium tetroxide product was not however observed.
Potentially the most interesting product was the 800bp fragment observed for all
the patients by hydroxylamine modification, which could have been due to a
mismatch at base 805 or 1444. 35S sequencing with primer Br was unable to
resolve the region around 800bp and resulted in a large compression. ABI cycle
sequencing, however, revealed a G in the patients at base 790 whereas the
consensus sequence at this point was an A. Hence on labelled patient antisense
strand a C/A mismatch would result giving the observed 800bp patient-
hydroxylamine product. The complementary cosmid labelled, osmium tetroxide
treated 790bp product, due to a T/G mismatch, was not seen. This mismatch lay
within the coding region, but unfortunately changed the third base of the triplet
encoding proline from CCC to CCA hence still coding for proline. Both patient
alleles differed from the consensus at this point. Consequently, it was the only base
change to be unequivocally detected by ABI sequencing. At a later date another
group published the OMP gene sequence (Buiakova et al„ 1994) and comparison
of my sequence to this revealed the change was probably due to a mutation in the
cosmid sequence and the patients in fact matched the wild type consensus
sequence.
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Figure 6.7 HOT analysis of the C3 PCR fragment
An aliquot of a sequencing reaction of the OMP Pstl clone was run alongside the
products of HOT analysis of the C3 fragment. This allowed bands produced by
mismatched bases to be sized. Shown here is the 454bp band in patient 9
produced by hydroxylamine treated heteroduplex in which the cosmid DNA was
labelled; the 409bp band in patients 4 and 21 produced by hydroxylamine
treatment of patient labelled heteroduplex DNA; the 112 and 144bp bands in
patients 4, 9, 17 and 21 detected by both hydroxlyamine and osmium tetroxide
treatment of patient labelled heteroduplex DNA.
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Figure 6.8 Sequence analysis of mismatched bases
a) The T normally found on the antisense strand at base 1196 in wild type DNA,
has been mutated to a C in one allele from patient 3, whereas both alleles in
patient 16 have been altered.
b) The G normally found in wild type DNA has been mutated to an A in one
allele from patients 3 and 9.
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In common with the C5 PCR fragment, several bands were observed in HOTs on
the C3 PCR fragment which appeared to be gel or reaction dependent. In general
these were ruled out due to their inconsistency. Two bands, however, were
particularly strong. These were the 112 & 144bp products, detected in patients
4,9,17 and 21 by hydroxylamine and osmium tetroxide treatment of patient labelled
heteroduplex (Fig. 6.7 and Table 6.4). These could have been due to mismatches
at 852bp, 820bp or 1495bp, 1463bp respectively (Fig. 6.6). Sequencing with
primer 3f indicated that there were no polymorphisms at 1463 or 1495. Similarly
sequencing with primer Br indicated an exact match to the consensus at 852bp.
The sequence around base 820 was extremely compressed and impossible to read.
Thus it was impossible to rule out the fact that the 144bp band might have resulted
from a mismatch in this region. The sequencing of the 3' untranslated region with
3r gave a very interesting result. Those patients which gave the two bands and
patient 18 (sib of patient 17) all produced sequence which appeared to be overlaid
until 1350bp where there was a strong compression, after which the sequence was
clear and easy to read. In patient P3 , however, which did not give the two bands
(112 & 144bp) in HOTs there was a compression at 1350, but prior to this point
the sequence was still easy to read (Fig. 6.9). It appeared that in the other
samples some sort of inversion or small deletion had occurred which put the
sequence out of alignment downstream of base 1350. This could mean that primer
3f was only sequencing one allele and hence explain why no mismatch was
detected. In order to test the theory that an inversion might have occurred, nested
PCRs on a 1:100 dilution of the C3 PCR product were set up as indicated below.
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The products obtained from patient P4 and the control patient P3 were all of the
size expected in the normal. Thus the overlaying of the sequence had not resulted
from an inversion, but probably from a small (since the PCR product size appeared
to be unaltered) deletion then insertion or vice versa at base 112 and base 144.
The exact nature of the change could be determined by cloning and sequencing







Figure 6.9 Sequence of the 3' untranslated region
Here sequencing reactions of P3 and PI7 patient DNA with primer 3r have been
run out adjacent to each other. Sequence in PI7, while fainter then P3, was
easy to read beyond 1350, where a compression has occurred. Prior to this
point, however, the sequence in PI7 contained many more bands than P3 and
indeed appeared to be overlaid with a different sequence.
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Cr 3r 3uun 3r 3uun
Primers Normal primer order Inverted primer order
Expected products Expected products
CF-3uun =>740bp =>740bp
Cf-Cr => 543bp =>same strand so no product
Cr 3uun =>same strand so no product =>197bp
Figure 6.10 Orientation of primers in the presence of an inversion
The line drawing on the left indicates the orientation of the primers as they were
designed, whereas the right-hand drawing indicates the orientation if an
inversion occurred between primers Cf and 3r. If such an inversion had
occurred, primer Cr would be complementary to the opposite strand and a
different set of products would result as indicated The product sizes expected
using the indicated primers for each orientation are given.
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caggctttgg tgattgggtg tggaggagtg agagggaggc gggcgtcagg 50
ggtagctcca aggtttaact taggtgactt cagatctcca atcaccaagc 100
cctctctggt cctgccttct ccacctgctc ctgcgggtct tgcatcttct 150
cctgtgtacc tccagtgagg agtc^tcccc accaccctcc ccatcagtgc 200




gggcggttgc cacagcaatt gacatcagcg acctggtccc 300
gccaccttcc gcctgcctgc agggcctgca ttatcgcttc 350
tgcggggact ggagtggagg cagatgggga ctcccacccc tgacacacac 400
cccattttga gaactgagtg gggctgggaa gagccagtgg caaagggagg 450
ggaagaggga agggcagaaa gtaggtgggs cccccctttg gtggcctctt 500
ctctccacgg ccccaggctc cagcccactt gggtccttgg cgttggtggc 550
agcagcactt gggccHIgc ggaggacagg ccgcagcagc cgcagctgga 600
catgccgctg gtcctggacc agggcctgac caggcagatg cggctacgcg 650
tggagagcct gaagcagcgc ggggagaagc gccaggatgg ggagaagctg
a(^,gcagcg
700
ctgcagccag cggagtctgt gtaccgcctc aacttcacgc 750
gctacagttc gagcgctgga atgtcgtgct ggacaagccj| ggcaaggtca 800
ccatcacagg cacctcgcag aactggacgc ctgacctcac caacctcatg 850
acacgccagc tgctggaccc cactgccatc ttctggcgca aggaggactc 900
ggatgccata gattggaatg aggccgacgc cctggagttt ggggagcgcc 950
tgtcggacct ggccaagatc cgcaaggtca tgtacttcct cgtcaccttt 1000
ggcgagggtg tggagcccgc caacctcaag gcctccgtgg tttttaacca 1050
gctcHHcag cagctgccag ctgctgctct cctctagccc acctgtgctc 1100
/tcccctgccc ctgccacttt cccccctgta tttttggggc cattattctc
gtccc^acc
1150
[gJotgctcagc ctgtcctctg cttgcccaga ggccccctga 1200
tttcctcctc tgcttctccc tggggccagc actccagctc acaggaagaa 1250
gattctgagg ctccatagcc tagaagctgg actggctgct gcattgctat 1300
agacgataga ggcctactag gggccagtgt gcatggacag tgaggccagg 1350
gccatctgcc ttctctctgc ttcattgtgg gagagagaga ctgagaaaga 1400
ccaagagaga cacagagaca gagattgaaa aacccagcat ccacttcctc 1450
cagagtcagg gagacagaga tgatggggcg tctccacggg gagtccagca 1500
agccggcatt cactgctccc tggccttggt gccctttgcc l03agcctgtg 1550
tctgggctgc tggtcccata acacgtcgac aaccctcagg atatggggca1 600
gggttgc
Figure 6.11 Confirmed mismatches in the OMP gene of Usher IB affected
individuals
The consensus sequence of the human OMP gene. Yellow and green boxed
sequence indicates the binding site for the Olf-1 transcription factor, and start (ATG)
and stop (TGA) codons respectively. Ovals and squares indicate confirmed
mismatches, the normal base is shown above, the colour of these correspond to the
potential mismatches shown in figure 6.6.
6.4 Comparative Mapping
Having excluded Omp as a candidate for Shaker-1, Steve Brown's group began to
construct a YAC contig across the sh-1 region using Omp as a startpoint. Using
microsatellites they were able to delineate the extent of the non-recombinant region
and from this several exon traps were isolated (Gibson et al., 1994). Two of these,
ET17 and ET58, were shown to contain open reading frames, and be conserved in
a number of species. Hence they were hybridised to a somatic cell hybrid panel
containing sub fragments of llq to see if they mapped to the region linked to
USH1B.
The hybrid panel used, and the preparation of the Southern blots for mapping have
been previously described in section 4.1. The exon traps had been cloned into a
vector which had sequence complementary to M13 primers flanking the cloning
site. The PCR amplified insert was isolated as a gel fragment which was labelled
by random priming, then hybridised to a Southern blot of the somatic cell hybrid
panel. In this manner ET58 was mapped to the same interval as OMP and hence to
the region linked to USH1B (Table 4.2). ET17 did not produce any signal on the
panel, which was not unexpected since on hybridisation to a zoo blot it failed to
give any signal in the human track.
Benoit Arvdiler, while working in our laboratory, began isolating a human OMP
YAC contig, and 5 of the YACs which he had isolated were available for
screening. This was done by making a Southern blot of an EcoRI digest of these
YACs and hybridising it with labelled ET58 insert as described above. Hence the
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two YACs which were positive for OMP were also shown to be positive for ET58.
These YACs were sized by preparing agarose plugs which were then run on a
pulsed field gel. The YACs were not clearly distinguishable from the yeast
chromosomal background, so the gel was Southern blotted and probed with 32 P
labelled CotI DNA to detect human specific DNA (see Figure 6.12). Thus both
YACs were shown to be 330kb and might in fact contain the same EcoRI








Figure 6.12 Sizing the OMP YACs
Agarose plugs were prepared and run on a CHEF pulsed field gel as described in
material and methods. Some of the YACs were the same size as the yeast
chromosomes hence the gel was Southern blotted and hybridised with Cotl DNA
to identify the YACs. Hence each could be roughly sized relative the markers,
and both were in fact 330Kb.
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6.5 Discussion
The overall results of mutational analysis on the human OMP gene are illustrated in
Fig. 6.11. Only one of the HOT products resulted from a change at the amino acid
level. Amino acid 59 lies within a region which is relatively poorly conserved
between human and rodents. There are 5 amino acid differences between aa56 to
aa67, and hence a change at this point may have very little effect on the protein
product. This change was not shared by patient PI8 who was the sib of patient
P17, indicating that it did not co-segregate with the disorder in this family, given
that both patient P17 and patient PI8 are affected. This made OMP unlikely to be
the cause of Usher syndrome in this family. Given the proximity of OMP to ET58,
which was later shown to be part of the myosin type VII gene (see section 7), there
is a possibility that this family is not linked to USHIB. Analysis of the haplotypes
segregating in this family would confirm if they were unlinked, or if a
recombination event had occurred between OMP and the disease locus. All of the
other changes were located in the untranslated region and were therefore unlikely
to have any affect on function of OMP. A single base alteration in the untranslated
region is unlikely to affect the function or expression of OMP. Thus it was
unlikely that OMP was the gene underlying Usher syndrome. In parallel to
carrying out mutational analysis on OMP, I was carrying out comparative mapping
using exon traps isolated from the shaker-1 region in mouse, to see if any other
likely candidates could be identified. The results of this analysis are discussed in
the next section.
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6.5.1 The efficacy of the different mutation detection methods used
No mismatches were detected by sequencing which HOT had failed to identify.
Several expected products were not seen in HOT analysis, although the mismatch
was identified by the presence of the complementary product. Of the 5 mismatches
which were not seen, 3 were T-G mismatches which are frequently missed (Jane
Prosser, personal communication). The remaining 2 were a T-C and a C-T
mismatch, while these are normally easy to detect they may have been missed due
to effects of the sequence context around the mismatch. Since the release of the
original paper on the HOT technique (Cotton et al., 1988) further analysis on the
reactivity of mispaired bases has been carried out. Bhattacharyya et al (1989)
observed that mismatching can result in chemical hyper-reactivity, which can
depend on the flanking sequences. Thus, some at least of the mismatched base-
pairs contain the potential to be recognised as chemically different, but this may be
modulated by sequence context. This, however, should not deter use of the
technique since as demonstrated here all of the mismatches are generally identified,
and the absence of the complementary product is therefore insignificant
Perhaps more worrying was the identification of strong false positives in the c5
product at 172 and 550bp. False positives are not generally observed in the HOT
technique. Most studies however concentrate on analysis of the coding region, and
it is feasible that sequences in the 5' untranslated region, which is highly GC rich,




Summary and concluding remarks
In the final stage of confirming base differences in the OMP gene of USH1B
affected sib pairs, mutations were identified in a novel myosin type VII gene in
shaker-1 mice and USHIB patients. The approach taken to identify the gene for
USHIB was that of the positional candidate (Collins 1995, see later), where
mapping to a chromosomal region was combined with a search for suitable
candidate genes in that region. Selection of a candidate gene depends on a number
of factors: expression in an appropriate tissue; location in the chromosomal region
linked to the disorder; and where the function is known it must be reconcilable
with the phenotype observed. Meeting these criteria does not necessarily
distinguish the actual gene from other likely candidates. The only way to do this is
to show (in affected individuals) there are no mutations in the false candidates;
identify mutations in the real gene; or as was the case with OMP a combination of
both. Candidate genes must be tested and ruling out a candidate gene is an
important step to fmding the real gene.
In USHII, phosducin and hCHML were both screened for mutations in affected
individuals (section 1.2.4.2) with negative results, and hence ruled out as
candidates. In developmental genetics, candidate genes must also be screened after
applying a similar set of selection criteria. Hence ZFY was considered as the testis
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determining gene (Page et al., 1987), but ruled out when its expression pattern
(Koopman et al., 1989) and absence from XX males (Palmer et al.,1989) proved
incompatible with this theory. The new candidate became SRY and its mouse
equivalent Sry (Sinclair et al., 1990; Gubbay et al., 1990) which were localised to
the smallest region of the Y chromosome known to be male determining and
conserved in other eutherian mammals. The case was strengthened when the
expression of Sry in the mouse was shown to be entirely consistent with a role in
sex determination (Koopman et al., 1990). In humans too SRY was shown to be
important for testis development when de novo mutations were found in the gene
in two sex reversed XY females (Berta et al., 1990; Jager et al 1990). Conclusive
proof that Sry was indeed the testis determining factor came when introduction of
Sry on a genomic fragment gave rise to normal testis development in female
transgenic mice (Koopman et al., 1991).
While eliminating a gene as the cause of a disorder or as a key to a particular stage
in development can be disappointing, information gained in the analysis may prove
useful in other investigations. This was the case for the fibroblast growth factor
receptor 3 gene (FGFR3) which was initially identified during attempts to identify
the Huntington's chorea disease gene (Thompsom et al 1991) and later shown to
be responsible for achondroplasia (Shiang et al., 1994).
The myosin type VII gene was isolated by Gibson et al (1995) from a mouse inner
ear cDNA library using the exon trap probe ET58, which was isolated from a YAC
mapping to the non recombinant region surrounding the shaker -1 locus. ET58
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had been shown to contain an open reading frame conserved across a number of
species and during the course of this project was mapped to the same YAC as
human OMP and hence to lie within the region linked to USHIB.
There are a number of features which made myosin type VII a good candidate for
both syndromes. The gene is expressed in the mouse inner ear and indeed has been
shown to be transcribed in the mouse cochlea (Weil et al., 1995) where
neuroepithelial defects are observed in shaker-1 mice. Previous studies have
instigated a myosin type 1 molecule as playing a pivotal role in the adaptation
motor. The adaptation motor is thought to allow hair cells of the inner ear to
maintain their optimal sensitivity to minute displacements by adapting to sustained
stimuli at the molecular level. The protein has been shown to be expressed near
the tip of stereocilia where transduction and adaptation occur (Gillespie et al.,
1993) and given the features of Usher syndrome and shaker-1 it is thought that the
myosin type VII gene is also involved. Defective cilia have been observed in
affected individuals (section 1.2.5) and this could explain the involvement of 3
different sensory systems in Usher syndrome, and the combination of vestibular
dysfunction and sensorineural deafness in shaker-1 mice. The most conclusive
evidence was of course the identification of mutations in the head region of the
myosin type VII gene in both spontaneous and ENU induced mouse sh-1 mutants
(Gibson et al., 1995). Of the seven available sh-1 mutants screened, three
mutations were confirmed: a 3' splice site mutation which produced an in frame 10
codon deletion; and two non conservative arginine to proline changes. The small
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soil nematode Caenorhabitis elegans has been intensively studied both at the
molecular genetic and the developmental level for a number of years. The major
myosin heavy chain gene, which was identified during analysis of muscle defective
strains, has been particularly well studied and a number of mutants and their
resultant phenotypes have been described (Dibb et al., 1985). Alteration of one of
the arginines which was changed to a proline in a sh-1 mutant in C.elegans
produces a slow moving phenotype and some thick filament disorganization,
confirming the importance of this amino acid for function. Analysis of USHIB
families also revealed mutations in the motor domain of the myosin type VII gene
in affected individuals (Weil et al., 1995): in two individuals two different
heterozygous missense mutations were observed; in another two individuals
heterozygous mutations which resulted in a premature stop codon, and hence a
protein truncated before the ATP and actin binding sites were detected; and in one
of the latter and another unrelated individual the same heterozygous 6bp deletion
within two 5bp direct repeats (suggesting replication slippage or slipped strand
mispairing) was seen. The presence of two defective alleles in one individual was
strong evidence that the myosin type VII gene was responsible for USHIB. The
mouse and human gene were therefore proposed to be orthologous.
Every known myosin molecule comprises a conserved head domain which includes
the ATP (hydrolysis of which allows myosin to convert chemical energy to force)
and actin binding domains and is responsible for generation of force, and a tail
domain which includes regions responsible for regulation and for interaction with
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proteins or lipids (Gillespie et al., 1995). Mutations in the head domain would
therefore prevent adaptation to sustained stimuli resulting in the features observed
in these syndromes. The absence of retinal defects in the mouse could be explained
by either the nature of the mutations observed or compensation by another myosin
molecule. Neurosensory nonsyndromic deafness type two (NSRD2) has also been
linked to llql3.5 (Guilford et al., 1994). This disorder may also involve mutations
in myosin type VII of a similar nature to those observed in shaker-1. Similarly
mutations in other myosin molecules may cause other forms of sensorineural
deafness.
Screening of the remainder of USHIB patients must now be carried out in order to
identify mutations, and the likely involvement of other myosin genes in the
remaining Usher Syndrome subtypes investigated. It may be that myosin type VII
is not always the gene responsible for USHIB, and as has been shown with
Retinitis Pigmentosa a number of genes may result in the syndrome (section
1.2.1.2 ), in which case it is important to consider other proteins which myosin
type VII might interact with and hence generate the same phenotype. Obviously
anything which prevents ATP or actin binding will prevent the protein from
functioning; binding of Ca2+ appears to modulate the rate of ADP release so this
pathway, which involves calmodulin, is also important (Warwick and Spudich
1987). So to is the interaction of the protein with the stereocilium membrane and
the microfilament core (Gillespie et al., 1993). Myosin type VII is the first
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molecule to be identified that is known to be involved in auditory transduction and
hence may prove to be the key to understanding neurosensory deafness.
In this work, analysis of the USHIB region involved mutational analysis of the
human OMP gene, mapping candidate genes from the sh-1 non recombinant
region, and physical mapping of human chromosome llql2-13. Physical mapping
involved the development of an improved method for isolation and efficient
mapping of inter-Alu PCR products. The modified method encompasses two
important features : a secondary PCR to remove Alu end sequences and hence
removes the need for a long preannealing step prior to hybridisation of such
products; and a cloning methodology which is nonselective resulting in a broad
range of markers. This method could be used to increase the density of markers in
any chromosomal region, although obviously sites with an abundance of Alu
repeats would result in more markers. Future application of this method would,
however, benefit from a few minor alterations;
• in addition to CotI the turboclones should be screened for MERs and other
medium frequency repeats
• pools of turboclones could be used to directly isolate YACs the end clones of
which could then be mapped on a somatic cell hybrid panel by Southern
hybridisation, or even the whole of an identified YAC could be mapped by FISH
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• the ends of turboclones could be sequenced to see if the polymorphic nature of the
Alu 3' ends could be used in linkage analysis and homozygosity mapping
approaches
Rapid changes are at present occurring in the realm of physical mapping. YACs
are seen as a weakness in any mapping project due their frequent deletions,
tendency to be chimaeric, and the inability to separate them from the yeast host
chromosome background by simple methods (Zabarovski et al., 1994).
Consequently several alternative cloning systems based on bacterial host systems
have been developed (Monaco and Larin 1994). These show a lower frequency of
chimaerism, a higher transformation efficiency in generating libraries, and it is
simpler to purify insert DNA away from the host genome. The two major E.coli
cloning systems are BACs (bacterial artificial chromosomes) which use an F-factor
based vector, and PACs (PI artificial chromosomes) where the vector incorporates
features of both the PI and F-factor systems. Ultimately the desire is to construct
MACs (mammalian artificial chromosomes) which could be used for transgenic
complementation analysis in tissue culture, but perhaps mostly due to their
potential use in somatic cell gene therapy (Huxley 1994). First, however, human
centromeres and origins of replication must be defined.
Similarly technical developments are occurring which will greatly simplify the
search for candidate genes particularly in polygenic and multifactorial disorders.
Many human genetic disorders are complex in their aetiology, for example diabetes
type I, and identification of candidate genes may be hampered by the fact that a
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number genes and environmental factors may be involved. The direct identification
of candidate genes without prior knowledge of their location in the genome, or
function, would represent a significant advance and may in the near future be
technically feasible (Jonsson et al., 1995). Such methods rely on the concept of
identity by descent (IBD) which is outlined below
• genomic sequences from two unrelated individuals are different (i.e. polymorphic)
• given low mutation rates, identical by descent segments in the genomes of two
unrelated individuals are identical in sequence
• through segregation and recombination of chromosomes, sequences IBD become
progressively fewer and shorter with increasing numbers of meioses separating two
relatives
Hence, sequences IBD should contain genes contributing to a phenotype which is
shared by distant relatives.
These provisos are not novel (Sanda et al., 1986) and indeed form the basis of
homozygosity mapping which is presently in vogue (Davies et al., 1994). In
homozygosity mapping regions IBD are sought by looking for sharing of
microsatellite alleles in affected individuals, and a physical region is thus identified.
Theoretically, however, it should be possible to take the method one stage further
and directly isolate sequences IBD by mixing, denaturing, and annealing genomic
DNA from affected distantly related individuals and enriching for heteroduplexes
which contain no mismatches while discarding homoduplexes and heteroduplexes
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with internal mismatches. Early attempts were fraught with difficulties, but current
technological advances in coincident sequence cloning methodologies have made
the process more tractable (Nelson et al., 1993 : Lisitsyn et al., 1993). Both
methods while at an early stage have shown a lot of potential and this approach
will in time save a great deal of repetitive work involved in the analysis of multiple
markers.
The human genome mapping project: progress and implications
Mapping
The progress of the human genome mapping project to date has depended on
developments in four major areas: the construction of a high resolution genetic
map; the construction of a high resolution physical map; rapid and facile
identification of expressed sequence tags (ESTs); and the development of
networked information systems to permit search and retrieval over the Internet.
Development of a genetic map has been greatly facilitated by the discovery of
simple sequence repeats such as CA repeats and microsatellites. These repeats
occur on average every 30,000bp throughout the human genome and are generally
highly polymorphic (>80% informative). In addition analysis of the degree of
polymorphism of these repeats in individuals is inexpensive, fast, and technically
simple - requiring a straightforward PCR (Hoffman 1994). Their primary utility is
to facilitate localisation of disease genes by family based genetic linkage studies.
The major source of characterised CA repeats to date has been the French Institute
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Gdndthon which was established and funded by the French muscular dystrophy
association, using monies acquired through nonprofit, private fundraising (Gyapay
et al., 1994). Polymorphic markers are the cornerstone of linkage analysis and
while the results obtained from such analysis allow them to be orientated relative to
each other, and provide estimates of the genetic distance between them, it is their
physical location on the human chromosome, which provides the key to
localisation of the disease gene. While estimates of the relationship between
physical and genetic distance may allow rough localisation of genetic markers on
the chromosome the real key lies in the integration of physical and genetic maps
(Cox et al., 1994). This problem is being addressed and graphical user interfaces
which allow the visualisation and retrieval of mapping data derived from different
mapping approaches are being constructed (Boguski and Schuler 1995).
Through time a number of different approaches have been taken in the
identification of disease genes, with varying degrees of success and potential levels
of application (Collins 1995). Functional cloning is where the identification of a
gene is based on the presence of a basic biochemical defect. The chromosomal
localisation of the gene is not required, and in most cases where such information
is available the gene has been cloned. The candidate gene approach also relies on
the availability of some functional information, in combination with educated
guesses as to possible candidate genes. In its purest form positional cloning
assumes no functional information, and the responsible gene is located purely on
the basis of its map position. The majority of positional cloning successes have
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relied on the presence of cytogenetic rearrangements, large deletions or expanded
trinucleotide repeats. The approach predicted to supersede all of the above is that
of the positional candidate. Here mapping to a chromosomal subregion, generally
by linkage analysis, is combined with a search for suitable candidates in that region.
The expanding success of such an approach depends on the availabilty of a high
resolution transcript map.
It is predicted that by the end of 1997 most human genes will be sequence-tagged
and placed on various physical maps (Boguski and Schuler 1995). Single pass
sequencing into the 3' untranslated regions (3'UTRs) of directionally cloned human
cDNAs is being used to uniquely identify human genes and in parallel efficiently
generate gene-based sequence-tagged-sites (Wilcox et al„ 1991, and Olsen et al.,
1989). There are a number of advantages in using 3'UTRs rather than other
portions of an mRNA sequence : it is unusual for them to contain introns, therefore
the PCR product size is the same from genomic DNA as cDNA templates; the
sequence is less well conserved so it is easier to distinguish between individual
genes and closely related paralogous family members; the presence of a poly A tail
and polyadenylation signal identifies true human mRNAs; and the sequence of this
region is more species specific. The total length of ESTs now sequenced amounts
to 5 million base pairs which accounts for 0.15% of the total length of the human
genome. More than 55,000 ESTs have to date been identified which correspond to
authentic genes, although only 10,000 of these are presendy logged in public
databases (Maddox 1995). In order to eliminate redundancy in the Genbank
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database a set of unique 3'UTRs were selected against which all new ESTs are
screened before mapping (Boguski and Schuler 1995). Similary, at the mapping
level redundancy is prevented by the establishment of another database (Rhalloc
which stands for radiation hybrid allocation) into which groups deposit the
sequences which they intend to map. Previously ESTs were assigned to a
particular chromosome, efforts now are however concentrating on assignment to
specific chromosomal regions using a combination of megabase insert yeast
artificial chromosomes and somatic cell hybrids (Berry et al., 1995).
Sequencing
The fact that obtaining the human genome in its purest form (i.e. the complete
sequence) would not immediately yield much practical information for application
to human diseases, and the sheer expense involved in such a project has meant that
to date this area has been of least concern to the Human Genome Project (Hoffman
1994). Indeed there is a fear that funding bodies will believe the identification of
genes to be sufficient and shrink from obtaining the complete sequence of the
genome (Maddox 1995). This would be unwise, since only 3% of the human
genome encodes protein. The function of the remaining 97% while unclear may
hold the key to explaining evolution and function of the human genome (Nowak
1994). Regulatory elements for genes are frequently located outside the protein
coding sequence and without these it would be difficult to gain a real conception of
how a gene functions. Repetitive elements are found throughout the genome of
higher organisms and, unlike the structure of genes which are frequently highly
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conserved between organisms, such repeats are often very simple in structure and
may even vary at the cellular level within a single organism (Wooster et al., 1994).
Their importance has recently come to the fore however, with the discovery that
mutations in a minisatellite may contribute to as much as 10% of all cases of
breast, colorectal, bladder cancer and acute leukaemia. It is thought that mutations
in the minisatellite upregulate the Harvey ras gene, which is involved in a major
growth regulatory pathway. Some repetitive elements also seem to have a function
in maintaining the integrity of chromosomes such as satellites located at telomeres.
Even introns are being investigated to see if they can encode regulatory RNAs:
support for this approach of course comes from the XIST gene which shuts down
one of the two X chromosomes in female cells via a putative regulatory RNA
which it encodes. Sequencing the human genome will not supersede, but
complement existing EST maps which will shed new light on global aspects of
gene organisation, evolution and expression (Boguski and Schuler 1995).
The importance of sequencing the human genome is thus firmly established. How
will this huge volume of work be approached? The production of the Human
Sequence Map was discussed recently by John Sulston at the Annual HGMP /
Gene Therapy Workshop (July 1995). Firstly he confirmed the importance of
complete sequence rather than just cDNAs in order to place all of the accumulated
information on a 'genomic ruler' and to formulate an archive for the future.
Sequencing sample sections of the genome will not only miss potentially interesting
regions, prevent the formation of a local map, but also fail to produce enough
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information to function as a genomic ruler for physical and genetic marker
placement. Curation of such a map would be an ongoing expense and in the end it
would more cost effective to obtain the entire sequence. Instead of base by base
sequencing the entire genome, however, the proposal is to shotgun sequence
bacterial clones which can then be automatically assembled on a radiation hybrid
map. This method is predicted to have an overall cost of 10p/ base which as a
percentage cost of the actual overall cost of the HGP is actually rather small.
Model organisms
In addition to mapping the human genome, mapping of genomes of a number of
other organisms, both vertebrate and invertebrate, has been undertaken. In the
simpler invertebrates basic principles of genetics and biochemistry are easily
studied, and the smaller genome size makes them more amenable to complete
sequencing and identification of genes. At the simplest eukaryotic level, the yeast
Sacharomyces cerevisiae has been an integral part of studies of basic eukaryotic
functions such as the cell cycle for many years, and has played an important role in
the identification of many homologous human genes. Sequencing of the yeast
genome (14Mb) is progressing at a rapid rate and it is hoped that as more genes
are identified then yeast mutants can be used to screen cDNA libraries and identify
their human counterparts, by their ability to complement, as well as determining
their function. Another important model invertebrate organism is the nematode
Caenorhabditis elegans. The small genome size (100Mb) and short life cycle of
this organism have lead to a number of studies into its development and behaviour,
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and most importantly a number of the genes required for normal development and
movement have extensive similarity to their mammalian counterparts. While
nowhere near as complex as the human genome, sequencing of this simple animal
genome was seen as a forerunner for evaluating technology and as a provider of
information essential for interpreting human sequence (Sulston et al., 1992). After
establishment of the C.elegans database (ACEDB) and publication of the first
2.2Mb of contiguous sequence (Wilson et al., 1994) this project is proceeding at a
rate of 2Mb/month, with 18 Mb sequenced by July of 1995 (Sulston the Annual
HGMP / Gene Therapy Workshop). While invertebrates have proven useful in
identifying human genes, differences in morphology and development mean that
they will never serve as comprehensive paradigms for human disease, nor will they
encode the whole subset of genes required for vertebrate development.
From the perspective of gene identification the ideal model would be a vertebrate
of minimum size and complexity, but maximum homology to the human genome.
This role is filled by the Japanese pufferfish Fugu rubripes (Brenner et al., 1993).
Fugu is a tetraodontoid fish and these share the same general body plan, and many
of the specialised functions of higher vertebrates. The Fugu genome is just 400Mb
which is 7.5 times smaller than the human genome, yet encodes a comparable
number of genes. In general this is due to smaller intergenic and intronic
sequences and less repetitive DNA (Baxendale et al., 1995). Evidence to date
indicates conservation of syntenic regions as well as in the sequence of individual
genes. Comparison of the Huntington gene of human and Fugu identified five
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regions which are highly conserved (>80%) between these two distantly related
species and hence may be functionally important. Another potential use of Fugu is
in the identification of gene family members. The size, complexity and large
number of repetitive elements in the human genome have made the identification of
gene family members a very complicated process. In Fugu however four dopamine
receptor like genes were identified by a straightforward degenerate PCR (Macrae
and Brenner 1995). The fact that teleosts are the most distant vertebrate
precursors of mammals means that all unconstrained sequences will have had the
maximum amount of time to randomise through mutations and only those
sequences required for functions common to all vertebrates will be conserved i.e.
coding and regulatory. This view was supported by the results analysis of the
function of non-coding regions conserved between mouse and Fugu Hoxb-4 genes
(Aparicio et al„ 1995). Thus Fugu could be used to identify functionally important
regions prior to transgenic analysis.
The ultimate experimental model for many human diseases has been the mouse,
due to their physiological similarity and the conservation of syntenic regions (see
section 1.2.6.5). Many naturally occurring mouse variants exist, several of which
model human disorders. Such physiologically similar disorders may result from
mutations in homologous genes, and the genes themselves may be located within
homologous chromosomal segments. The identification of the myosin type VII
gene, which maps to homologous segments of the genome in mouse and man, and
results in disorders which are phenotypically very similar, is a clear example of this
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(Gibson et al., 1995; Weil et al., 1995). In some cases, however, the same gene
may have a slightly different function in different organisms and the resultant
phenotype may not be the same, as was observed with PAX3 (Steel and Harvey
1992). Hence mapping of the mouse genome has been proceeding at a similar rate
to human (Dietrich et al., 1994). Now, however, a genetic linkage map of the rat
is being rapidly compiled (Jacob 1995). Rats have proved valuable models for
several human diseases or traits, such as hypertension, diabetes and cancer (Gill et
al., 1989) and hence the ability to genetically map these would be invaluable.
While theoretically this is possible, the amount of space required to house enough
rats for a high resolution positional cloning project is prohibitory (Frankel 1995).
In addition techniques are well developed which allow the manipulation of the
mouse genome, and genetically altered mouse strains can be produced which then
allow the phenotype and function of genes to be studied (Fassler et al., 1995).
Hence perhaps the best route would be to carry out initial mapping in the rat,
followed by manipulation of candidate genes in the mouse.
Politics and ethics
It has been proposed that the identification of a gene that predisposes individuals to
a human illness may represent the journey through the bottleneck in the
understanding of that disease, allowing the development of diagnostic and
therapeutic advances (Collins 1995). Once a gene has been identified, however,
the way forward is not as simple as it may at first seem.
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Identification of the affected gene improves diagnostic capabilities for a disorder,
but to what end? Once the function of the gene is understood, probably by study
at the biochemical and physiological level in model organisms, more appropriate
drug therapy, means of preventative medicine, and possibly even gene therapy can
be devised. The gap between the identification of the defective gene and the ability
to treat the disorder has ethical implications. In addition, the choice of which
disorders are funded at this level and who carries out the research is embedded in
politics.
The scientific community was shaken a few years ago when J Craig Venter listed
his first set of 600 ESTs and indicated his intention to patent them. Feelings that
such basic information should remain in the public domain were high, and
fortunately the application was refused. Renewed controversy has arisen,
however, with the impending publication of the Genome Directory (Maddox
1995). The Genome Directory will not only contain Venter's latest compilation of
ESTs, but also the latest version of the physical map produced by Gdndthon, and
hence will be of immense benefit to groups trying to locate disease genes. The
problem comes from the restrictions attached to the use of the directory. Venter is
head of The Institute of Genome Research (TIGR) which although in itself non
profit making has an agreement with the commercial organisation Human Genome
Sciences (HGS) which in turn has an agreement with the pharmaceutical company
SmithKline Beecham. The restrictions require any discoveries made on access to
the directory leading to potentially valuable applications to be disclosed first to
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HGS which would then have the first option to exploit them. This problem is
being circumvented by the US pharmaceutical company Merck, which has
provided a grant of $10 million to Washington University to replicate construction
of the EST catalogue entirely in the public domain. Ultimately, however the choice
of which database scientists select to search will probably depend on the reliability
of the information contained in them rather than any restrictions.
At the outset of the HGP it was decided to direct at least three percent of its
annual budget to a programme called Ethical, Legal and Social Implications (ELSI)
(Nelkin 1992). The aim of the programme was to formulate a responsible social
policy on the implications of research and potential misuses of information about
genetic predisposition, but even this was not immune to political complications
(Anderson 1992). In a number of cases, academics and even committee members
were discovered to have commercial interest in companies to whom they were
recommending the allocation of funds or areas of research. The end conclusion
was that in all circumstances scientists should reveal all existing or potential
conflicts of interest
Perhaps the greatest ethical dilemma comes when one considers human dignity.
Many people believe the HGP to be a precursor to an inevitable return to eugenics
because it will provide the rigorous science and practical techniques necessary for
large scale public health strategies (de Dinechin et al., 1993). The history of
human eugenics is the source of some embarrassment and Nazi atrocities
produced a backlash against the view that the state had a legitimate interest in who
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reproduced (Paul and Spencer 1995). Understandably this led to the belief and
indeed hope that eugenics was dead. This may not in fact be the case, since forty
years on recommendations with a eugenics feel are again being made - the
International Huntington Association and the World Federation of Neurology in
their 1990 guidelines deemed it acceptable to refuse to test women 'who do not
give complete assurance that they will terminate a pregnancy when there is an
increased risk' of Huntington's disease (Went 1990). Freedom of choice must be
maintained at all times and the availability of genetic screens must not be allowed
to buttress crude eugenic arguements or erode public support for health care
(Butler 1994).
In general the recommendations are that screening should be limited to diseases
which are treatable or preventable and should always be preceded by counselling
(Knoppers and Chadwick 1994). This then highlights another problem - the lack
of medically trained geneticists. Science regulates public debate to a much lesser
extent than many scientists believe and the importance of good non-coercive
communication cannot be emphasised enough (de Dinechin et al„ 1993).
The final problem is that of autonomy and potential discrimination. Genetic
constitution is by its very nature shared by members of the same family, hence in
some cases a person's right not to know may clash with another's right to know
and vice versa. While respect for privacy and confidentiality of genetic information
is crucial, it is felt that it is important to communicate information to family
members that are at high risk, but consent is essential before disclosure to any
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other third party (Knoppers and Chadwick 1994). Third parties may take the form
of insurance companies or employers, and it is important to protect individuals
against genetic discrimination. At present health care is focussed on treatment
rather than prevention of genetic disorders, and such information would be of little
positive use to employers or insurance companies. For this reason the formulation
of a 'Genetic Bill of Rights' may be envisaged i.e. 'an explicit statement of
protections and duties to try to guarantee human self-determination in spite of an
increasingly transparent genome' (de Dinechin 1993). It is important that
governments do legislate on the outcome of the HGP, because as stated by
Knoppers and Chadwick (1994) - 'The accountability of the HGP is at stake. So is
our present obligations of stewardship to humankind and to future generations.'
It is not enough for the Human Genome Project to simply be a source of new
knowledge, and those involved have a responsibility to society to help in
interpretation and correct use of the information gained. Scientists must be aware
of all potential outcomes of their results and be prepared to be involved in
preventing the misuse. It is also important to ensure health care professionals are
prepared for the impending ethical problems imposed by the HGP. Everyone
needs some sort of basic understanding, and in the next few years perhaps the most
important aspects of the HGP will be the education of the general public, and the
provision of legislation to protect their rights.
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